mhtx_10q.htm

0001477932-22-008553.txt : 20221114 0001477932-22-008553.hdr.sgml : 20221114 20221114172059 ACCESSION NUMBER: 0001477932-22-008553 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN SCIENTIFICS INC CENTRAL INDEX KEY: 0001099132 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 850460639 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28411 FILM NUMBER: 221387811 BUSINESS ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-726-2107 MAIL ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 10-Q 1 mhtx_10q.htm FORM 10-Q mhtx_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934

For the quarterly period ended September 30, 2022

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ____________to____________

MANHATTAN SCIENTIFICS, INC.

(Exact name of small business issuer as specified in its charter)

Delaware		000-28411		85-0460639
(State of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

244 Fifth Ave, Suite 2341

New York, New York, 10001

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (212) 726-2107

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value

(Title of Class)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were 559,281,064 shares outstanding of registrant’s common stock, par value $0.001 per share, as of November 14, 2022.

TABLE OF CONTENTS

PART I

Item 1.	Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021	3
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021 (unaudited)	4
	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2022 and 2021 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21

PART II

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosure	23
Item 5.	Other Information	23
Item 6.	Exhibits	24
SIGNATURES		25

Table of Contents

PART I – FINANCIAL INFORMATION

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2022			2021
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	288,000		$	232,000
Prepaid expenses		8,000			15,000
Due from the sale of assets - current portion		-			300,000
Total current assets		296,000			547,000

Investment in equity securities		1,064,000			2,901,000
Property and equipment, net		2,000			4,000
Other assets		2,000			2,000
Total assets	$	1,364,000		$	3,454,000

LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	115,000		$	102,000
Accrued expenses - related parties		1,351,000			1,129,000
Notes payable, net of discounts		139,000			130,000
Total current liabilities		1,605,000			1,361,000
Total liabilities		1,605,000			1,361,000

Commitments and Contingencies - Note 7		-			-

Class D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively		1,058,000			1,058,000

STOCKHOLDERS’ EQUITY (DEFICIT)
Capital stock $0.001 par value
Class A Convertible Preferred, authorized 182,525, 0 and 0 shares issued and outstanding, respectively		-			-
Class B Convertible Preferred, authorized 250,000, 49,999 and 49,999 shares issued and outstanding, respectively		-			-
Class C Redeemable Convertible Preferred, authorized 14,000, 0 and 0 shares issued and outstanding, respectively		-			-
Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively		559,000			559,000
Additional paid-in-capital		68,996,000			68,996,000
Accumulated deficit		(70,854,000	)		(68,520,000	)
Total stockholders' equity		(1,299,000	)		1,035,000
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (Deficit)	$	1,364,000		$	3,454,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	THREE MONTHS ENDED						NINE MONTHS ENDED
	SEPTEMBER 30,						SEPTEMBER 30,
	2022			2021			2022			2021

Revenue	$	9,000		$	-		$	50,000		$	50,000

Operating costs:
General and administrative expenses		175,000			175,000			548,000			565,000
Research and development		2,000			3,000			7,000			8,000

Total operating costs and expenses		177,000			178,000			555,000			573,000

Loss from operations		(168,000	)		(178,000	)		(505,000	)		(523,000	)

Other income (expense):
Gain (Loss) on fair value adjustment of investments		104,000			(978,000	)		(1,809,000	)		(3,069,000	)
Gain on settlement of legal fees		-			7,000			-			7,000
Interest expense		(7,000	)		(7,000	)		(20,000	)		(20,000	)
Total other income (expense)		97,000			(978,000	)		(1,829,000	)		(3,082,000	)

NET INCOME (LOSS)	$	(71,000	)	$	(1,156,000	)	$	(2,334,000	)	$	(3,605,000	)

INCOME (LOSS) PER COMMON SHARE:

Weighted average number of common shares outstanding (Basic and Diluted)		559,281,064			559,281,064			559,281,064			559,281,064

Basic and Diluted income (loss) per common share (Basic and Diluted)	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 and 2021

(UNAUDITED)

	Preferred Stock - Series B				Common Stock				Additional					Total Shareholders'
	$0.001 Par Value				$0.001 Par Value				Paid-In		Accumulated			Equity
	Shares		Amount		Shares		Amount		Capital		Deficit			(Deficit)
Balance
December 31, 2021		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(68,520,000	)	$	1,035,000

Net loss		-		-		-		-		-		(647,000	)		(647,000	)

Balance
March 31, 2022		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(69,167,000	)	$	388,000

Net loss		-		-		-		-		-		(1,616,000	)		(1,616,000	)

Balance
June 30, 2022		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(70,783,000	)	$	(1,228,000	)

Net loss		-		-		-		-		-		(71,000	)		(71,000	)

Balance
September 30, 2022		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(70,854,000	)	$	(1,299,000	)

	Preferred Stock - Series B				Common Stock				Additional					Total
	$0.001 Par Value				$0.001 Par Value				Paid-In		Accumulated			Shareholders'
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity

Balance
December 31, 2020		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(64,881,000	)	$	4,674,000

Net income		-		-		-		-		-		134,000			134,000

Balance
March 31, 2021		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(64,747,000	)	$	4,808,000

Net loss		-		-		-		-		-	$	(2,583,000)		$	(2,583,000)

Balance
June 30, 2021	$	49,999	$	-	$	559,281,064	$	559,000	$	68,996,000	$	(67,330,000)		$	2,225,000

Net loss											$	(1,156,000)		$	(1,156,000)

Balance
September 30, 2021	$	49,999	$	0	$	559,281,064	$	559,000	$	68,996,000	$	(68,486,000)		$	1,069,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	FOR THE NINE MONTHS ENDED
	SEPTEMBER 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,334,000	)	$	(3,605,000	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		2,000			1,000
Loss on fair value adjustment of investments		1,809,000			3,069,000
Amortization of debt discount		19,000			20,000
Gain on settelement of legal fees		-			7,000
Changes in:
Prepaid expenses		7,000			(5,000	)
Accounts payable and accrued expenses		13,000			(12,000	)
Accounts payable and accrued expenses - related party		222,000			228,000

Net cash used in operating activities		(262,000	)		(287,000	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of investments		28,000			-
Proceeds from sale of assets held for sale		300,000			300,000

Net cash from investing activities		328,000			300,000

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of note payable		(10,000	)		-
Net cash used in financing activities		(10,000	)		-

NET INCREASE IN CASH		56,000			13,000
CASH, BEGINNING OF PERIOD		232,000			353,000

CASH, END OF PERIOD	$	288,000		$	366,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

NOTE 1 – BASIS OF PRESENTATION

The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2021, filed on April 6, 2022. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

Operating results for the nine months period ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

As of September 30, 2022, the Company has an accumulated deficit of 70,854,000 and negative working capital of $1,309,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted.

These factors raise substantial doubt about the Company’s ability to continue as going concern within one year from the date of filing these financial statements. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

The condensed consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary, Metallicum, Inc. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

CASH AND CASH EQUIVALENTS:

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

CASH CONCENTRATION:

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2022 and December 31, 2021, we had cash balances of $34,000 and $0, exceeding the federally insured limits.

PROPERTY AND EQUIPMENT:

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.

INTANGIBLE ASSETS:

License Agreements

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two (2) patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022 and December 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2022 and 2021, the Company received $300,000 and reduced the amount due from the sale of assets to the balance of $0.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

MARKETABLE SECURITIES:

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended September 30, 2022, no allowance was recorded for credit losses.

REVENUE RECOGNITION:

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

The revenue was generated was from minimum royalty payments from the license agreement.

FAIR VALUE OF FINANCIAL INSTRUMENTS:

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2022 and December 31, 2021 because of the relative short term nature of these instruments.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of September 30, 2022, the Company holds 51,766,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2022 and December 31, 2021, consisted of the following:

	Total fair value at September 30, 2022		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	1,064,000	$	1,064,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

LEASES

The Company leases a facility with terms of month-to-month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore, is not required to capitalize the lease.

INCOME TAXES

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10, clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2022 and 2021, there were 28,922,917 and 28,922,917, respectively, potentially dilutive shares that need to be considered as common share equivalents. As a result of the net loss for the periods presented, the potentially dilutive shares for the periods ended September 30, 2022 and 2021 are anti-dilutive.

The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended September 30, 2022 and 2021:

	Three Months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(71,000	)	$	(1,156,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.00	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.00	)

The following table shows the computation of basic and diluted earnings (loss) per share for the nine months ended September 30, 2022 and 2021:

	Nine months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(2,334,000	)	$	(3,605,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

STOCK BASED COMPENSATION

The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as, a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements.

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has not completed its assessment of the standard but does not expect the adoption to have a material impact.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS

As of September 30, 2022, the Company owns 51,766,508 shares of Imagion, resulting in a non-controlling interest of Imagion’s issued and outstanding common stock. Based upon Imagion’s trading price on September 30, 2022, approximately $0.03 per share, the fair value of the Imagion shares was approximately $1,064,000. During the nine months ended September 30, 2022, the Company recorded a loss on fair value in its investment of $1,809,000.

Below is reconciliation for the changes to the investment in Imagion for the nine months ended September 30, 2022:

Balance as of December 31, 2021	$	2,901,000
Change due to the sale of securities		(28,000	)
Change in the unrealized fair value of securities		(1,809,000	)
Balance as of September 30, 2022	$	1,064,000

NOTE 4 – NOTES PAYABLE

On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 1 million shares of IBX common stock. The amortization of debt discount for the nine months ended September 30, 2022 was $19,000.

On September 30, 2022, the Company made $10,000 repayments and the notes payable balance was reduced to $140,000 from $150,000.

On October 24, 2022, the Company made $30,000 repayments and the notes payable balance was reduced to $110,000.

Notes payable	$	140,000
Less: Discounts on notes payable		(1,000	)
Notes payable, net of discounts	$	139,000

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

NOTE 5 – CAPTIAL TRANSACTIONS

Stock Activity

During the nine months ended September 30, 2022, the Company had not issued common stock.

Options

At September 30, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0. A summary of the Company’s stock option activity and related information is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable		Aggregate Intrinsic Value
Outstanding as of December 31, 2021		26,500,000	$	0.04		6.06		26,500,000	$	15,000
Granted		-		-		-		-		-
Exercised		-		-		-		-		-
Expired		-		-		-		-		-
Outstanding as of September 30, 2022		26,500,000	$	0.04		5.61		26,500,000	$	0

Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of September 30, 2022 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.05		3,000,000		2.75	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.63	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.75	$	0.14		3,000,000	$	0.14
$	0.02		15,500,000		7.81	$	0.02		15,500,000	$	0.02

The Company did not recognize compensation expense during the three months ended September 30, 2022.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

NOTE 6 – LICENSE AGREEMENT

On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with the Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.

During the nine months ended September 30, 2022, the Company received $50,000 as a minimum royalty payment.

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Legal matter contingencies

The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted, when there is more information available of when an event occurs requiring a change.

NOTE 8 – RELATED PARTY TRANSACTIONS

As of September 30, 2022 and December 31, 2021, the Company had accrued expenses to related parties of approximately $1,351,000 and $1,129,000.

As of September 30, 2022, the amounts are due to the Company’s sole officer for compensation of $336,000 and the chairman of the board for compensation of $939,000 and the members of the board of directors of $78,000.

NOTE 9 – SUBSEQUENT EVENTS

During October 2022, the Company sold 200,000 shares of IBX common stock.

During October 2022, the Company made $30,000 in repayment to a note holder and the notes payable balance was reduced to $110,000.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Form 10-Q contains “forward-looking” statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which we may participate. In addition, these forward-looking statements are subject, among other things, to our successful completion of the research and development of our technologies; successful commercialization of our technologies; successful protection of our patents; and effective significant industry competition from various entities whose research and development, financial, sales and marketing and other capabilities far exceeds ours. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions we make to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report.

OVERVIEW

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has one operating wholly-owned subsidiary: Metallicum, Inc., (“Metallicum”). Manhattan Scientifics is focused on technology transfer and commercialization of these transformative technologies.

The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. Nanotechnology is the use and manipulation of matter on an atomic and molecular scale. To achieve this goal, the Company is actively seeking to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long-standing relationship with the Los Alamos Laboratories in New Mexico.

Metallicum

In June 2008, we acquired Metallicum and its licensed patented technology. We entered into a stock purchase agreement with Metallicum to acquire all of the outstanding capital in exchange for 15,000,000 restricted shares of our common stock. An additional 15,000,000 shares of our common stock will be payable to Metallicum in the event of meeting certain milestones. At December 31, 2011, one milestone was met: Metallicum was granted an exclusive license by the Los Alamos National Laboratory on patents related to nanostructured metals. In September 2009, we entered into a technology transfer agreement and sale with Carpenter Technology Corporation, (“Carpenter”) wherein Carpenter was to fully develop, manufacture and market a new class of high strength metals. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-on technical assistance and Carpenter provided a list of all customers and contacts.

On May 1, 2019, Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), and Metallicum, Inc., a wholly-owned subsidiary of the Company, entered into an Overarching Agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. The Company anticipates royalty income as the nanotitanium is commercialized for use in medial prosthetics. Royalties will be 10% on sales of licensed dental products and an average of 5% in all other sales of licensed products.

Table of Contents

Imagion

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, Senior Scientific owned patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated. On November 17, 2016, Senior Scientific merged with and into Imagion, a Nevada company. Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On November 29, 2016, the Company announced a plan to have Imagion pursue an IPO and listing on the Australian Stock Exchange (ASX).

As of September 30, 2022, Manhattan Scientifics presently owns 51,766,508 shares of Imagion, with a fair market value of approximately $ 1,064,000, based upon the closing price per share of Imagion common stock on the ASX. The Company accounts for its investment in Imagion in accordance with ASC 825-10 and elected fair value option. We initially held 31% of the total issued and outstanding shares of Imagion and had one seat on the Board of Directors of Imagion. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

Novint

We made an investment in Novint Technologies Inc. (“Novint”) in 2001. Novint is currently engaged in the development and sale of 3D haptics products and equipment. Haptics refers to one’s sense of touch and Novint’s focus is in the consumer interactive computer gaming market. The Company owns 1,028,425 shares of Novint’s common stock. The fair value of the Novint shares are not recorded on the balance sheet as of September 30, 2022.

RESULTS OF OPERATIONS

THREE MONTHS ENDED SEPTEMBER 30, 2022 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2021

REVENUE. Revenue was $9,000 and $0 for the three months ended September 30, 2022 and 2021, respectively.

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $175,000 for the three months ended September 30, 2022 compared with $175,000 for the three months ended September 30, 2021.

RESEARCH AND DEVELOPMENT. Research and development costs were $2,000 and $3,000, for the three months ended September 30, 2022 and 2021, respectively.

OTHER INCOME (EXPENSES). Total other income for the three months ended September 30, 2022 totaled $97,000 compared to the total other expense of $978,000 for the three months ended September 30, 2021. The decrease is primarily attributable to the loss on fair value adjustments of its investment in Imagion during the period for the amount of $874,000.

Table of Contents

NET INCOME (LOSS). During the three months ended September 30, 2022, the Company had net loss of $71,000, compared to net gain of $1,156,000 for the three months ended September 30, 2021. The decrease of $1,085,000 is primarily attributable to the decrease gain on fair value adjustment of investment.

NINE MONTHS ENDED SEPTEMBER 30, 2022 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2021

REVENUE. Revenue was $50,0000 and $50,000 for the nine months ended September 30, 2022 and 2021, respectively.

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $548,000 for the nine months ended September 30, 2022 compared with $565,000 for the nine months ended September 30, 2021. The decrease is primarily attributable from the decrease of accounting, advertising, consulting, and legal fees.

RESEARCH AND DEVELOPMENT. Research and development costs were $7,000 and $8,000 for the nine months ended September 30, 2022 and 2021, respectively.

OTHER INCOME (EXPENSES). Total other expense for the nine months ended September 30, 2022 totaled $1,829,000 compared to the total other loss of $3,082,000 for the nine months ended September 30, 2021. The decrease of $1,260,000 is primarily attributable to the decrease loss on fair value adjustments of its investment in Imagion during the period.

NET INCOME (LOSS). During the nine months ended September 30, 2022, the Company had net loss of $2,334,000, compared to net loss of $3,605,000 for the nine months ended September 30, 2021. The decrease of $1,271,000 is primarily attributable to the decrease loss on fair value adjustment of investment.

LIQUIDITY AND CAPITAL RESOURCES

The Company had Stockholders’ deficit of $1,299,000 and the working capital deficit was $1,309,000 on September 30, 2022. The Company had an increase of $56,000 in cash and cash equivalents for the nine months ended September 30, 2022.

Based upon current projections, our principal cash requirements for the next 12 months consists of (1) fixed expenses, including consulting and professional services and (2) variable expenses, including technology research and development, milestone payments and intellectual property protection, and additional scientific consultants. As of September 30, 2022, we had $288,000 in cash. We believe our current cash position may not be sufficient to maintain our operations for the next twelve months. Accordingly, we may need to engage in equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

On October 17, 2019, we executed a secured note with our only independent director for $100,000 and a secured note with an unrelated party for $50,000. The secured notes are due on October 17, 2022. The Company agreed that the notes bear interest at 10% per annum, to be paid in advance with shares of Imagion Biosystems Limited common stock (“IBX”), calculated at $0.015 per share or 3,000,000 shares of IBX. We currently plan to sell IBX common stock to raise funds for operations, we have sold 750,000 shares of IBX common stock as of September 30, 2022.

Table of Contents

CASH FLOW INFORMATION

The Company had cash and cash equivalents of approximately $288,000 and $232,000 at September 30, 2022 and December 31, 2021, respectively. This figure represents an increase in cash of $56,000.

OPERATING ACTIVITIES

The Company used approximately $262,000 of cash for operating activities in the nine months ended September 30, 2022, as compared to using $287,000 of cash for operating activities in the nine months ended September 30, 2021.

The change is mainly from the decrease in the loss on fair value adjustments of its investment in Imagion during the period.

INVESTING ACTIVITIES

The Company received approximately $328,000 of cash from investing activities in the nine months ended September 30, 2022 as compared to, received approximately $300,000 of cash for investing activities in the nine months ended September 30, 2021.

The change is mainly from the sale of investment in Imagion in the nine months ended September 30, 2022.

FINANCING ACTIVITIES

During the nine months ended September 30, 2022, cash used in financing activities was $10,000 compared to $0 of cash for financing activities in the nine months ended September 30, 2021. The decrease was primarily a result of repayment of note payable.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of our patents, fair value of our common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Fair Value of Financial Instruments:

The Company recognizes the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Table of Contents

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2022 and December 31, 2021, because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of September 30, 2022, the Company holds 51,766,508 shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the ASX and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.

Property and equipment:

License Agreements:

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two (2) patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

Due from the Sale of Assets:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Table of Contents

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three (3) years in equal increments on the anniversary date of the agreement, May 1. During May 2022 and 2021, the Company received $300,000 and reduced the amount due from the sale of assets to the balance of $0.

Marketable Securities:

The Company considers securities with original maturities of greater than 90 days to be available-for-sale debt securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available-for-sale debt securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended September 30, 2022, no allowance was recorded for credit losses.

Revenue Recognition:

The revenue was generated was from minimum royalty payments from the license agreement.

Accounting for Leases:

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements as under the practical expedient the lease consist of terms less than one year, and therefore is not required to capitalize the lease.

Table of Contents

Stock Based Compensation:

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

Basic and Diluted Earnings (Loss) Per Share:

OFF BALANCE SHEET ARRANGEMENTS

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to include disclosure under this item.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

We conducted an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of September 30, 2022, that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

Table of Contents

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting:

Resources: We had one full-time employee in general management and no full-time employees with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to insure that all transactions are accounted for accurately and in a timely manner.

Written Policies & Procedures: We need to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions, and prepare, review and submit SEC filings in a timely manner.

Audit Committee: We do not have, and are not required, to have an audit committee. An audit committee would improve oversight in the establishment and monitoring of required internal controls and procedures.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject from time-to-time to litigation, claims and suits arising in the ordinary course of business. As of September 30, 2022, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

Table of Contents

ITEM 6. EXHIBITS

Index to Exhibits

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-101.INS**		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

EX-101.SCH**		Inline XBRL Taxonomy Extension Schema Document

EX-101.CAL**		Inline XBRL Taxonomy Extension Calculation Linkbase

EX-101.DEF**		Inline XBRL Taxonomy Extension Definition Linkbase

EX-101.LAB**		Inline XBRL Taxonomy Extension Labels Linkbase

EX-101.PRE**		Inline XBRL Taxonomy Extension Presentation Linkbase

EX-104**		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

_________________

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 14^th day of November, 2022.

	MANHATTAN SCIENTIFICS, INC.

	By:	/s/ Emmanuel Tsoupanarias
	Name:	Emmanuel Tsoupanarias
	Title:	Chief Executive Officer (Principal Executive, Financial and Accounting Officer)

EX-31.1 2 mhtx_ex311.htm CERTIFICATION mhtx_ex311.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Emmanuel Tsoupanarias, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2022 (the “report”) of Manhattan Scientifics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2022	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(Principal executive, financial and accounting officer)

EX-32.1 3 mhtx_ex321.htm CERTIFICATION mhtx_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of his knowledge, that:

(1)

The Quarterly Report of Form 10-Q for the period ending September 30, 2022 (the “Report”), of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 14, 2022

By:

/s/ Emmanuel Tsoupanarias

Emmanuel Tsoupanarias

Chief Executive Officer

(Principal executive, financial and accounting officer)

EX-101.SCH 4 mhtx-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - CAPITAL TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - COMMITMENTS AND CONTIGENCIES link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - CAPITAL TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - CAPITAL TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - CAPITAL TRANSACTIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mhtx-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity File Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Document Quarterly Report Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Document Transition Report Entity Address State Or Province CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Class A Convertible Preferred Stock [Member] Series B convertible preferred Stock [Member] Class C Redeemable Convertible Preferred Stock [Member] ASSETS Current assets: Cash and cash equivalents Prepaid expenses Due from the sale of assets - current portion Total current assets [Assets, Current] Investment in equity securities Property and equipment, net Other assets Total assets [Assets] LIABILITIES Current liabilities: Accounts payable and accrued expenses Accrued expenses - related parties Notes payable, net of discounts Total current liabilities [Liabilities, Current] Total liabilities [Liabilities] Commitments and Contingencies - Note 7 Class D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively STOCKHOLDERS' EQUITY (DEFICIT) Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (Deficit) [Liabilities and Equity] Preferred Stock Value Class B Convertible Preferred Stock [Member] Class D Convertible Mandatory Redeemable Preferred Stock [Member] Capital stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Revenue Operating costs: General and administrative expenses Research and development Total operating costs and expenses [Operating Costs and Expenses] Loss from operations [Operating Income (Loss)] Gain (Loss) on fair value adjustment of investments Gain on settlement of legal fees Interest expense [Interest Expense] Total other income (expense) [Nonoperating Income (Expense)] NET INCOME (LOSS) [Net Income (Loss) Attributable to Parent] INCOME (LOSS) PER COMMON SHARE: Weighted average number of common shares outstanding (Basic and Diluted) Basic and Diluted income (loss) per common share (Basic and Diluted) CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Equity Components [Axis] Preferred Stock Series B Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, December 31, 2020, shares [Shares, Issued] Balance, December 31, 2020, amount Net income Balance, September 30, 2021, shares Balance, September 30, 2021, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES: Net loss [Net loss] Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization Loss on fair value adjustment of investments [Gain (Loss) on Sale of Investments] Amortization of debt discount Gain on settelement of legal fees [Gain (Loss) Related to Litigation Settlement] Changes in: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Accounts payable and accrued expenses - related party Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from the sale of investments Proceeds from sale of assets held for sale Net cash from investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Repayments for note payable [Repayments of Notes Payable] Net cash used in financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE IN CASH [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] CASH, BEGINNING OF PERIOD [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid Income taxes paid BASIS OF PRESENTATION BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Significant Accounting Policies [Text Block] INVESTMENT IN IMAGION BIOSYSTEMS NOTE 3 - INVESTMENT IN IMAGION BIOSYSTEMS NOTES PAYABLE NOTES PAYABLE Debt Disclosure [Text Block] CAPITAL TRANSACTIONS CAPITAL TRANSACTIONS Stockholders' Equity Note Disclosure [Text Block] LICENSE AGREEMENT LICENSE AGREEMENT [LICENSE AGREEMENT] COMMITMENTS AND CONTIGENCIES COMMITMENTS AND CONTIGENCIES Commitments and Contingencies Disclosure [Text Block] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Schedule of Subsequent Events [Table Text Block] BASIS OF CONSOLIDATION USE OF ESTIMATES CASH AND CASH EQUIVALENTS CASH CONCENTRATION PROPERTY AND EQUIPMENT INTANGIBLE ASSETS DUE FROM THE SALE OF ASSETS MARKETABLE SECURITIES REVENUE RECOGNITION FAIR VALUE OF FINANCIAL INSTRUMENTS LEASES INCOME TAXES BASIC AND DILUTED EARNINGS (LOSS) PER SHARE STOCK BASED COMPENSATION RECENT ACCOUNTING PRONOUNCEMENTS Schedule of fair value measurement of assets and liabilities Schedule of basic and diluted earnings (loss) per share Schedule of changes to the investment in Imagion NOTES PAYABLE (Tables) Schedule of debt discount Summary of Company's stock option activity Exercise prices and weighted-average contractual lives of stock options outstanding BASIS OF PRESENTATION (Details Narrative) Accumulated deficit Working capital deficit SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Quoted prices in active markets for identical assets [Member] Level 1 [Member] Significant other observable inputs [Member] Level 2 [Member] Significant unobservable inputs [Member] Level 3 [Member] Investment in equity securities Numerator: Net income (loss) Denominator: EX-101.CAL 6 mhtx-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 mhtx-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 mhtx-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Entity Registrant Name	MANHATTAN SCIENTIFICS, INC.
Entity Central Index Key	0001099132
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		559,281,064
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	85-0460639
Entity Interactive Data Current	Yes
Entity File Number	000-28411
Entity Address Address Line 1	244 Fifth Ave
Entity Address Address Line 2	Suite 2341
Entity Address City Or Town	New York
Document Quarterly Report	true
Entity Address Postal Zip Code	10001
City Area Code	212
Local Phone Number	726-2107
Security 12b Title	Common Stock, $0.001 par value
Document Transition Report	false
Entity Address State Or Province	NY

XML 10 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 288,000	$ 232,000
Prepaid expenses	8,000	15,000
Due from the sale of assets - current portion	0	300,000
Total current assets	296,000	547,000
Investment in equity securities	1,064,000	2,901,000
Property and equipment, net	2,000	4,000
Other assets	2,000	2,000
Total assets	1,364,000	3,454,000
Current liabilities:
Accounts payable and accrued expenses	115,000	102,000
Accrued expenses - related parties	1,351,000	1,129,000
Notes payable, net of discounts	139,000	130,000
Total current liabilities	1,605,000	1,361,000
Total liabilities	1,605,000	1,361,000
Commitments and Contingencies - Note 7	0	0
Class D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively	1,058,000	1,058,000
STOCKHOLDERS' EQUITY (DEFICIT)
Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively	559,000	559,000
Additional paid-in-capital	68,996,000	68,996,000
Accumulated deficit	(70,854,000)	(68,520,000)
Total stockholders' equity	(1,299,000)	1,035,000
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (Deficit)	1,364,000	3,454,000
Class A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock Value	0	0
Series B convertible preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock Value	0	0
Class C Redeemable Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock Value	$ 0	$ 0

XML 11 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Capital stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	559,281,064	559,281,064
Common stock, shares outstanding	559,281,064	559,281,064
Class A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	182,525	182,525
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class C Redeemable Convertible Preferred Stock [Member]
Preferred stock, shares authorized	14,000	14,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	49,999	49,999
Preferred stock, shares outstanding	0	49,999
Class D Convertible Mandatory Redeemable Preferred Stock [Member]
Preferred stock, shares authorized	105,761	105,761
Preferred stock, shares issued	105,761	105,761
Preferred stock, shares outstanding	105,761	105,761

XML 12 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenue	$ 9,000	$ 0	$ 50,000	$ 50,000
Operating costs:
General and administrative expenses	175,000	175,000	548,000	565,000
Research and development	2,000	3,000	7,000	8,000
Total operating costs and expenses	177,000	178,000	555,000	573,000
Loss from operations	(168,000)	(178,000)	(505,000)	(523,000)
Gain (Loss) on fair value adjustment of investments	104,000	(978,000)	(1,809,000)	(3,069,000)
Gain on settlement of legal fees	0	7,000	0	7,000
Interest expense	(7,000)	(7,000)	(20,000)	(20,000)
Total other income (expense)	97,000	(978,000)	(1,829,000)	(3,082,000)
NET INCOME (LOSS)	$ (71,000)	$ (1,156,000)	$ (2,334,000)	$ (3,605,000)
INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic and Diluted)	559,281,064	559,281,064	559,281,064	559,281,064
Basic and Diluted income (loss) per common share (Basic and Diluted)	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.01)

XML 13 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Total	Preferred Stock Series B	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, December 31, 2020, shares at Dec. 31, 2020		49,999	559,281,064
Balance, December 31, 2020, amount at Dec. 31, 2020	$ 4,674,000	$ 0	$ 559,000	$ 68,996,000	$ (64,881,000)
Net income	134,000	$ 0	$ 0	0	134,000
Balance, September 30, 2021, shares at Mar. 31, 2021		49,999	559,281,064
Balance, September 30, 2021, amount at Mar. 31, 2021	4,808,000	$ 0	$ 559,000	68,996,000	(64,747,000)
Balance, December 31, 2020, shares at Dec. 31, 2020		49,999	559,281,064
Balance, December 31, 2020, amount at Dec. 31, 2020	4,674,000	$ 0	$ 559,000	68,996,000	(64,881,000)
Net income	(3,605,000)
Balance, September 30, 2021, shares at Sep. 30, 2021		49,999	559,281,064
Balance, September 30, 2021, amount at Sep. 30, 2021	1,069,000	$ 0	$ 559,000	68,996,000	(68,486,000)
Balance, December 31, 2020, shares at Mar. 31, 2021		49,999	559,281,064
Balance, December 31, 2020, amount at Mar. 31, 2021	4,808,000	$ 0	$ 559,000	68,996,000	(64,747,000)
Net income	(2,583,000)	$ 0	$ 0	0	(2,583,000)
Balance, September 30, 2021, shares at Jun. 30, 2021		49,999	559,281,064
Balance, September 30, 2021, amount at Jun. 30, 2021	2,225,000	$ 0	$ 559,000	68,996,000	(67,330,000)
Net income	(1,156,000)				(1,156,000)
Balance, September 30, 2021, shares at Sep. 30, 2021		49,999	559,281,064
Balance, September 30, 2021, amount at Sep. 30, 2021	1,069,000	$ 0	$ 559,000	68,996,000	(68,486,000)
Balance, December 31, 2020, shares at Dec. 31, 2021		49,999	559,281,064
Balance, December 31, 2020, amount at Dec. 31, 2021	1,035,000	$ 0	$ 559,000	68,996,000	(68,520,000)
Net income	(647,000)	$ 0	$ 0	0	(647,000)
Balance, September 30, 2021, shares at Mar. 31, 2022		49,999	559,281,064
Balance, September 30, 2021, amount at Mar. 31, 2022	388,000	$ 0	$ 559,000	68,996,000	(69,167,000)
Balance, December 31, 2020, shares at Dec. 31, 2021		49,999	559,281,064
Balance, December 31, 2020, amount at Dec. 31, 2021	1,035,000	$ 0	$ 559,000	68,996,000	(68,520,000)
Net income	(2,334,000)
Balance, September 30, 2021, shares at Sep. 30, 2022		49,999	559,281,064
Balance, September 30, 2021, amount at Sep. 30, 2022	(1,299,000)	$ 0	$ 559,000	68,996,000	(70,854,000)
Balance, December 31, 2020, shares at Mar. 31, 2022		49,999	559,281,064
Balance, December 31, 2020, amount at Mar. 31, 2022	388,000	$ 0	$ 559,000	68,996,000	(69,167,000)
Net income	(1,616,000)	$ 0	$ 0	0	(1,616,000)
Balance, September 30, 2021, shares at Jun. 30, 2022		49,999	559,281,064
Balance, September 30, 2021, amount at Jun. 30, 2022	(1,228,000)	$ 0	$ 559,000	68,996,000	(70,783,000)
Net income	(71,000)	$ 0	$ 0	0	(71,000)
Balance, September 30, 2021, shares at Sep. 30, 2022		49,999	559,281,064
Balance, September 30, 2021, amount at Sep. 30, 2022	$ (1,299,000)	$ 0	$ 559,000	$ 68,996,000	$ (70,854,000)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,334,000)	$ (3,605,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	2,000	1,000
Loss on fair value adjustment of investments	1,809,000	3,069,000
Amortization of debt discount	19,000	20,000
Gain on settelement of legal fees	0	7,000
Changes in:
Prepaid expenses	7,000	(5,000)
Accounts payable and accrued expenses	13,000	(12,000)
Accounts payable and accrued expenses - related party	222,000	228,000
Net cash used in operating activities	(262,000)	(287,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of investments	28,000	0
Proceeds from sale of assets held for sale	300,000	300,000
Net cash from investing activities	328,000	300,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments for note payable	(10,000)	0
Net cash used in financing activities	(10,000)	0
NET INCREASE IN CASH	56,000	13,000
CASH, BEGINNING OF PERIOD	232,000	353,000
CASH, END OF PERIOD	288,000	366,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	$ 0	$ 0

XML 15 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2022

BASIS OF PRESENTATION

BASIS OF PRESENTATION

NOTE 1 – BASIS OF PRESENTATION

XML 16 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

9 Months Ended

Sep. 30, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

USE OF ESTIMATES:

CASH AND CASH EQUIVALENTS:

CASH CONCENTRATION:

PROPERTY AND EQUIPMENT:

INTANGIBLE ASSETS:

License Agreements

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

MARKETABLE SECURITIES:

REVENUE RECOGNITION:

The revenue was generated was from minimum royalty payments from the license agreement.

FAIR VALUE OF FINANCIAL INSTRUMENTS:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2022 and December 31, 2021, consisted of the following:

	Total fair value at September 30, 2022		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	1,064,000	$	1,064,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

LEASES

INCOME TAXES

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended September 30, 2022 and 2021:

	Three Months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(71,000	)	$	(1,156,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.00	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.00	)

The following table shows the computation of basic and diluted earnings (loss) per share for the nine months ended September 30, 2022 and 2021:

	Nine months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(2,334,000	)	$	(3,605,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

STOCK BASED COMPENSATION

RECENT ACCOUNTING PRONOUNCEMENTS

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

XML 17 R9.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS

9 Months Ended

Sep. 30, 2022

INVESTMENT IN IMAGION BIOSYSTEMS

NOTE 3 - INVESTMENT IN IMAGION BIOSYSTEMS

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS

Below is reconciliation for the changes to the investment in Imagion for the nine months ended September 30, 2022:

Balance as of December 31, 2021	$	2,901,000
Change due to the sale of securities		(28,000	)
Change in the unrealized fair value of securities		(1,809,000	)
Balance as of September 30, 2022	$	1,064,000

XML 18 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

9 Months Ended

Sep. 30, 2022

NOTES PAYABLE

NOTES PAYABLE

NOTE 4 – NOTES PAYABLE

On September 30, 2022, the Company made $10,000 repayments and the notes payable balance was reduced to $140,000 from $150,000.

On October 24, 2022, the Company made $30,000 repayments and the notes payable balance was reduced to $110,000.

Notes payable	$	140,000
Less: Discounts on notes payable		(1,000	)
Notes payable, net of discounts	$	139,000

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 19 R11.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS

9 Months Ended

Sep. 30, 2022

CAPITAL TRANSACTIONS

CAPITAL TRANSACTIONS

NOTE 5 – CAPTIAL TRANSACTIONS

Stock Activity

During the nine months ended September 30, 2022, the Company had not issued common stock.

Options

At September 30, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0. A summary of the Company’s stock option activity and related information is as follows:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable		Aggregate Intrinsic Value
Outstanding as of December 31, 2021		26,500,000	$	0.04		6.06		26,500,000	$	15,000
Granted		-		-		-		-		-
Exercised		-		-		-		-		-
Expired		-		-		-		-		-
Outstanding as of September 30, 2022		26,500,000	$	0.04		5.61		26,500,000	$	0

Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of September 30, 2022 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.05		3,000,000		2.75	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.63	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.75	$	0.14		3,000,000	$	0.14
$	0.02		15,500,000		7.81	$	0.02		15,500,000	$	0.02

The Company did not recognize compensation expense during the three months ended September 30, 2022.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 20 R12.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT

9 Months Ended

Sep. 30, 2022

LICENSE AGREEMENT

LICENSE AGREEMENT

NOTE 6 – LICENSE AGREEMENT

During the nine months ended September 30, 2022, the Company received $50,000 as a minimum royalty payment.

XML 21 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTIGENCIES

9 Months Ended

Sep. 30, 2022

COMMITMENTS AND CONTIGENCIES

COMMITMENTS AND CONTIGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Legal matter contingencies

XML 22 R14.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2022

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

As of September 30, 2022 and December 31, 2021, the Company had accrued expenses to related parties of approximately $1,351,000 and $1,129,000.

XML 23 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2022

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

During October 2022, the Company sold 200,000 shares of IBX common stock.

During October 2022, the Company made $30,000 in repayment to a note holder and the notes payable balance was reduced to $110,000.

XML 24 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)

9 Months Ended

Sep. 30, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION

USE OF ESTIMATES

CASH AND CASH EQUIVALENTS

CASH CONCENTRATION

PROPERTY AND EQUIPMENT

INTANGIBLE ASSETS

License Agreements

DUE FROM THE SALE OF ASSETS

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

MARKETABLE SECURITIES

REVENUE RECOGNITION

The revenue was generated was from minimum royalty payments from the license agreement.

FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2022 and December 31, 2021, consisted of the following:

	Total fair value at September 30, 2022		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	1,064,000	$	1,064,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

LEASES

INCOME TAXES

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended September 30, 2022 and 2021:

	Three Months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(71,000	)	$	(1,156,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.00	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.00	)

The following table shows the computation of basic and diluted earnings (loss) per share for the nine months ended September 30, 2022 and 2021:

	Nine months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(2,334,000	)	$	(3,605,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

STOCK BASED COMPENSATION

RECENT ACCOUNTING PRONOUNCEMENTS

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

XML 25 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)

9 Months Ended

Sep. 30, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

Schedule of fair value measurement of assets and liabilities

	Total fair value at September 30, 2022		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	1,064,000	$	1,064,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

Schedule of basic and diluted earnings (loss) per share

	Three Months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(71,000	)	$	(1,156,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.00	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.00	)

	Nine months Ended
	September 30, 2022			September 30, 2021
Numerator:
Net income (loss)	$	(2,334,000	)	$	(3,605,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

XML 26 R18.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Tables)

9 Months Ended

Sep. 30, 2022

INVESTMENT IN IMAGION BIOSYSTEMS

Schedule of changes to the investment in Imagion

Balance as of December 31, 2021	$	2,901,000
Change due to the sale of securities		(28,000	)
Change in the unrealized fair value of securities		(1,809,000	)
Balance as of September 30, 2022	$	1,064,000

XML 27 R19.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

9 Months Ended

Sep. 30, 2022

NOTES PAYABLE (Tables)

Schedule of debt discount

Notes payable	$	140,000
Less: Discounts on notes payable		(1,000	)
Notes payable, net of discounts	$	139,000

XML 28 R20.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Tables)

9 Months Ended

Sep. 30, 2022

CAPITAL TRANSACTIONS

Summary of Company's stock option activity

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable		Aggregate Intrinsic Value
Outstanding as of December 31, 2021		26,500,000	$	0.04		6.06		26,500,000	$	15,000
Granted		-		-		-		-		-
Exercised		-		-		-		-		-
Expired		-		-		-		-		-
Outstanding as of September 30, 2022		26,500,000	$	0.04		5.61		26,500,000	$	0

Exercise prices and weighted-average contractual lives of stock options outstanding

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.05		3,000,000		2.75	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.63	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.75	$	0.14		3,000,000	$	0.14
$	0.02		15,500,000		7.81	$	0.02		15,500,000	$	0.02

XML 29 R21.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
BASIS OF PRESENTATION (Details Narrative)
Accumulated deficit	$ (70,854,000)	$ (68,520,000)
Working capital deficit	$ (1,309,000)

XML 30 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Investment in equity securities	$ 1,064,000	$ 2,901,000
Quoted prices in active markets for identical assets [Member] \| Level 1 [Member]
Investment in equity securities	1,064,000	2,901,000
Significant other observable inputs [Member] \| Level 2 [Member]
Investment in equity securities	0	0
Significant unobservable inputs [Member] \| Level 3 [Member]
Investment in equity securities	$ 0	$ 0

XML 31 R23.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net income (loss)	$ (71,000)	$ (1,156,000)	$ (2,334,000)	$ (3,605,000)
Denominator:
Weighted-average basic shares outstanding	559,281,064	559,281,064	559,281,064	559,281,064
Weighted-average diluted shares	559,281,064	559,281,064	559,281,064	559,281,064
Effect of dilutive securities	0	0	0	0
Basic earnings (loss) per share	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.01)
Diluted earnings (loss) per share	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.01)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 32 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2018
Common stock owned shares	51,766,508
Proceeds from sale of assets held for sale	$ 300,000	$ 300,000	$ 300,000
Remaining amount of assets			900,000
Cash FDIC insured amount	250,000
Cash exceeding insured amount	$ 34,000	$ 0
Adjusted asset valuation				$ 120,000
Sale of asset			$ 120,000
Income Tax Examination, Likelihood of Unfavorable Settlement	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Weighted average number diluted shares	28,922,917	28,922,917
Minimum [Member]
Property and equipment useful lives	3 years
Maximum [Member]
Property and equipment useful lives	10 years
In 2009 [Member] \| Patent license agreement [Member] \| Los Alamos National Security LLC [Member]
Licenses purchased price	$ 33,000
Amortization period	10 years
Fair value of common stock issued	$ 2,000,000
Annual license fee	$ 10,000

XML 33 R25.htm IDEA: XBRL DOCUMENT

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
INVESTMENT IN IMAGION BIOSYSTEMS
Balance as of December 31, 2021			$ 2,901,000
Change due to the sale of securities			(28,000)
Change in the unrealized fair value of securities	$ 104,000	$ (978,000)	(1,809,000)	$ (3,069,000)
Balance as of September 30, 2022			$ 1,064,000

XML 34 R26.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Change in unrealized gain in investment	$ (1,809,000)	$ (3,069,000)
Imagion Biosystems, Inc. [Member]
Change in unrealized gain in investment	$ (1,809,000)
Common stock owned shares	51,766,508
Trading price per share	$ 0.03
Fair value of investment	$ 1,064,000

XML 35 R27.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
NOTES PAYABLE
Notes payable	$ 140,000
Less: Discounts on notes payable	(1,000)
Notes payable, net of discounts	$ 139,000	$ 130,000

XML 36 R28.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended			9 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Oct. 24, 2022	Sep. 30, 2022	Oct. 17, 2019	Sep. 30, 2022	Sep. 30, 2021
Amortization of Debt Discount				$ 19,000	$ 20,000
Repayments for note payable	$ 30,000	$ 10,000		10,000	$ 0
Notes Payable	$ 110,000
Individuals [Member]
Secured note			$ 50,000
Price per share			$ 0.015
Interest rate			10.00%
Debt due date			October 17, 2022
Minimum [Member]
Notes Payable		140,000		140,000
Maximum [Member]
Notes Payable		$ 150,000		$ 150,000

XML 37 R29.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details) - USD ($)	9 Months Ended	12 Months Ended
CAPITAL TRANSACTIONS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
CAPITAL TRANSACTIONS
Number of Options, Outstanding Beginning Balance	26,500,000	26,500,000
Number of Options, Granted	0
Number of Options, exercised	0
Number of Options, expired	0
Number of Options, Outstanding ending Balance	26,500,000	26,500,000
Number of Options, exercisable granted	0
Number of Options, exercisable exercised	0
Number of Options, exercisable expired	0
Weighted Average Life
Weighted Average Life, Outstanding Ending Balance	5 years 7 months 9 days	6 years 21 days
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 0.04
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Expired	0
Weighted Average Exercise Price, ending	$ 0.04	$ 0.04
Aggregate intrinsic value
Aggregate intrinsic value, beginning	$ 15,000
Aggregate intrinsic value, granted	0
Aggregate intrinsic value, Expired	0
Aggregate intrinsic value, Exercised	0
Aggregate intrinsic value, ending	$ 0	$ 15,000

XML 38 R30.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details 1) - $ / shares	9 Months Ended
CAPITAL TRANSACTIONS (Details 1) - $ / shares	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of Options, Outstanding Beginning Balance	26,500,000	26,500,000	26,500,000	26,500,000	26,500,000
Exercise Price 0.05 [Member]
Number of Options, Outstanding Beginning Balance	3,000,000
Weighted Average Remaining Contractual Life	2 years 9 months
Weighted Average Exercise Price	$ 0.05
Number of Options Exercisable, Outstanding Beginning Balance	3,000,000
Weighted Average Exercise Price, exercisable	$ 0.05
Exercise Price 0.06 [Member]
Number of Options, Outstanding Beginning Balance	5,000,000
Weighted Average Remaining Contractual Life	2 years 7 months 17 days
Weighted Average Exercise Price	$ 0.06
Number of Options Exercisable, Outstanding Beginning Balance	5,000,000
Weighted Average Exercise Price, exercisable	$ 0.06
Exercise Price 0.14 [Member]
Number of Options, Outstanding Beginning Balance	3,000,000
Weighted Average Remaining Contractual Life	1 year 9 months
Weighted Average Exercise Price	$ 0.14
Number of Options Exercisable, Outstanding Beginning Balance	3,000,000
Weighted Average Exercise Price, exercisable	$ 0.14
Exercise Price 0.02 [Member]
Number of Options, Outstanding Beginning Balance	15,500,000
Weighted Average Remaining Contractual Life	7 years 9 months 21 days
Weighted Average Exercise Price	$ 0.02
Number of Options Exercisable, Outstanding Beginning Balance	15,500,000
Weighted Average Exercise Price, exercisable	$ 0.02

XML 39 R31.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details Narrative) - USD ($)	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of Options, Outstanding	26,500,000	26,500,000	26,500,000	26,500,000	26,500,000
Aggregate intrinsic value			$ 0	$ 15,000
Stock Option [Member]
Number of Options, Outstanding	26,500,000			26,500,000
Aggregate intrinsic value	$ 0

XML 40 R32.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT (Details Narrative)	9 Months Ended
LICENSE AGREEMENT (Details Narrative)	Sep. 30, 2022 USD ($)
LICENSE AGREEMENT
Minimum Royalty Payment	$ 50,000
Royalty percentage on dental products	10.00%
Royalty percentage on other licensed products	5.00%

XML 41 R33.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accrued expenses - related parties	$ 1,351,000	$ 1,129,000
Sole Officer [Member]
Accrued expenses - related parties	336,000
Chairman [Member]
Accrued expenses - related parties	939,000
Board of Director [Member]
Accrued expenses - related parties	$ 78,000

XML 42 R34.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended			9 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 31, 2022	Oct. 24, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Repayments for note payable		$ 30,000	$ 10,000	$ 10,000	$ 0
Notes Payable		$ 110,000
October Two Thousand Twenty Two [Member] \| Subsequent Event [Member]
Common stock sold	$ 200,000
Repayments for note payable	30,000
Notes Payable	$ 110,000

XML 43 mhtx_10q_htm.xml IDEA: XBRL DOCUMENT 0001099132 2022-01-01 2022-09-30 0001099132 mhtx:OctoberTwoThousandTwentyTwoMember us-gaap:SubsequentEventMember 2022-10-31 0001099132 mhtx:OctoberTwoThousandTwentyTwoMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001099132 mhtx:BoardOfDirectorMember 2022-09-30 0001099132 mhtx:ChairmanMember 2022-09-30 0001099132 mhtx:SoleOfficerMember 2022-09-30 0001099132 us-gaap:StockOptionMember 2021-12-31 0001099132 us-gaap:StockOptionMember 2022-09-30 0001099132 mhtx:ExercisePriceRangeSevenMember 2022-01-01 2022-09-30 0001099132 mhtx:ExercisePriceRangeSixMember 2022-01-01 2022-09-30 0001099132 mhtx:ExercisePriceRangeThreeMember 2022-01-01 2022-09-30 0001099132 mhtx:ExercisePriceRangeTwoMember 2022-01-01 2022-09-30 0001099132 mhtx:ExercisePriceRangeSevenMember 2022-09-30 0001099132 mhtx:ExercisePriceRangeSixMember 2022-09-30 0001099132 mhtx:ExercisePriceRangeThreeMember 2022-09-30 0001099132 mhtx:ExercisePriceRangeTwoMember 2022-09-30 0001099132 2021-01-01 2021-12-31 0001099132 mhtx:IndividualsMember 2019-10-01 2019-10-17 0001099132 2022-10-24 0001099132 2022-10-01 2022-10-24 0001099132 srt:MinimumMember 2022-09-30 0001099132 srt:MaximumMember 2022-09-30 0001099132 2022-09-01 2022-09-30 0001099132 mhtx:ImagionBiosystemsIncMember 2022-09-30 0001099132 mhtx:ImagionBiosystemsIncMember 2022-01-01 2022-09-30 0001099132 srt:MaximumMember 2022-01-01 2022-09-30 0001099132 srt:MinimumMember 2022-01-01 2022-09-30 0001099132 mhtx:InTwoThousandNineMember mhtx:PatentLicenseAgreementMember mhtx:LosAlamosNationalSecurityLLCMember 2022-01-01 2022-09-30 0001099132 2018-01-01 2018-12-31 0001099132 2019-12-31 0001099132 2019-01-01 2019-12-31 0001099132 mhtx:SignificantUnobservableInputsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001099132 mhtx:QuotedPricesInActiveMarketsForIdenticalAssetsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001099132 mhtx:SignificantUnobservableInputsMember us-gaap:FairValueInputsLevel3Member 2022-09-30 0001099132 mhtx:SignificantOtherObservableInputsMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0001099132 mhtx:QuotedPricesInActiveMarketsForIdenticalAssetsMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001099132 us-gaap:RetainedEarningsMember 2022-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001099132 us-gaap:CommonStockMember 2022-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2022-09-30 0001099132 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001099132 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2022-07-01 2022-09-30 0001099132 2022-06-30 0001099132 us-gaap:RetainedEarningsMember 2022-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001099132 us-gaap:CommonStockMember 2022-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2022-06-30 0001099132 2022-04-01 2022-06-30 0001099132 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001099132 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2022-04-01 2022-06-30 0001099132 2022-03-31 0001099132 us-gaap:RetainedEarningsMember 2022-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001099132 us-gaap:CommonStockMember 2022-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2022-03-31 0001099132 2022-01-01 2022-03-31 0001099132 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001099132 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2022-01-01 2022-03-31 0001099132 us-gaap:RetainedEarningsMember 2021-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001099132 us-gaap:CommonStockMember 2021-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2021-12-31 0001099132 2021-09-30 0001099132 us-gaap:RetainedEarningsMember 2021-09-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001099132 us-gaap:CommonStockMember 2021-09-30 0001099132 mhtx:PreferredStockSeriesBMember 2021-09-30 0001099132 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001099132 2021-06-30 0001099132 us-gaap:RetainedEarningsMember 2021-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001099132 us-gaap:CommonStockMember 2021-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2021-06-30 0001099132 2021-04-01 2021-06-30 0001099132 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001099132 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001099132 mhtx:PreferredStockSeriesBMember 2021-04-01 2021-06-30 0001099132 2021-03-31 0001099132 us-gaap:RetainedEarningsMember 2021-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001099132 us-gaap:CommonStockMember 2021-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2021-03-31 0001099132 2021-01-01 2021-03-31 0001099132 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001099132 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001099132 mhtx:PreferredStockSeriesBMember 2021-01-01 2021-03-31 0001099132 2020-12-31 0001099132 us-gaap:RetainedEarningsMember 2020-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001099132 us-gaap:CommonStockMember 2020-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2020-12-31 0001099132 2021-01-01 2021-09-30 0001099132 2021-07-01 2021-09-30 0001099132 2022-07-01 2022-09-30 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2022-09-30 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:ClassDConvertibleMandatoryRedeemablePreferredStockMember 2022-09-30 0001099132 mhtx:ClassDConvertibleMandatoryRedeemablePreferredStockMember 2021-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2022-09-30 0001099132 mhtx:SeriesBConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:SeriesBConvertiblePreferredStockMember 2022-09-30 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2022-09-30 0001099132 2021-12-31 0001099132 2022-09-30 0001099132 2022-11-14 iso4217:USD shares iso4217:USD shares pure 0001099132 false --12-31 Q3 2022

0.001

105761

250000

14000

182525

49999

105761

950000000

559281064

0 0 0 0

-1809000

26500000

0 0 0

0 0.04

0 0 0 15000 10-Q true 2022-09-30 false MANHATTAN SCIENTIFICS, INC. DE 000-28411 85-0460639 244 Fifth Ave Suite 2341 New York NY 10001 212 726-2107 Common Stock, $0.001 par value Yes Yes Non-accelerated Filer true false false 559281064

288000

232000

8000

15000

300000

296000

547000

1064000

2901000

2000

4000

2000

1364000

3454000

115000

102000

1351000

1129000

139000

130000

1605000

1361000

1605000

1361000

105761

1058000

0.001

182525

250000

49999

14000

950000000

559281064

559000

68996000

-70854000

-68520000

-1299000

1035000

1364000

3454000

9000

50000

175000

548000

565000

2000

3000

7000

8000

177000

178000

555000

573000

-168000

-178000

-505000

-523000

104000

-978000

-1809000

-3069000

7000

20000

97000

-978000

-1829000

-3082000

-71000

-1156000

-2334000

-3605000

559281064 559281064 559281064 559281064 -0.00 -0.00 -0.00 -0.01

49999

559281064

559000

68996000

-68520000

1035000

-647000

49999

559281064

559000

68996000

-69167000

388000

-1616000

49999

559281064

559000

68996000

-70783000

-1228000

-71000

49999

559281064

559000

68996000

-70854000

-1299000

49999

559281064

559000

68996000

-64881000

4674000

134000

49999

559281064

559000

68996000

-64747000

4808000

-2583000

49999

559281064

559000

68996000

-67330000

2225000

-1156000

49999

559281064

559000

68996000

-68486000

1069000

2334000 3605000

2000

1000

-1809000

-3069000

19000

20000

-7000

5000

13000

-12000

222000

228000

-262000

-287000

28000

300000

328000

300000

10000

-10000

56000

13000

232000

353000

288000

366000

NOTE 1 – BASIS OF PRESENTATION The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2021, filed on April 6, 2022. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented. Operating results for the nine months period ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements. As of September 30, 2022, the Company has an accumulated deficit of 70,854,000 and negative working capital of $1,309,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted. These factors raise substantial doubt about the Company’s ability to continue as going concern within one year from the date of filing these financial statements. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

-70854000

-1309000

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS BASIS OF CONSOLIDATION: The condensed consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary, Metallicum, Inc. All significant intercompany balances and transactions have been eliminated. USE OF ESTIMATES: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.CASH AND CASH EQUIVALENTS: The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows. CASH CONCENTRATION: The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2022 and December 31, 2021, we had cash balances of $34,000 and $0, exceeding the federally insured limits. PROPERTY AND EQUIPMENT: Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes. INTANGIBLE ASSETS: License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two (2) patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022 and December 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors. DUE FROM THE SALE OF ASSETS: Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2022 and 2021, the Company received $300,000 and reduced the amount due from the sale of assets to the balance of $0. MARKETABLE SECURITIES: The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended September 30, 2022, no allowance was recorded for credit losses. REVENUE RECOGNITION: The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable. The revenue was generated was from minimum royalty payments from the license agreement. FAIR VALUE OF FINANCIAL INSTRUMENTS: The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices for identical assets and liabilities in active markets;Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andLevel 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2022 and December 31, 2021 because of the relative short term nature of these instruments. During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of September 30, 2022, the Company holds 51,766,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss. Our financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2022 and December 31, 2021, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total fair value at September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted prices in active markets for identical assets (Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Total fair value at December 31, 2021</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Quoted prices in active markets for identical assets (Level 1)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> LEASES The Company leases a facility with terms of month-to-month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore, is not required to capitalize the lease. INCOME TAXES The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10, clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits. BASIC AND DILUTED EARNINGS (LOSS) PER SHARE In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2022 and 2021, there were 28,922,917 and 28,922,917, respectively, potentially dilutive shares that need to be considered as common share equivalents. As a result of the net loss for the periods presented, the potentially dilutive shares for the periods ended September 30, 2022 and 2021 are anti-dilutive. The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended September 30, 2022 and 2021: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(71,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,156,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> The following table shows the computation of basic and diluted earnings (loss) per share for the nine months ended September 30, 2022 and 2021: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Nine months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,334,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,605,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> STOCK BASED COMPENSATION The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as, a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.RECENT ACCOUNTING PRONOUNCEMENTS In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has not completed its assessment of the standard but does not expect the adoption to have a material impact. The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

The condensed consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary, Metallicum, Inc. All significant intercompany balances and transactions have been eliminated.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of September 30, 2022 and December 31, 2021, we had cash balances of $34,000 and $0, exceeding the federally insured limits.

250000

34000

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.

P3Y

P10Y

License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two (2) patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022 and December 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At September 30, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

33000

2000000

P10Y

10000 Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2022 and 2021, the Company received $300,000 and reduced the amount due from the sale of assets to the balance of $0. 120000 120000

300000

900000

300000

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the three months ended September 30, 2022, no allowance was recorded for credit losses.

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable. The revenue was generated was from minimum royalty payments from the license agreement.

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices for identical assets and liabilities in active markets;Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andLevel 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of September 30, 2022 and December 31, 2021 because of the relative short term nature of these instruments. During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of September 30, 2022, the Company holds 51,766,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss. Our financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2022 and December 31, 2021, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total fair value at September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted prices in active markets for identical assets (Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Total fair value at December 31, 2021</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Quoted prices in active markets for identical assets (Level 1)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

51766508 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total fair value at September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted prices in active markets for identical assets (Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Total fair value at December 31, 2021</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Quoted prices in active markets for identical assets (Level 1)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1064000

2901000

The Company leases a facility with terms of month-to-month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore, is not required to capitalize the lease.

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10, clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2022 and 2021, there were 28,922,917 and 28,922,917, respectively, potentially dilutive shares that need to be considered as common share equivalents. As a result of the net loss for the periods presented, the potentially dilutive shares for the periods ended September 30, 2022 and 2021 are anti-dilutive. The following table shows the computation of basic and diluted earnings (loss) per share for the three months ended September 30, 2022 and 2021: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(71,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,156,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> The following table shows the computation of basic and diluted earnings (loss) per share for the nine months ended September 30, 2022 and 2021: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Nine months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,334,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,605,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>

28922917

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(71,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,156,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Nine months Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,334,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,605,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>

-71000 -1156000

559281064

-0.00

-2334000 -3605000

559281064

-0.00

-0.01

-0.00

-0.01

The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as, a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has not completed its assessment of the standard but does not expect the adoption to have a material impact. The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS As of September 30, 2022, the Company owns 51,766,508 shares of Imagion, resulting in a non-controlling interest of Imagion’s issued and outstanding common stock. Based upon Imagion’s trading price on September 30, 2022, approximately $0.03 per share, the fair value of the Imagion shares was approximately $1,064,000. During the nine months ended September 30, 2022, the Company recorded a loss on fair value in its investment of $1,809,000. Below is reconciliation for the changes to the investment in Imagion for the nine months ended September 30, 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change due to the sale of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in the unrealized fair value of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,809,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

51766508 0.03

1064000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change due to the sale of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(28,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in the unrealized fair value of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,809,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,064,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

2901000 -28000

-1809000

1064000

NOTE 4 – NOTES PAYABLE On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 1 million shares of IBX common stock. The amortization of debt discount for the nine months ended September 30, 2022 was $19,000. On September 30, 2022, the Company made $10,000 repayments and the notes payable balance was reduced to $140,000 from $150,000. On October 24, 2022, the Company made $30,000 repayments and the notes payable balance was reduced to $110,000. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Discounts on notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable, net of discounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">139,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

50000

October 17, 2022

0.10

0.015

19000

10000

140000

150000

30000

110000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Discounts on notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable, net of discounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">139,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 140000 -1000

139000

NOTE 5 – CAPTIAL TRANSACTIONS Stock Activity During the nine months ended September 30, 2022, the Company had not issued common stock. Options At September 30, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0. A summary of the Company’s stock option activity and related information is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">WeightedAverage Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">WeightedAverageRemaining Life</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.06</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.61</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of September 30, 2022 are as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td> </td><td> </td><td colspan="2"/><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Options Outstanding</td><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Options Exercisable</td><td> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Exercise Price</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Number Outstanding</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Weighted Average Remaining Contractual Life</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Weighted AverageExercise Price </td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Number Exercisable</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Weighted AverageExercise Price</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;">$</td><td style="width:11%;">0.05</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">3,000,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">2.75</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;">0.05</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">3,000,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;">0.05</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">$</td><td>0.06</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">5,000,000</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">2.63</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.06</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">5,000,000</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.06</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">$</td><td>0.14</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">3,000,000</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">1.75</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.14</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">3,000,000</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.14</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">$</td><td>0.02</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">15,500,000</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">7.81</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.02</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">15,500,000</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.02</td><td> </td></tr></tbody></table> The Company did not recognize compensation expense during the three months ended September 30, 2022.

26500000

0.04

P6Y21D

26500000

15000

26500000

0.04 P5Y7M9D

26500000

<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td> </td><td> </td><td colspan="2"/><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Options Outstanding</td><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Options Exercisable</td><td> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Exercise Price</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Number Outstanding</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Weighted Average Remaining Contractual Life</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Weighted AverageExercise Price </td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Number Exercisable</td><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Weighted AverageExercise Price</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;">$</td><td style="width:11%;">0.05</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">3,000,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">2.75</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;">0.05</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">3,000,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;">0.05</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">$</td><td>0.06</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">5,000,000</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">2.63</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.06</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">5,000,000</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.06</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">$</td><td>0.14</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">3,000,000</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">1.75</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.14</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">3,000,000</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.14</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">$</td><td>0.02</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">15,500,000</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">7.81</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.02</td><td> </td><td> </td><td> </td><td style="vertical-align:bottom;">15,500,000</td><td> </td><td> </td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;">0.02</td><td> </td></tr></tbody></table>

3000000

P2Y9M

0.05

3000000

0.05

5000000

P2Y7M17D

0.06

5000000

0.06

3000000

P1Y9M

0.14

3000000

0.14

15500000

P7Y9M21D

0.02

15500000

0.02

NOTE 6 – LICENSE AGREEMENT On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with the Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the nine months ended September 30, 2022, the Company received $50,000 as a minimum royalty payment. 0.10 0.05

50000

NOTE 7 – COMMITMENTS AND CONTINGENCIES Legal matter contingencies The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted, when there is more information available of when an event occurs requiring a change.

NOTE 8 – RELATED PARTY TRANSACTIONS As of September 30, 2022 and December 31, 2021, the Company had accrued expenses to related parties of approximately $1,351,000 and $1,129,000. As of September 30, 2022, the amounts are due to the Company’s sole officer for compensation of $336,000 and the chairman of the board for compensation of $939,000 and the members of the board of directors of $78,000.

1351000

1129000

336000

939000

78000

NOTE 9 – SUBSEQUENT EVENTS During October 2022, the Company sold 200,000 shares of IBX common stock. During October 2022, the Company made $30,000 in repayment to a note holder and the notes payable balance was reduced to $110,000.

200000

30000

110000

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )N*;E4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " ";BFY54O,1&^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*';+#B;U96.G%@8K;.QF;+4UBV-C:R1]^SE9FS*V!]C1TN]/ MGT"MB=*$A,\I1$SD,-^-ONNS-''#3D11 F1S0J]S71)]:1Y"\IK*,QTA:O.A MCPBB:>[!(VFK2<,$K.)"9*JU1IJ$FD*ZX*U9\/$S=3/,&L ./?:4@=<U"G*M_8N<.L$MRS&Y)#<-0#ZLY5W;@\+;;OLSK5J[/ MI'N#Y5=VDLX1-^PZ^77U\+A_8DHT0E2<5WR]%T**1J[Y^^3ZP^\F[(-U!_>/ MC:^"JH5?=Z&^ %!+ P04 " ";BFY5F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M )N*;E7!38.QH 4 . = 8 >&PO=V]R:W-H965T&UL MM9E=<^(V&(7_BH9V>K7$E@PD; DSX$VZ3'?9;*#MI)U>*+8 3VS+E65(_GTE MV]CLCOSB\2PWP5_G1(\E2T?2Y,#%2[IC3*+7*(S3V]Y.RN2]9:7>CD4TO>() MB]6=#1<1E>I4;*TT$8SZN2@*+6+;(RNB0=R;3O)K#V(ZX9D,@Y@]")1F443% MVYR%_'#;P[WCA<=@NY/Z@C6=)'3+5DS^D3P(=695+GX0L3@->(P$V]SV9OB] MZ^2"_(D_ W9(3XZ11GGF_$6?+/S;GJU+Q$+F26U!U<^>N2P,M9,JQW^E::_Z MGUIX>GQTO\_A%S<]Y+,-S4+YR \?60DTU'X>#]/\+SH4 MSP[L'O*R5/*H%*L21$%<_-+7\D6<"!2H64!* ?E.@ <- J<4.#EH4;(1J11/$NAI74JB[@=+)J6I[UA> MJ9\7>M*@'Z///):[%-W%/O._U5NJ+%6!R+% Y?TQLJ' 9F!_T=OD\3ZK';GOK0 M4B;VK#?]Y2<\LG\UX?T@LV]@!Q7L '*?WL4RD&_HD6T#C1M+M*01,R'#/I]G MRX^S]7JV1"MW<;=<+^X7[NH=6BS=*Q,R:-81>5@A#]L@NRQ6P"%:J%;\BGYG M;R9HV,FV;6R/Q]@QMEI0VY%Q5#&.P))]X%ZF>EZ)UF^)L39A.;;[7TU(H*HC MTG6%= V6::9X_)SI/J1;$Q.LW] P-;T*%Y1UA+JIH&[ 0KF9$#E2D'JJ+3XQ M*G2WBE3';JPVV*W?QZ3O8!,D*.P(.:X@QVT^N%5$PQ#-LU3=3HWC#FPC16:L M/U#5$0W;]6!JMX+;J5B"7!XE-#;V)&=L&ELGK.N*=Y(5Y 4-BP&134=04E-2AI-2J4'^0C2[B0FG@EJ6LPPT& MXT0],CPP$7 ?[&W.6%6YK3&XP09=6>ML@UN%F_L@5('.59!;+LQM%O99\KA/ M/4]-1(0R\0M#(^\E<@VN@PV&\TA5M^5P4E;QO;IL;L"PW5?'R'B)7(/K8(-; M)IO3(;.9$#9K;+>7"#JX3CH8CBK'OHA'D9KVKB3W7M0 HV=KZ$LF4TEC7_5, M1MX?%&;*UU"X#7,WO3JPGPZ'8W*#[=%@8NU-C'7PP7!6*1D7L<>%ZFII/L/7 M?2U3W)F*YIK?-W=+L/.'.R/+)1(0KB,0;I6!UO05+7S5?(--X!7,RRQZ-O8F M\S.6-\.^/1C9(V=LY+U$+")U+"*M8M$BEDP4ZS9ZE*''\=6$>\:Q83B%55TY MZWQ$6N4C/2( -7G&1,TC^^1F@(W)'=9V!:QS$6F5BV:^K]S3ZO>3>@R9RCL_ MXT<& _6V-BI#SO;&' CKN_+6^8C H0;B-8T5\S-^JRQ071IQ!N;*O41 (G5 M(JT"TA'2U2=?!%KS0VQ$/1.3V $]3?-06-85L0Y&!,XRW]7E U R.)+#)-1GU";:OC7R72$"D M3D $CBLKYF5"5QTFSV@=R-!<=;#):21^AWZVKU0318F: >QIV/!57B('.74. M,V:-:R>PKBMD'8*<5B'HV/44*5Z-(P^"[X/8,U;T M&HSX1^0-W?<"Z/)_H?5)NZT_\! M4$L#!!0 ( )N*;E7G?R2D,08 -(< 8 >&PO=V]R:W-H965T&ULK5EM;]LV$/XKA#>L'>#4$F7YI4L,.+:+&DN3+'8[K,,^,!(= M$Y5$E:239K]^1TF5K(IB[,$?$NOE[O0<>;SGH73^Q,47N:54H6]QE,B+SE:I M]&VO)X,MC8E\PU.:P)T-%S%1<"H>>C(5E(294QSUL.,,>C%A26=RGEV[%9-S MOE,12^BM0'(7QT0\7]*(/UUTW,[W"W?L8:OTA=[D/"4/=$75Q_16P%FOC!*R MF":2\00)NKGH3-VW,\_3#IG%)T:?Y-XQTJG<<_Y%GRS#BXZC$=&(!DJ'(/#S M2&]$9=5!(-V07J3O^ M])X6"?DZ7L CF?U'3X6MTT'!3BH>%\Z (&9)_DN^%0.QY^#V6QQPX8 /=? * MAVSD>CFR+*TY461R+O@3$MH:HNF#;&PR;\B&)7H:5TK 709^:C*[N9XOKE>+ M.8*CU__SK>4_!0[5K+R@><)D_ M +<\8$73-\ASN@@[&!O<9W;W.0W WBMH2EB(Z#=H3Y(: >81_+TG&^ UC5R_%9U?HO.MZ.8[BC:"QTAM M*9(PA(AOB@*"E1$4%95RH1N3";K?0/4C[J:%YSBMP :8H.AU_?;Q\[=(T;W M(*:(&+EG45:+1KHHPIR(+TX5K9YTQ8ZNE9 FTR#@.V (E))G<@^=3IP<2T557.?:R6[Z TCHS()&1,&EE(BV3E($K=>9[QIP M&PQ=Z":MP"OJ<^W<=\T5+<<[:R*:7D(F\YDPHC;0G#CN8:Z"-0 M(M,M \3\'HV3@P36:%R ;I>(!A?9 J&G;' M5B99K6]FO[^_N9HO[E:OT.*/C\OU7^CU?/%N.5NNS5LJ*[$?S2DGBE;?<%5< MC^U"F2H#PS1IX MV:X^!I68P%;>GDS#D.G= 70AO=$Y8\E90%(&7112(5\5>PDCZ":;GP&;FRK"P/N.U[ZGQ!7O8SOOKV_6TRMTM9Q>+J^6Z^5B MU44?%I\_3Z^7UXOO36)Z/4CO#S2^I^(?8PK6\$>_A#E1M/I@5.H##T[<_[%5SAR=_HFBU=.O1 VV MBYH?Y_T3B7;4F/7+&L9J4L=7:1ALUS K*K2ZND3!7K&FQQ2K-?[1LW6B:/71 MJ,0*/K58P2<5*Z>*5G]C6HD5SRY6#BY6KRD5&N]*;29U?)60\.Q"(F^L,W17 M"NK_W6/M3SIVWDX5K3XNE5KQ[._UCR];[Z3O^4\5K9[^WIM^N_PYO&R;+_ ; M96LSR?'U]CXXZ:]]'XAX8(E$$=V C_-F"#4O\@]H^8GB:?8-ZIXKQ>/L<$L) MR#1M /Z>Y_^NH$!6YA&R9POE,:JXE<% MCP\R/%+VS'< GV/PIB/K)T0R9UM\_4.(L)O: *Q_&9#642$7+*MS1,&Q$^3 MHM!V':=K1R2(K?$PW;=@XR'=BS"(8<$0WT<183_N(:3'D86MEQU/P78GU Y[ M/$S(%I8@?D\63*[LHHH?1!#S@,:(P69D3?#=U$T3TH@_ CCRDVVD6EE1^JP6 MG_V1Y2@B"&$M5 DB/PXPA3!4E23'/WE1JSBF2CS=?JG^,6U>-K,B'*8T_#/P MQ6YD]2WDPX;L0_%$CY\@;\A3]=8TY.D[.F:QW9Z%UGLN:)0G2X(HB+-/\CT? MQ$D"[KR2X.8)[J4)MWG";=IH1I:V-2."C(>,'A%3T;*:VDAGDV;+;H)8G<:E M8/+;0.:)\?3KXVS^N)S/D-Q:?OWR>3;Y)A?WDR^3Q^D<+3_-Y]^6Z)<%81"+ M'8A@3<)?T0?T#MF([^1>/K2%Y%#5['5^S/OLF.XKQUQ"MU7AL!20)!0B1GO7Y^GW>%$L+0@81[J.LO M*]A+"RJA',;.C>-(F,-I&TU1&NUM07MKIJ51)"]_'9;LQ8ZRX%_PZVBS@MX) MQ\!SLM<9\261&G6GH.Y<3QUPOJ\G[E0X/&_@]K'3[9P17Q*I$7L%L7<]L?P= MY(+$?A!OZ["]B[$OB=2PNP5VUXP=$L[1!$UI? F@E4(:"%_&8$Q\-%2=8/^ M>H!H!>SONA:,U96GW/&$K&%D2=/@P Y@C7_^"7>=W^IT_$;%M$'TBD'TC(,H MF[Y&*KW*><%]UW.]L]/7&*8A]POD?BODUW72KW"<*]H4H4$."LA!*\@&:0P: M24T1&BEV2F]S+A##%#V!#_+N1VFAK2[,1[I6&&]539_+B>?C_T$;>5'MJN]4 M/:0Q3(0%31>=,40'+0T:FQVZI4)PU7PKM*80G;8T9MS@S*E& M[ML+PUC^:F&\435]&*7G8[/IMQ1&U4BI>%>K91/,L:_P=02P,$% @ FXIN M5:QRP%#_! 1!8 !@ !X;"]W;W)KSPY>P+VV12T!Z;_O^H'!D3!, MZR_XP=E=G;,K::W^GB4_^1I D(\HC/E 6PNQ>=!UOEA#Y/%[MH$8_UFR)/($ M/B8KG6\2\/S,* IUTS#:>N0%L3;L9^]>DF&?;448Q/"2$+Z-(B_YYPE"MA]H M5#N\> U6:Y&^T(?]C;>"&8BWS4N"3WKIQ0\BB'G 8I+ 7=E*##/%G M 'M^ MOV3DD-A2O;/\-"D)VZF_!0I[]DGV.[5@:66RY M8%%AC".(@CB_>A^%$"<&Z$=M8!8&YF>#UAD#JS"PKHW0*@Q:UT:P"X.,NIYS MSX1S/.$-^PG;DR1%H[?T)E,_LT:]@C@ME)E(\-\ [<1P-)TX[F3F.@3O9M/O MS\[C'!]F<[R,WSUN$,-O?$ M,GXGIF&:BO&,KC>G*CK_+[K[GZ-7Q+#*HK R?U;S1:$JA3Q82QTL70D?^,9; MP$##I8Y#L@-M^-LOM&W\H$(R-L0_+C7D)5R-DE.;NV'*<;2#P1Q"NR8%SP M!Q5+N\D::]*9TZ0SMR%GE32TRS2T:VOL*\28AY!XL4\\'_>B@(LT+SL@\(&- M"P>NRDSNU#XI"=JQY0J\#N;(,+O5E>M0 6O;9PNQ4RK0N3#+.'C)8IU)X..4 M"]D&FR:AHMV11F#*I&60)5.601V9L SJGJ7;+>EV:^G.F%JX!UK+,"]$H!>K4"?&>N 6<^']A M4YH6/6%+$L0[R)^4NA11*DDV6K(N"MQ=3R6,"DB[AKRAN2JD9;1[Y\4YZ9CI M97%0%0Y"A'"0(H053I8EJ"=%X?)T.)((,D2>-LYE1^XE1U7:YI&V64O[.1: MFXHX3'XE35-673'WKX,Y*IBI:#HNXZJ4CVTPK>W9#@N@6$."I;Y@$9";@KWZ MF\>2!M)3T9=A9\I= :1=4U7N"J1E=,WS(AP[2UK?6D[<.7F>C*9C%U>$Z6RF M9BXW?G<=JJ"NP%%JMQ7<%4C3LN35PU4AK;9Q?KNGQ\:3UG>>%=X$/WCP@V@\ MGD[([-OCJZML1&FCG6BCWIQ&O;E->:OFYMB-TOIV]$=V!@38B^YP;UX!B;?1 M.TY47(MQID;I KWV,#!A6\$%=BUI"W/SY/%@D?4P3A!NSWVQ4D7_:/?,+C7: MK<\5?374N1[J7@6M"G=L8FE]%RM)4*YM8;;A8ZM34?!JT3J7/B)'ER'.98A; M0+JG$]ZX-^@G8?234[$(DE5V',F1VC86^5E(^;8\\GS,#OH^O7^B#R.J>.^D M1Z39*=S1?7Z^.O:251!S; J6&,JX[V BD_S(,G\0;).=R;TS(5B4W:[!\R%) M ?C_DC%Q>$@#E ?'PW\!4$L#!!0 ( )N*;E6&PO=V]R:W-H965T&ULO9MM_"N-VVMS,.4828'QU M/)/8,)?V+DGCI)V^)+:2,,>#"SBY?OL*S(&)5D@^:^Y>7$S\UZ[87:WT"_;T M-I,9^3:.@^R_"QJEKV<#-/CVB]OP MZ;DH?S&:33?!$UW2XGYSD[&K46-E'<8TR<,T,3+Z>#8X1Q]\,BX'5(J_0OJ: M[[TVREMY2-,OY<7E^FQ@EC.B$5T5I8F _7BA/M+XAN[2W2J.\^M]XK;7F MP%AM\R*-Z\%L!G&8['X&7^M [ U 1# UP/PFP'8%@P@]0"BZL&J!UAO/8P% M ^QZ@/UF@"6Z::<>X%2QWP6KBO0B*(+9-$M?C:Q4,VOEBRI=U6@6X# I*VM9 M9.S=D(TK9O/KJX5WM?06!GNUO/YTN3B_8Q?+._;CLW=UMS2N?79U/?_CX_6G MA7>[_-7P_KR_O/O'.%EX_N7\\NZ=<7*?!-MU6-#U.V-HW"\7QLG/[Z:C@DVO M=#):U5.YV$T%"Z9REQ9!! R;]P^[8:5(LXRNC661KKX82YJ%-#_^CS-0L!6RQ!9-P$X7IXF1CS8!/"]^3WV[JE!6L*[):\($O" MY"DW3LY7JVV\C0(696-!'\-56+R)\8BEOLD_;O*/*T^6P--%$ 7)BKYG-ESGDE?9]@2[R'2LKM+3.3E?D[%.LDB3 M+/+=R0KB=)L42LG:.7'VX^N,+=,TNW&;\[HWB@6O8#G@#'F\S'$G$X<3^KQP MZ%@NR^F>LA,YJXF%C2>$@5'N_J;0RDD^D$ MP&X"8*N5SI)NBKIVS*I$T/Y"_QQD3>T@*%2]7@Y=Z+;20N=5HH6N :YTWJ%@I?-"MM+'UEA8Z.,F=.,? ML:'U.CFTSL=*=0F1VQH$]XM<4R;CTBODP,K::'3F*?3F*_)6"=3R&P1R]2Q][)W M3YLW0'SJ=7-H4ZJMR;H2(!.U):WS\W59ZR9MCXN1CBU8GC3$G^=,A^\I\UK8 MUYT "=B> )^"_@0HAXYKN8ZP0:&6+)$.M)2>8?J]'%SU:G )R(15KQ4O=5GK MYJP%3*2#,.4Y(XH'3R1G3$ "%SWO4U3TO%)R^$0M9Z)C0!/Q<#?$MDN P,AA M4R[Q ']<,!2FU(U%BYQ("W/^ODTD+50K="(UZ@1DP@Z@E3MU6>LFK25/I 4] MY4GC"0]C#!Q!D1P^ 0G< I3Q$U .G3$IJUY4]BV HGX"E;0 'O.&"-G\'.?] M;@X]G&NUYFFUYJO$I)N,%C"1(F$>>_;N=7-P#P*(%>I!O$S8@W3.S]=EK9NT MEFU1/]QJ.WOS'"PX>T_D/8B7P#V(]RGJ00"E]Y^]<8N<6!$YE?\*!@:PW\O! MSW74B!.0"9_L:"5.7=:Z.6N)$RL2I_(?P^"<09?8#9__&BWFD*T_]0%RP/"Y2B0>XXV(AGU$W$BW&846,4W_: M@\&8];HY>/T#5 BM?UXF7/\ZY^?KLM9-6HN.N!\=O^.A#YPTGNB("[ WEB,F M(('7/^]2M/X!W'0FR.FI^I8WL2)O'KGI:<5-K(:;@$Q8]%IQ4Y>U;LY:W,2* MN'GDIL?SGD],F((&+7IDV :5LTVMI$Q]#FQ@@*TR@#S?TNSF4-K5:\[1: M\W59ZR:L)5*LG4CA-J^52+$:D0(R89O22J2ZK'63UA(IUDZD<-( YD-X B I MEB,I(($;E3*20M,;FZXM_OP1:9&4Z$!2Z>FFW\NA94_4D!20BZ_Q\7=:Z M.6N1E.A 4GG.>.@#3Z1$3J2 !/[(H3*1 DK)B92T1$J.(5("\!]R$/"G8")' M4KG$ _QQP5"84C<6>Y]=U<*D^P\6X&+2RJ1$C4D!F; !:&527=:Z26N9E&AA M4GG2 .Q#&$,]0$ZE@ 3N @#/?<,Q L)BR\,B ME7B -RX4T@EUX]"2'CGBP>(!Y]Y^-P>O?^ CLM#ZYV7"]:]S?KXN:]VDM71) M%#]->^2YMW;C=-<_=.X%E%RA\Q)X_?,ZT?H'IB.'7Z>PB0W M(OK(QIJG8U8CV>[K;+N+(MU47[]Z2(LBC:N7SS18TZP4L/>PTY?[]6<#A5",TY7R)0$S,SPSXYG'S/"%)K_8#H"CURB,V4UKQ_G^ MNMUFW@XBPB[I'F+Q9$.3B'!QFVS;;)\ \5.E*&QCP^BV(Q+$K=$P75LFHR$] M\#"(89D@=H@BDKS=0DA?;EIFZWUA%6QW7"ZT1\,]V8(+_'&_3,1=N[#B!Q'$ M+* Q2F!STQJ;UQ//K=^OSU'GAS!-A,*'AS\#GNYM6OX5\V)!#R%?TY3OD M#G6D/8^&+/U%+[FLT4+>@7$:YW2GZ M\N?789L+*-)@V\M?>YN]%C>\=H >:,QW#,UB'_RJ?ENX4/B!W_VXQ5J#+NPO MD65\0]C 6(%G\GEU4P/'*L)JI?:LIK"6$9NO%@]HL9RMQFO;N4/CR=K^8:_M MF7NM"EMF]DIM5M;T-=L3#VY:HF@9),_0&OWUA]DU_E;Y?"9CE0A<%1&XTED? M.:(%A90QE9.99C?5E'WF>72!+>O*,(QA^_G8 86@U34ZQX(5<)T"7$>;GK'_ MCR@MT8TX0YR*=N31V M"0+% '<0>C0!]D>B_RL=RT2-LAPX,?/$8B2::$![$ MVZP+!3P ILQFYYS9/).Q2L"Z1<"ZVFQ.01CU I*UWMA')*()#_Y+%U2>9^8Z M1YG#]?36A0'S*.'F*OP]NMX%6CK4C(=#5@' M!=:!%NL=D;40(P:<"UY^#W (6Q*B#8 ROH,:DH]8ZQ*]1JBF4?*_(.Q)O M@8GT*RLUUSY3J9[+6M77(TXWM8E9)K G@8_@59SVF#H/N8G&,.>.U*4NFMNO MB4N$6+_-O71#,[0G;^1)--ZTIWA> MBY-1 B$1AR0AEO WI2-6O22QHDF6=EY'-9JT:AY&133\K+A'H /D.;A$:([P Q M(G;D:8XS%>S<5^2O+M:4N9*=33T]5S&_XR5,< A#.PA])#Y-TW4EV.5H(5W[)#O]QD,>7PWL95ON?6JARBV&P*N8:$X9+! ML9[!:\UY$\1$?**C$D]5L[,[$13HV4&*L MDW.GJX!XBNJK,$L*QWH*E["^H=O9G>TXL@06P%GG6MQ7M!B%G-7M-N,L*1GK*=E]7"[OTY'1^!Y-;7=R MOW ?5[/*^$ALBOEB]3!>VPM'V6[P6>GY7-:J$2GI&>OIV8XY"+LRU!ZA,YF M>\5J,1,>IY/0#^NWYO4DF^R69K)!\P-)MD',Q%?G1I@T+GLB5DDVN\UN.-VG MX\\GRCF-TLL=$!\2*2">;ZC@@?Q&OJ"8H(_^!U!+ P04 " ";BFY5]R'_ M(E\' #($@ & 'AL+W=OKZM6KTSK=6G?G2Z(@[BMM_-FH#*'^-)WZK*1*^HFMR>!-85TE V[=>NIK M1S*/0I6>+F:S=]-**C,Z/XW/OKGS4]L$K0Q]<\(W527=[I*TW9Z-YJ/NP7>U M+@,_F)Z?UG)-2PI_U-\<[J:]EEQ59+RR1C@JSD87\T^7QWP^'OA3T=8/K@5[ MLK+VCF]N\K/1C &1IBRP!HE_&[HBK5D18/S=ZASU)EEP>-UI_S7Z#E]6TM.5 MU?]5>2C/1A]&(J="-CI\M]O?J/7G+>O+K/;QK]BFLXO%2&2-#[9JA8&@4B;] ME_OZ3]]2!?5',8Y-?;']=B+G[Y MZ<-B/C\1!TV)'R4)%#JMK3)KT1C9Y"I0+I0)Y%0E"F6DR934P@<9",49O"CE MAL2*R A8JZ6+YU%NF74Y3A,R.I1B38:2 M$:QV4<>2LL:IH&"=9:[OLU*:-8DK6U7*Q_[S+R9N,3M97E_%J_G)OR?B(OH( M_'HW9D6>#C.46V%L -1,-SD)L"!L$2WGRF?:^@9A0HO[NU$NH7HU6V":]?QA M8IR6;-.S\HL*!&8R,I+9"F?#87 3#CJ OS+8OK2-!D02/ +8?&;-7XU)/;:/ M2J?KH [FF ^!$X#%E:-@.W9R 3U=#/\3\?/9'4DGB)N+^$P952MRXF@>VP/^ M%DHGP0M0H\6[U#8FXB:Q8VME&!YXJ:3!K&$<,6*O=;MHG%'HLKE@M/!Z&$N9 M_X5&'0^.N^!N2Y65 L7 -Q*N(GDU.$.B.0ZAD0%!'PL#9[S'.(R>(EY2N0?# M79H@/3!E?,]&A[7&7YN+6.5XE$_$+1[)F"3[,@9=0E2I2[=RB<\EYU!!ZMQZ?.D\.A#5M%<;\B 4/"S';$JL&%12(^4Z+[ MG:>P-J3,_4<%.UE.7E.<%[&:GX8H92\:5"W-+O(@8\]M*FYWL([-1&4J9M#[ MV?C#V^/Q;#:+#AA:IS#ROL3H,EFK(*/#/\_'1[./?'0B+BF3C>^B[5.<5&RT MCZUOE=8=&2B&= ;Z]O6CR'/:8 ^L0;I'.GHXE_(5.E,N=#HYPTWN6<9)Y5_6 M6SK;K%/C 48PWH K3+>'7$.#BA.4\I*8[5=[W@,;(DK-QI(L0N$:S_PRH-R5S$,?& MAT!\4W#TN -DTI>BP.Z<:+-:L;3A[N\4F55>.7W0F]69^ MC54HQ^J4)G*7Z1%+3AGF.\/IAK5<)1RMYO33A%Q,PTK>D:CEKIV5;><_K!UO M=J)N'%8L5M]W\*XK\:0!Z5F<9FDU*7!G82EEF6]6:)"( ZC(;;-"T%;XM7FP M!CK0P-B'#@;3>HLG&;FTM(!=:]IAU<^0.![@;QO2YQ>\'NAKEC^DTV!AB-5# M!?](3:19[)NTF!8('L$R\<4I^1[)AA[9[D2'] M!R 1V[8II8+E?M@A\U+WR8Y)BO4&U-OLCKV=&D?_23XD4HX(-;;_+A M:;..4*U))#W .A&EW6*(N'':H+NF.AQ.!\>2;S)>ZHI&M[N(CUF&,0)7#_V( MG0Z^+J#BU_$;"MH5IU7ZT- _[3_37*2O$P_'TS>>+]*M,5(P!@N(SB;OWXZ$ M2]]-TDVP=?Q6L;(![25>EOB=08X/X#TO7]T-&^@_7IW_'U!+ P04 " "; MBFY5^E+A>.8: !240 & 'AL+W=OV/GN*^OM)B^^E$MC*O5ME6;E3R?+JEJ_?OJTC)=FI%JN"Z,3FK1*G_:[W>=/5]IF)^_>TK-/Q;NW>5VE-C.? M"E76JY4NMN]-FF]^.NF=N =W=K&L\,'3=V_7>F&FIOJ\_E3 MZ=^E<2N3%;: M/%.%F?]T,NB]?O\,Q]. 7ZS9E,%GA2>9Y?D7_#).?CKI(D F-7&%*VCXY\$, M39KB0@#&5UGSQ&^)$\//;O4/='8XRTR79IBGO]JD6OYT\O)$)6:NZ[2ZRS<_ M&SG/):X7YVE)?]6&QSZ_.%%Q75;Y2B8#!"N;\;_ZF^ AF/"R>V1"7R;T"6[> MB*"\TI5^][;(-ZK T; :?J"CTFP SF9(E&E5P*\6YE7OII]O;@9W_U2W']1T M_'$R_C >#B;W:C W(\G']6GV^OQ<#R:JL'D2MV-K@?WHRMU,[B_']U- MWSZM 9[]GA_5#H7I=K'9N?3D"J2E,\F)-W?_U+ M[WGWS2.G>>9/\^RQU?\-IWE\O\GM_4CUU5__\K+?Z[U1?VY[]7XP'4]Q\O!V M,H6!5X/[\>WDM;I?&A7GP$!9:1+\5.:I370%7^8VTUEL=:K*"AZ ^JA*9;,X MK1.C*IBGXSBO\6$^5SBLU*262K74#T;-C,F422U(.!ZCHSY/1WCPT?1^#-@83?G0P"%K76C2 M9P#_D<,B1E!=VVH+VJ1:NC/;; $K #+L.@5(%B8SA<;#P>]FC=B#N8BCSYG% M;U-7P[8M1IJSLBB;@$74):G[-)ZP MR4K/YZ"(F00KA ;7A5&FX@FIU3.;VLK* HDMXS0OZX(A@",A_+CAL4F\.+(! M3L#/!_%#!( ? 95Y@<=D<&B7PCR8K#8TQGQ;(W^5*JD+Q%PSA_ (",F!3H,6 MR1T.',>5-"O61;'%20\ZK3UP0^8,$I47;TJUAGD 1J3FVA:/#P6F6@$'@'&( MOT0M5- 3V"U@*,,06,B-DP %_HP<=-1Q,?R;) MI ^C?WP>_S*X'DWNA1T%+I) FY@"D LRL 1#"$R56N 5!.8!L,*H7]=%O-0( M(K,E,'%A%T"D%%BH C0#P]*1"V/4BNU$7BA@5D]>P"^=PRV%[#=#%)=+A4U^E2 3U@ K4A, .EK0BCB I@I+Q(4 MJ@JXHJPZ:H1BE,!949 1$RO]+_BK$WA&+$N*=K4N\@'(_F'PJ<%T M.D*]!$^@\" ?;%" ]8ELT M+YQTH0N2"X )"%O4<44"@<@I $:P!6 @4L![HF;(-,09RMEXX"\M]''(TS$P M56F=P6Y\A@[;:G1:NMGC ;0M"'X*-'GP2RL J]KDZK1_YK% +*FR/#L_/!R5\-(6B4S@ MW=B^@"]5V%E=Z5E*BME-TPVM@ %G!E$LAB;D0^98Q!,>J.'*&3@J8^,H >N5-1+V/Y1?WQOPI#($U2(O];IM7D)D[G*G1I\OJW7J M=YD;PN637M=[#'^6LZ\^C]2'N]L;=?_S2$W!?<2XQFGS":@9LLB!7X_&.X4O MX%23V5%+DS*?E.#<*8OH1KJ(GPGV; 8$W'*8 9MCT -NZ(R]D0>2(& XX!=+ MHXJ\7BQY+3"?2R*FSOP/'&G4B$B0#Y#,U0J<)2!LBG@ ,!KP1 !V063$!\]A&"A$:(]R ,( <870TR8J5)4V DH"FX33"(9(7< M!33P$+JA-?T.B+0#1K- 59R.7H>$5+"0H:4*ASEB23%#"PKX0Z:.<,P"]-N(4R TH0G94=Z>CM:,H2'>@ MZ^W#$F>0U#0V4U2)^,F*,Z":(-S=Z^6/ K7C@GAG.#@CJ<3D7W6),'B BIT^.+S@*& ,=O_(,?&$&J: MF6Q;2;B=_84P'-@:685$!N+OFCR8VCF M_8$%@+8X_LDK62S.4\RLME?*S+=*PC?2=T3YKS4%/'$AZDLP#YH' "E*76Q; M07M@8&] S_0\\O&;UY:-@@RPS2?SY^60(*ECAVH6K@0DRGOBQ!]-)D+4E^,* MQ&FWHVX&=W\?W0_0#9V.AI_OQO?CT=$0N&2;BRD)LLN[(:YETP2G1*^2=<^K M+J!@6THPJQ^T30YN%NTXHX[KU.*C@#;<%?B=8"S0)HB6.H/M*;S:%WV$ M&F,04HU MQPB[E/\[8R9H3%T^YF*1T%'I9T8]*;((?4F_6N=5^1EDT$GWX#B M_H*R2;001*2I+BAL+FIB(W*97!09!&, 2&)F56O;3% $ZRUR8#?X[&601"A( M>E!R 5C5UBL7V&$HR#]@4HIXB))>G+'HJ ^XQ/[!#X !I XP3SH;(IW@"$,? M2@ EB!A+PW3@?&*6>!. &/*V<(5F*;5?#-O!C#2P,XB-#^#M8F/+:2F2!.@7H6B3!7QA*$P@$QK('!4A!-$>!D)V1CES>DO1%Z(]ZT M@\%G6PYMBC,V, H654F^(9491C_C'4"<0?*[>/>:M6Z 94H@FIB"5"!7P-]+ MTIT8VKDX7L,.X!@XTRMI H5>LO/H5_H+:T9D.*(HZ[4@>^KU1H1GA<&M52)Q MV"M!&"OT "STF]&N$LW;R(K8TBXQ.F^"7_;J73+,DWR+D2O_!I!E\3822X4: MFI/MDJ[!_ *I&70_76Y 5G?K"0U:IP9\)JB*I4G3 M42HGEATQ[>>-4*/0W9G(CT1*%PV !]EI!QF>@?;@X%SN]V%I$>78MM%!#$A" MB**F#9D@5"?!.-:B7K.[F"X8$7'^CE,4@=GSVN 8^^Q#6CHIWW$V:2F4"!0K M*EUX@)P7_6-G:/S#@];F@YRNE1!F1V4_B(H FF!/<78:-+4 Z*B[T2^C"80F M=Z/A["_AV\!7^K( :O 8E^0=T+H?**(/O3=GAZ:5 '_2N %NVF Z]+.>=Y]'ZDZ. M] 'E9@B8+4#CB,M&'!>@E>@)[+*&QCL1U=;%WY34P(Y:K/4+B07*MAU MB]%4F.L]#V:II@3''@<.>S@C!D(M=6P0RN@)<]!% 2P"J MY$#V", =3XL .2J/01NUJQX;(ZMMCZZ%),$R0AQ2T&2,BSSE \V1*# P&.1S MPBB%1BRF3WL&[O\QG'N/HEVQ(GQ0=@RL=<$I&=E5Y 57ZJA?,;68NHBIC5+1 MJUSHVTH&&R-^XV(3&:Q=21.%$+^130"*VQ7X ;C M._7+X/HS)2L^C">#R7 \N%;CR?3^[O/-?@4L4&8[*K95I@W\UT/*!(5;@:BJ MEWU0:A]PD5]HD9LF#F<3<=541R/E5,/A\2+W3I:%U)BJGA=Z9;!IANLR- >) M'$#/ <;'P>!3A^'Q=D,R/I[=O[&G(:D]CKCS.DTD#\.A&3G;F<2\\)DR@&B; MA2\!*%?2W:I3REA;B0C.G%R+3M7D *^H_I(\Z*P"OR6O2Q=%.,/HMVK693\< M#4.!WG(@XZZ&X2(1#;80MPJBUC C@E$K\V#IE+9.2ZHW:734PQ*VGH'V;]$_ M3 GM1&<080%_VW+)9 J\4 OL7<3+;5,%D((\XDI4(PKN-W !?C.N5D/%HAGV MEE"$8K-U+7Q$TK$SLL[VQY(D'N*0G?,#8X'?/2,G#VUVBO42DGM9B!A#4HI4 MK$9P&1/!JJ_5-4Y4/>XDZ;]1_^ 848)#I"[; O!#CS4$6-?S)?0LW\BJ_4=6 M=9'FCZ_Y]1'(?FA!64G<8@E6>!>V-ZL\,>DYL"O)D$\5T61F [W7>N(I'#YF M)DH*RKO05BU*[QT-YS/*+CS*?FFV=Q"1)@TR6%A&L%]K$P"8@]DE<84]#P!* M>'H,SI GVRDQX#B827'%7A/ J3@N$O* VFV7D& :BO/N/H/&J*TF B$<_TI*A-T J#"P)W&C^FQ$I0 MD7_;3PCIW]6\ .H@UJ)_?-&9/$T$EBIP*M-4?N(1I6DG@WXL0?MB)P'@@L? M7%-G#(MQU:(7<,9XI1?XZWN;EUOP@5>EM'YI-0%/.-&^%.S\;IGA?>^FC%78 MQ<(0S.B_<-[*IK7+-&&_65$N[=II^M1H'\8FINEYD_&R$:8=6LSL0$8A.F9Q M@%)K;FM CQY8!:R(E.@]O.R57)[WNLR4B]JRXT(15\G&QW*B@= :*G978&RX M-M"&S<-0+YYJK'.E.-)/S_+LL"OE-:=3MI@1.C3RK'WT-K:HKB?Z-!/* QLL MQ<-Q[@,UE)@BQGZ0MBJ;PY*$$H#$@&]L73IPUR5%9F3VLYLP1&X>FU.,R0NW\%H.I0Q=%9?%U@$% >[TQJBQ=V M-97JLA>]>/X\NNR^# JSGBVSA',!L@O[FP%K_4 M+R4.FZ04FNX27>ZD8<..FXZZK8O#?!IR)ZIDNR=(7K[P8$C,NB !YS33[U.( MD0NZFYAJGJ.HP8(0>I"I"67X8%FY[=[L&?C#;M2I&+4S-0VXF_,S^XZAC.ZW M1Q]R(67DQ5D@=%(?HD"YL;I/5"_J/N>>M?;G<_K_T.GW+96?TP=OVY9@4;[6$..8HFS[ M5#K)*9-%2O]9'_GY;SJKL5(G94%B6M2,+H>>A$E!RA6""7#M&@?;<)OJ%<9T M2!RD [H:B>4DHW$G$U$@0:!#-4E+="S1X$>NK[>@ZD6$JH"KT$VIHVDJ;!;' M'K/A[P>MWA\BA+$:J?0W7W;S@6RH';;L$.EXB2CE9 55OL&>Y.D# MZ8YV:RX@!#06XA;761O,KE!T:><0$1MJXG2!:77$'0S[#7945;O)+FA@=HVQ MKA_:+4=16?O(04?>?0OB$$9I? .F3@P\))S#U,-@.:\F3!%PJE9X9K_E.6CR M;Q7M#V92D'-?///-*>Y>ISBV882VU*SJLI*" MA^25OH 7L,QSD0V4N4.HV>]6H8!J7I.["P-%D="^ )AOLG%UH0"&&>QH'ER- MQ9?P1!BX0+C3N(90>_R $FD".9],[ZAAXS01^AP;GB"F*C"D$H^MH2_2L<[$D>0<4$NBV\4( MGTSQ!SQZDP!=-\EXZ%8"%_,?)?5U4P@?-M)(U]F><#8^2I,Y(NE&[$B9&$ZF MOW"B>:?^),\1ZSBA,, ^F6MC#)%$>!<%/6=?R'G8(3ERU[::[5**EV;.F;6: M@EQW$[9>HS $E2(J58O&5#='8Q543]5E][]"H07D<.N?!PXVE(8#K/A$ M 5:;M*H/C')4A %'1#LM&A%?$#+20 X1MN^G:_B6CH59^)6($M[9:)C#7R:R M7$D8['<@ Z538BH?*N[RPH$<=IC\YTX)Y["P8G.VCL6J)3R>!M(%"1**U[B& M=(G@:GS]&2]XC09WD_'DXQ3\HMOI]$Q]&MVIZ<^#NQ$U=1S+BO>?=WVR>R2Q MB/H$W#W%N"*2(%L:>$H;2X,%#*# UD0X_-::J.)!8HY*TQ#=_M!P_91%&7, M1@E3;NBZ)[(\*%@-<4A6D_L9-)U*L /N'YH3W"CHE'+=^>\)T,Q4[=IG #6U MZ[JK1)PB> @-4NM&#^J%#3@(VNDG4*( 8$6A*&=NKG )I#'LZ2*Z<-<0_)V. MG::?WQW__$\=/VJWX1PY8*N)MY7):J?W9$?.,"-X*/3<],M:Q8?MNXLZY"'" M'/:H@4-D#M/?A7&UZS LCOXX-CQ=CY_/)<4J:A*EY!X92.\U :#VW*'L.Q>& M?,=<8;@7LO\R>@4A^ZO>"_[=?XV":R2HYM8Y^AF6JMR>/B&V,Q-T07 _"V1*PTXOCPXO2A\7N/>FI2K]!1RHO7 M:K*G8IZHTQ<<6]+G7M2[?"Y?KTR6TU54G/GK+G?SD0^P].7EJZC_D@+VUN>1 ME^6&7DW$>P[_[>WAD"F['%N9U>=QC,.YNAUW0OET]5TZ'9KU;V>*C&Y&_3!/ M3(+A_YLLT8\NY+H@?;V(GO.]H_]DKNC](:[ 6=/[V^'?T<$!IV9X>_-I-)G2 MW='CB012\^><5T>N,5G);+-_P\4W$& &5U*]"S;M;B&R;WS1$6VL2"7Z,8R)$%+T'\/TC6H[L+%N(? E-A6S (+8$UI-6:R,O\)9 2'27YH'3 MA4[&0EZ\=U/?.,T\8U>Y]J8+!I# XK8G;MNY?H8A:6D@G0 MLLGXL)>YYKX1P!HG/( MO2144;3F2GJJ,=6,+3>MUQ1P6ZY;@QKP@#A66MDD]KA_I)G?Z9G=^")TD?%\ M-J5!+GK88JIA1?-N+B4',M.C9V M3;9FD1,'>[Q)(QBG^"D1T)SGL1:MR^[E^647.;H4$=J]X[6#VMW[BB[%A=XR MRX-OD\IW[V7O7[0X>GY)>1H48WLD*:BN@;@I71^O=+/LAG9,V&]4'BG+'-]&8-Q+0$ 54#GCASNIB2/W M.@I"UN4&9% ]<"! +8A13,II]QTSS/52J-$P-^$T5RG9![1]N!OW *D96CH\ M<]/L0+D&O#G(;1ESZ]IWD=&#BUJXV\AII2$R?4D<#;""1-N@($F2(H5;3:D0+N1WA@[4A2S.3%\96\QK]C9]!73GN7KO3&R<@L*'55B>'<"N0OK<"O.1@N[OPNZBS$W4ACLR<5-MU[,%!) M5915 "<%4YZLID2U_2ZHNG\0JEW/ S/5H@0-O]8AN$#3O,&&>RT1ZB0W/(O= M(D:V.R3P#+E!NDGFO&8XOVWP!OP2O/>8 MFCE,[79>7)[PFT'<%U"E]-:\65Y5^8H^8L'<%#@ ?I_G>>6^X ;^-8KO_@=0 M2P,$% @ FXIN5>QDEEMC P _0< !@ !X;"]W;W)K1SSIY=>5>CK=)W)D>T\% (:<9!;FUY&H8FS;%@ MIJM*E/1FK73!+"WU)C2E1I9Y4B'")(H&8<&X#"8COW>M)R-56<$E7FLP55$P M_3A%H;;C( YV&^_Y)K=N(YR,2K;!%=H/Y;6F5=BJ9+Q :;B2H'$]#L[CTVG? MX3W@(\>MV7L&E\FM4G=N,<_&0>0,H<#4.@5&?_=X@4(X(;+QI=$,VI".N/^\ M4__/YTZYW#*#%TI\XIG-Q\$P@ S7K!+VO=J^PR:?(Z>7*F'\+VQK;#$(*V, M545#)@<%E_4_>VCJL$<81K\@) TA\;[K0-[E);-L,M)J"]JA2()+)2TN8&9S#![R@_)76LQV5F<)@<%5UAVH1=U((F2Y(!>KTVY MY_5Z_S#E6K'_O*)KG%-3LA3' 76&07V/P>35BW@0G1WPVV_]]@^I3Y97-S/H MP5OX&^,'I9\WWL1[]6*8Q/'9;Z/"N0&U!CHEB\4MZO:H.F!SA M5E$P^@MI* M T=QYW@PZ!Q%0S YHXB..2_8AAJT0SUNJ)>XW "G=@6IY-N4/B6MA*@W+1+$ M[G&\Q^,S ]R8"C-@,@.:/,;2@Z.DJBBH]:F+TKLN3*E[,ZA*VOF1;S7SA%+S M%($ SZ7#RE*K!TZC ,4CO(RZ40]*0OA4ZFS7C&NX9Z)"Y]+M-)%V^6Z9^5$G M[D2#?B>*HBY<5MJY<#Q)1P5%W4GH.NFW%=:8*NV #(0RQF6Q9X=*RBT52MY3 M"6FJ^C)2[&%T4L?V YH*Z75DR@5G?F[2X/=ATIS)#65@E5_N"?&VGBWX3]R? MTH$()JG>S'\'EY@V@-@#8G@)2>&"5]E@RF5S7+R]CH9 M>O";'9RL.6@EZ<(2_"OY>'I"^]RV%D1_ZNQG[V2M/39XKL?#O9%]V\[KD?X=7E^,"Z8WG)I'X)JH4??X* !=7S;UPJK2#_A;9>FZ M$\YW<^H'8#>KY6RNX4+T-[XDV]02P,$% @ FXIN57*)HZM9 P PP< M !D !X;"]W;W)K&ULI57;;MM&$/V5 >,&"2"( M%\F)XT@"+,=%#3BQ$:=M^C@B1^+">V%WEY;5K^_L4F*EUE:!]H77A24KMI4GO?G*>I*VM2Z(:F(M[:5>H:2UA%D))ID67O M4H5")[-)/+NSLXEIO12:[BRX5BFTFSE)LYXF>;([^"I6M0\'Z6S2X(KNR?_< MW%G>I3U+)11I)XP&2\MI2OHO+U-#E+H*(EMM)_ M->N?:.O/:> KC73Q"^M.-A\G4+;.&[4%LP5*Z.Z/3]LX[ '.LA< Q1901+L[ M1='*3^AQ-K%F#39(,UM81%[BMXOYS=4D M]4P9+M)R"Y]W\.(%^ ?X;+2O'5SIBJI#?,JF]/84.WOFQ5'">VJ&,,H&4&1% M<81OU/LWBGRC_^I?!Q\_#P\E<>X:+&F:$MW9!\IF;U^E;_+/AXQ;MP;-S[& M_N_&'84_;US@A#&\?G56Y/E'.% !MQIN2V\69"%_'V*65]IXXD?I:T -0E?B450M2N"& ">GV2#+LF'D. (!U5+8/ZN ML"B&!PIQ98DQOD;/'^K "T+K6)@E(%T3\W\^P%?YQTJ8[WX V/C8:F*%AXJX4K3 M:A\C%WWE?(+JZH="_0"_?K8T1&M7 K!&!R>#?>/J-=">U TI*AV?#]:0*V M&QG=QILFMNF%\=STX[+F*4LV"/#]TK KVTU0T,_MV9]02P,$% @ FXIN M594K22ZU P J@D !D !X;"]W;W)K&ULI59M M;]LX#/XKA#?L4^>WO+37)@'@A*5(:;85\5!M$#<]Y5JBQL]&ZO/0\%6\P9\H5)1:TLA8R9YJF M,O54*9$EUBC/O-#WAU[.>.%,1E8VEY.1J'3&"YQ+4%6>,_ERC9G8CIW V0D> M>+K11N!-1B5+<8'Z1SF7-/-:E(3G6"@N"I"X'CM1<'G=-_I6X2?'K>J,P7BR M$N+13&;)V/$-(<)IYAE!HAH_--@.NV6QK [WJ'_:7TG7U9,X51D MOWBB-V/GPH$$UZS*](/8_HV-/P.#%XM,V7_8UKHA[1A72HN\,:9YSHOZRYZ; M.'0,+OQW#,+&(+2\ZXTLRQNFV60DQ1:DT28T,["N6FLBQPN3E(66M,K)3D^F MT7RVC+[!\B&Z6T33Y>S^;C'R-"&;=2]N4*YKE/ =E#_@NRCT1L%MD6"R;^\1 MHY96N*-U'9X$7&#I0L\_@] /PQ-XO=;-GL7K_4\W:Y3^<113()>J9#&.':H MA?()GW,( OGR["(+@" EW.WH#"0HOX M$2)3$%R_P$TE>9&"WB 4A 9YG4LTN03*A,9\A;)-QYG5G(J\9,4+;%@"A=# ME:I(/18YF8,R.[AP7YK24Q#I=W'"X=G ]\]\WP?J&4JS(C%D1&-IX!D5;YI* M3)E&X(4FMHK'\,2R"D&LX;/O0K1K*T;0X6?C<'ZE:D8-;-T+C.NT&[66C( 3 M0JY[G%'@"IB"M>?3+ECM914\HJ7O![3/*F"N$N>0Q'JX_ MH&F1QK5O?(U'$!L MLH0HM;=6>ON3^ON?2=&Q)#L;S!NXAK8N ;=D'X&W_7[ M,'3]X;XX&-C!7Y(5AN77]K?S8U]6>BZ=BPW;Q+=)+)K M=2+WTXX?]AQ\=(X:^"Z!CTQLK ?0,X&QP0G=\\&AM!'8SQ &'>UA[U#:",PG MZ'=0@AWVGK016*/0G+5=GL[=B^"(N)$L.WTEX75?D1B+M.#_FC.0TU-$U06* MSV:,D+SV+KV1^&'SCZ*FVE[4,DJN_?5_7Z%?.= MR93J%3)J)%:6_CE=!TM]OAAAY3*(T"K:^%T+N)V:!]GDW^ M U!+ P04 " ";BFY53F#C]=T# "I" &0 'AL+W=OE5!8*](N6QYLW;X;#H49;I;^9'-'":R&D&0>YM>5M&)HT MQX*9OBI1TLY*Z8)9FNIU:$J-+/-&A0B3*+H,"\9E,!GYM86>C%1E!9>XT&"J MHF!Z=X=";<=!'+0+3WR=6[<03D8E6^,SVJ_E0M,L[%@R7J T7$G0N!H'T_CV M[L+A/> OCENS-P87R5*I;V[R.1L'D1.$ E/K&!A]-CA#(1P1R?C>< :=2V>X M/V[9/_G8*98E,SA3XF^>V7P<7 >0X8I5PCZI[1_8Q#-P?*D2QO_"ML;&!$XK M8U71&)."@LOZRUZ;/.P97$=O&"2-0>)UUXZ\RH_,LLE(JRUHAR8V-_"A>FL2 MQZ4[E&>K:9>3G9W8/B!AZ4 MM+F!N>[_S_Q%A37!RG M<%?CUI0LQ7% M6]0;S"8O'\77T;#$P(O.H$7I]C_F\#3%(]?7N9P">_?72=Q M/(1_,<(7"0]L!['+:GS3 YLCS%11,KGK 4J+&C/@TBI@=%?6&I&NGJ5JM#DP MD$J>L=6*"\XLX6S.=08ETW8'OSF?231\\6L+M^97XN&''I1:;7C&Y1JH?SAF M?$U%9>@B@N IW6V$Y6Y?"Z@5<$NU-)LNP&*:2R74FB#*H_:4N?O&T;3+9>;5_,ED1>T/!NXDHILN]S[33L.],C 5K*#/ M(W.MBPFX9TNEF57Z(.Q*6BZ\#;Z67'NPD^U6!#,6-DSP#%+!>.$B]"AL$:77 M::"LM*D8Z2.$J=)\[_29S#S4,''LH-PAG6WI;6^T\U&E\-C8_-].')>^$4A7>^1(BC7QW/6BO3H!Q-(SVCUD_4PE5X M5J641I!>NT?20.IHOJJ7Y)NM7N' MI_7S\P^\?L0?F%YS:4#@BDRC_M4@J"]0.[&J](_14EEZVOPPI_\2J!V ]E=* MV7;B''3_3B8_ %!+ P04 " ";BFY5)#YHY"\# #=!@ &0 'AL+W=O M?&9NV=94E3Y+C]=\?)2=I!K0!!@P(8HDB'Q\I\WG2:?-L*R('/VJI M[#2JG&NNX]AF%=5HA[HAQ2>%-C4ZWIHRMHTAS$-0+>,T23[%-0H5S2;!]F1F M$]TZ*10]&;!M7:-YN2.INVDTB@Z&KZ*LG#?$LTF#):W)?6N>#._B(THN:E)6 M: 6&BFET.[J^&WO_X/"/H,Z>K,%7LM7ZV6\>\FF4>$(D*7,> ?FQHSE)Z8&8 MQO<]9G1,Z0-/UP?T/T+M7,L6+BX]7J:E M#?_0];[IEPBRUCI=[X.902U4_\0?^SZ-R^;!9+E:;-=RN[F'^N-H\_+E8S1\6 MZTGL.(/WB[,]VEV/EKZ#]@666KG*PD+EE/\<'S.S([WT0.\N/0NXIF8(%\D MTB1-S^!=',N]"'@7OZG<'FW\-IH?F&O;8$;3B"?"DME1-/OX8?0IN3G#=7SD M.CZ'_LMH7F!+4M".[" ,1@X\95EK#"D'STIWDO*2 %4.6.R!+ \+AG'LA*O8 MTBJ>T &X"AT(_EE0VAU0Y LT:-P+. T^'Q,B(Y@92U+.E* Q.B/R2^8@V+83 M>8N2X[3A/<-R_K(T7(ZC0=CR/6G9!@JZ@*X26<7"TZUY"$]&[X37) NLB2"UM=P6- 1D'6ZEX&',?7+,,FUR5!GUQ=ZNYS"^Y'?9 MWT&:W,Q/^QIL?"]=1=P;- :5HWP(CS[\!'C \LF,FU<2/C/F_[%4^-,0SWS9 MR+VLM7^J7KN#".Y02,:BOGCV105\A7QC.N.N6^[/]U88WUR$K$+F-WSK78Y/ M)*%"7:\^1^M1NV][R7IU[X5_B:847(BD@D.3X>?+"$POIOW&Z28( MV%8[EL.PK/C[0\8[\'FAM3ML?(+C%VWV/U!+ P04 " ";BFY5X%_'0:X" M U!@ &0 'AL+W=O]OVC 0_5=. M:=5/%?E%"[2 !)1IE=86 =NTCR8YB-4XSFRGT/]^9PN!EQI1WOJ^3# 73+5EB03=KJ00S%*J-KTN%+'4@D?M1 M$-SZ@O'"&_9=;J:&?5F9G!6+Y&Y=I^PK6NCC@=)I8T4>S I$+RHGVRW?P]'@&YP A#M 9'3 M73=R*A^88<.^DEM0MIK8[,&-ZM DCA?V2UD81;><<&8XGWX;+:/+\Z+O&^*W57ZRYQK77-$)KAX\R<)D&J9%BNE'O$^Z&G'10=PX M.DNXP+(%<7 -41!%9_CB9MC8\<7_9=B:J_TYEUV6.UVR! <>;8-&]8;>\.HB MO WNSRAM-TK;Y]C_4>EYKN>7Y12Z<'71C<+P'DY3PTB#7 .]=8-BA:IY]<"* M%!XPV6=#EZ5/DR%,I"A9\0X92VG%$E5A"K@CS]"HP4A:W)P9RI5,&8ZN 2M+ M)7><5@KS=[@,K^.;\#H( M>&PC#JV;!U4D_=F0E9%48#4PAIA;;9D2 W;N=> M@Y8Y$LV:)\1 +@8)%9 \YER!^"_C^+9I;QF2C'%:>'=IXY5D*OT!O>6VH M3TQM>*$AQS5!@U;GQ@-5FU0=&%DZ8UA)0S;CCAGY.BI;0/=K*0&<" !N!0 &0 'AL+W=O O#P;N7R? M\%AB8[;&X"I9*?7D)E?Y-(B<(>2864=@]'K&"^3<@-EBAO_A*;-C2DYJXU5HA.3 M U'*]LU>NG/8$IQ$'PB23I!XW^U&WN4ELRR=:-6 =ME$3N5*ZC[*P MFE9+TMETL9PMYE^7\YL'F#_2TK>/,V2G< %5@,81H>01$FR@S?L:QQZWO!_:FP1H_<1KC7&IF(93@/Z M]PWJ9PS2@[WX.#K;87#4&QSMHO^;P=V(F]N'.9S"P=Y)$L=G\ <1+FM=R@W< M9E:M4/NC/01;(%PH43'Y"D;QG,+1811%8 I&98):P]7L.V1*".H@^AFSI\'? M28+E"/O#EE2ZWJW8*S6R!:N @506H:#=2,QD[J4N9H#2V(HCM1EG,D-HF"%Q M7F>8.^E^''OFX+TC#[=Z0*#>^$XW9+V6MFV'/MI?)N=M#_U*;V^B:Z8WI33 M<4W2:/#I* #==G<[L:KR';52EOK3#PNZ$%&[!%I?*RJGF[@-^BLV_0E02P,$ M% @ FXIN54OK\UR_&P 6%< !D !X;"]W;W)K&ULW3QK<]NXM7\%X^9V[!G9D>0X<9+=S"B*DM6M+:>6LWO[$2(A"PU% M*GS8T?[Z>UX 08FBL]O;#[?3:5:2B8.#\WZ!/SUF^==B94RIOJ^3M/CY:%66 MFS?/GQ?1RJQU<99M3 I_66;Y6I?P-;]_7FQRHV-:M$Z>#_O]E\_7VJ9'[WZB MWS[G[W[*JC*QJ?F3^XQ 7TQ*_6/!;!9X5'66395_PRC7\^ MZB-&)C%1B2 T_.?!C$V2("3 XYL /?)[XL+PLX/^D0X/AUGHPHRSY#<;EZN? MCRZ/5&R6NDK*V^SQ%R,'ND!X4984]*]ZY&=?O3A24564V5H6 P9KF_)_]7ZG/'M4.3X-T/ #'956 W(V1:[,RQS^:F%= M^6[^Y?IZ=/L/=?-1S:>?9M./T_%H=J=&X_'-E]G==/9)?;ZYFHZGD[D:S3ZH MV\G5Z&[R05V/[NXFMW-U_#E+;&1-6J M4),T-G%S_7,XAC_+T)WE_; 3X-QLSM1YOZ>&_>&P ]ZYI\TYP3O_M]"FC2"\ MWXOV_5 !WQ0;'9F?CT##"I,_F*-W?_W+X&7_;<=I7OC3O.B"_N[]:#Z=XUG& M-[,YX/UA=#>]F;5AV0WG;F54E '+TL+$^*D $8AU"5^6-M5I9'6BBA)^ .4M M"V73**EBHTI8IZ,HJ_#';*FN=;K29:E3-0A%M2AL;,%V]-2U*74"DE>M>8D:);"IO4\1BDY+V+4T>92M-SK= M@MHF@)X Y+>;!,Y^ M;U*3:R0G_-ULD%^P%KGR);7X;8Y B36CMHU1$<@2!:#F#6$S-' R7A!JR*=YUM<]*"3RB,W9EG\ZU\NAX-7 M;PNU@76 1D\MM#3_A8PA?9C\_B3&N6D+D4W01]Y4G[JNGB0O6>PP$O3UHO;MAW+7)%V+I3;/.09-, M++;"IJB3L:HV2(AGPXM^K]_OT^F-CE:!SL&3I2TK$JU'H\!RQRJK\AJP34%_ MB$YS-#_KA ).#I%U#O)(Q@<$ M:T-"@]0'%43:K_4_X5\=PV]D",AAKC=Y]N#, M7HXRN['@)NWO)F:7"@X.5H%52R#(6+/YP<@=+!%2EA]"GV-S@;#2^3T@ JP7 M^PCF!ZU=E0-5S]1O*_"Z9/ZUE_G7G;(ZG=V-9I^F[Z\F:C2?3]JM>3>(*QN1^(SNP?2RB$Y34/+^ M92_T>2I;E, [TMB(_3'('E$03\ZQ 0@;\E<\*-#V7N>D^T %$*6\BDI2>F1' M#E0!GPZ./@%.QVJ!8DJRJ%QT"!*M12(:9NF.;S[X!PJL( M_M4V=L(#/WK,'P'RL_/^!5HJ,&4K"_8R-Q3:IQ1^H1OQWI]![]$!?!@8MP2D MX,H!6^9BIX^&)IP(I@4JS]+3]<71M*YO'LH!WXS@!HO#<+JI2+Q)R=VZ9 MKGD%(K\P2&()&$+)9QU!.N&!:CU80,"YM&7P=R?4X ?*/^ $<),6G!X->JJ* M(EJ'U1D$L['@!P7TZYKBMM9;].X2Z)*AV\!/>;;5"8:9&&YADH^LZ#E1 M9%PR/ ?+\.LF4.1N3L8&%F@A^/X).$:YR@I(7N A9J1>0$MGIN(8Y6KJ[&W M2C5;J\*$>E"::)5F27:_93-#YH(QA;B]6FI2!Q:0S0;0\ E%J"^X:HUR+J*4 M)-FV>$K<02Q:CD5B?T[^>4'!F,@?R?I:YU]-64>H0](.?+8 9^.B_SK@!=$K M*F3L?ZB\OC<0GZ:(JD59&O2;LH3$W)5.C;%[6NG$[[(T1,MG@[Z/BOY%R>[P M&H-^75OJ=QK]#U\FZN/MS;6Z^V6BYI (8$Y\V(-T0VLOC\S X%$T$F2*&+@D M\ 72-'*Y:F42EM@"@G=ED?$H(9)'@"]?@"AM.7$%,F :#6G&@B.Q!])E$'V0 M7$M/Y5EUOV)8$#JL2*QTZO_ N6N%+ 5-!1NQ7D-H"B*6($< C1H]4<5=%%D$ M@N- [&,T1[*2ID!. ?NR<0.M\CFG)-LH 4%B20D.AEGD3@N3)"#2(%T0,L)# MI+44*F%PDX+; ]%Z D7: 2LR(%^X'",N2=(!D"%0N3D5M!NA+>3/OW,H!I1' MA9- [4Q]8B#P'+CHG6O!5B4)5B:;T)*S?=2TG.RO,3Y;Q6EEU$NAE0H#S80 M$,D+G6\;9:# U5^#Q1MXXN,W;[=K4QU0FT_FS\OI4%Q%CM2L7#%HE,]"2#[J MVI884B<52-/^F>JRID&E?M!I3:]'MW^;W(TP"I]/QE]NIW?3]L+B$W#:"RL% MQQQ86J.X9+=P8MDU VTQJF:+][H/A-\64B+1#]HFY).]WM1 SUQ0@W JB=' M!N^:F9WT-[!AR(PJA>TIH=TW.(@U9GUDD$%:LK51Q_BW$Q;!VM'O5]PZ44=7 M$1N,)BD@]R'-MRHK*"AE=WAZDOX!( M;!9E8]M42 3P[C,04(&2O#?.!*?!I[QX,4\AYXC]^4[+YSPW4,Y+UQ'Q:9L%3&$H8B 1' MP&0QR"8)B+V1;,+AX"MJ;9OBBD=X"H"J.'LD0QUF?],=1)P; M]+OX]()M?4!E*H2;B,H"P*Y OE=DL3&U=943#3M ..( M,1HGX_H:#?*9[[9PY1R)#&K#4A=_J7@6R8Y83/:NKW8C[DP4O2*G\QK!5G': M(887H#T\N"?Q-"X-IAS:MM=* 2G!4=;X2(X/S4GP'%M1;]E=3AL\T>,:+9=H M F?KK<$A\=G'M'!:OA/B$BC4"%0K:OIYA%SL_F-GJ*/25F_S44[7:#-P>+2? M1/8 FV!/";%J,C40Z$S+AG4@,>P, &XGOTYFD)K=3L8WGV;30XV$)Z#<-4,G M)DKA>VKH-B(\!Q\+0XJ6#F1[JQ*C:!X@\17;C[[$.:J7S$N0.[#6ZGT&_WKK M>XR?AOVW'T?S]_1Q\/:D;5D!^,=U[.&6C>9CO^IE_V5/WPL/^Z7+K:AXTP4,QZ2*Q]U+R%NHZ8+04UOIPA^6X M[IASF(.//9R0U*)I//00&H5C>,Y+AS_:(_8-,/S@CJD@6@!2!>?L!Q ^\[P( MB*.R"$Q@LX'W: 3:]B L9 GVIZ*0@R9E6F0)'VB)3($'@X=\Z1]5WXB;]K7F M(-,Y1',?QC3;O40/*DE"B)!S'4QV%7U!2&?J-ZSG)BXY;))4C#EWR;?2J,#B MAG%IF#RLW3P *B%^(T<$'+=K"""Y2+3%@A%G7-Y-[96U.BU2/6@SZ)Q\>?=Q M-+U5OXZNOE"%Z.-T-IJ-IZ,K-9W-[VZ_7!]J('=#;2\8M9JM>-?#-*8M@O"] MS:RAF5%@--3E$&SZ1P3R*P&YKHL?["$_U$,./>6,5/OS8H&<51&APT[%,M=K M@Z-NW BD-2AN ?:<7WT:C3Z?,3[>;4K!SRO>=PZTI+++98ZL2F(I?G$^3+E& M*H4&^$P%8 Q-1$, *3>9L57'U+"PDA"=. LCUEU3_+^FAE_\H-,2PK:L*EP2 MY>("OU4-E],0](LY)@N!M7%-,Y>(:0@%<*N@5!"6H;!4P-I0./>ADX(:G!KS ME' 212_ #S7X'];A=I)32#!!TVRQ8C8%0;@%1Z M24WA9_%6H X[H+I$^\=A?NO [(< "B3)"B17XUW8\ZVSV"2G(*ZD0[X^1XM9 M#/3>S)KGN]HN)Y)=NY)]FN]O<.(;'I0-L0NDOU6F0#! M# ( 4E?8LP51HE,7GJ%,-NN0('&PDM*JO 4V,V%#$E!;@OI9C2Y%2QHAKG_6,6ML 5KW53F/!D9DLJZBE M-,UV*O+%09?2D^D$B@MI$B>-]XC24\4*4IQ3#,O"D_?J*0APUDAG^B6O3##1 MA@!!.HU_IL!&8)Y]WZ^'Z3\TGP/F(-)B?_R4 \6\B"PU8%6JJ?O(3Q2F60O[ ML:KXJYWZA\N= W=- VZLQF6#7R 9T[6^Q[^^MUFQA6A\73RA7:<% U+U9VXRQ]8K3/XF-3#\O*\[(1 M5ET:PNQ01B4ZY'& 4QN>H\'< D0%O(C,A'A\.2JY.!WT62CO*\N!"R6Q& E$8X+'VB"R>01#B U3=D20!)) !,#4;IUU=#=D'#C&F'4 M(O2#'&$4N4LJF9!JAP1&PXLR1UCUF7OL'.K^FBN(-_5RY>]B_YET)?W8IG&7 J173C>#/ 2.>3?40C/ MAWTNQTB\*5&ACTL]* G8I*)2CS/I8J<*'8YXG:F;*F^7TU ZT23;/47R^H4' M0V96.2DX5]G^F$'LN?2_SNZ6&:H: 'RC[LC5A#K<.E70#&_V''Q[&'4L3NU$ MS0/IYO+4?F H3P^;3[>%D/+D^4F@=-*4HY2]]KK/U*#7?\ECFY3_MX^YL40U>B_=5IA5U9: MP*0K:)!=YR(.2[%4H07/XX:$6H?XZYXAII(H$\A^C'!BRZ5=XTXF&DCZ1X>J M2\48SV*JS]M 4;CGZT]$*&9)0]D*)O7 M"8 -8)Z1HPAG8["H1:FT74+Z;V@HVV7AY8'8-YQHV;'+S1'6X-*%&ZUW=S@< M.$I!FT>NYUTYJO<8ASC*D"=H<&S@1^(T+&U'RX5P83V$R_(BJ?O7-(*K4(VQ MD-:R$>K+JQ=^,+2N'C3"B+IJ+;/90IO"U[#]?"#?N*&DO1:$IJZNJZ*4YI:4 M\[Y"R+/*,M%(U/0VTNS/0U'VN*PHMH<'Q6K2OH"8'RAS/< AP7L:!YN'90$(J0C&$5 MCNZC9KYN7K,\L%>-N?(SQ^I3'.Z#!#+'_%'"TYJ_R,&HEDQ8[BEG'9#593+2;J2.C 3 R?17 MKN_O]!KE=Z0Z+L@-B$_J1G9#(A'=Q2TL.?!SZ43(CLR-:*>[G&+0+#F+QMB9 MFY_#BPVH#$&740823ED&3]%EG-) B%? "P>R:XV>(0*VW+2JX3$UV U$_L:LL\",S2$@43T=L9Q>GR-TLCUC(U)_>QH+;=T+&Q^K$65\)Y9+1S^RJ7E M!LYH?]H>.)V04/F\>%<66@KV8<^%IV)<=,:&S?DZ5JN&\G@>R,1O=UNUOOHV MZ+ZPAA=LQW0MZ,/TZ@O>!)Z,;F?3V:35K??#7W: MT7@8ONS[?L)$TCWU&71JCJE;3^H8,IA6V$A&>. !RNU0\+$$4DGW/;8@)\[W MTZ.[$]?A@#8:$"SXB2H\TCUX5#0PZQI2O;2B"#\8ZY9\$B)L=&*X43 !Z&[< MO"=$4U,VN^L!UC00[RY=(2S1SBJ"Z08$2\KVN3CV 4&@ M9,&>+FD.=PW1WYD)J^_HN..?_DO'[S4'O0X'Y>OA\KNY8TO SU4_) M+?M8#1"UIXYD3UP[]).@N>$9W^%E[_40+F M#AGOPGJ&8FL <2CW'LF$^)M.%L:OMO-BM6F5$P!A]T/3]P<5+^?K!I!F])@!7_K8KW7SD M%I&^N'C=&UY23:3Q>>)UN>97750XA?_M[>&(*;L<@LSF\S#%X5S],W="^?3A M23ZUK?JW"T5*MQU_6"9FP>/_ER(Q[)W+I6/Z>MY[R3?[_I.E8O"GI )6=054 M]77W0?==]?G=S?AO"L(J"*7&-]>?)[/YP5OO3X Z6#0AYW+*#1.459,6+*S[ M-]?\9 B6YJ6&?\\!A0-$7I4OJ:]U3*&2@> VVQH>#8\M!*(X(8N L>:_+(VT MK)HQ,-UG.*: S=\/HP9B@74O?.72"5W@DF8+3F5298"U;!]ENJOO.AC87R9L M"?NG,-V P\A=/M^&IN3QXHQ8[2NJEV(AMX%5(?Y("*X?J8+!-?:B A1;X/?$ M@88Y'$].<'^SQ_XTYJ:LY:;7*[QS$S+=E;3@=&%HT\KYK;LKX-\G<)B6A9LS M=S=0F*9U0/@^T2!@\PC"9*3LQ@_(T85+G!$@1(NZNL6Q[8;?K^-O+0:7TI&T M]4M)"H\3D?/@?7$7P^/^W)\Y(^KX<[L;_LTA5YHU8U.<(9+,,M^["S-\Q$L& ML MB9\^?J7[/CKM/4U.9@]REX=<;--F&^>_*8D=/1KN->=GLK7 M0,Z+IHSC@VB,(28+A/V1#DEG]L/C='I' M(\/CY@X&S7@"XSDF!/-YDUY-X- M%3WJ\W3-WEWT+TXO^BC1A:C0[HW)'=+NWD-VY3R,T5D?_/Q;MON&A_T+1 ?/ M+^5=@VKL+KR /%BZ<,HHUM,QM8DY2$X:"6^@V4*JFIC--%6\&7CRQ!IND32G M8S$ML:439;2*B;]$%#XGN;Y4E/)V1M;WB_'Y74YU10CUNU@&W2]1N9W@NW : M;V2[O9G!Y_'D\-!H-TA(;D?5/=8-(2J4\A/A+@P8S;^H679&?SW%Z? /9E'* MF!5^E+%PJBX4SMW>$(]N1&F/Y]6BS#80B;UXU3\=]D^DF9Q#%EC2VT#P^R\F M!L]_+Z#KL7/0@DFS\GOS"#^QQ-2@+P<7IR_Z)V_"P7<4GG%0]Y@&\H5;-C;1 M'?NXIH6.XYPZ1TB;P@VHRW#4;AK+XO2=&E!%D>';5(Q[41,8(&H8_? 5 =*# MO0&54&%XLAX,'AP(2 O*&Y%)W'WS&.N:M,(TK(VYD%A(I04]+N[&(V5J@?X5 MSUS/SE!=!6__\I3/TKJY=%2OX-HC[C9QMG",JE:0A!S/)^,3.$5B\IY4/Z@. MXC;P4RE2B%X#@4P>-(,:TVV!SB$^ +LG17R*'?E:;1U5<@CJ&_&#"S?)4$^E M[91WW4U+#@A"L'*G$,-C$GAW KG/[F@K(4Z#NG\(N_,_B=U$X^PP-:S=>WS0 M-)9408'0"(O*;!S%H/XAK/I_$JO=> =[ 6)Z#;\D)KB.5K]EC$=W$>LX,[R* M@S$FMCLDR P%7[HNEW-G97_CNCV/+$3WAZV@4/VR-,-F1FTQ,-[8BP/;]PMZ M9C_Z[LA6)_$\>-DI9.SW]$I7S 2W[OJ?_5OS9VQ"]+K1_G=\Y>0S2$MX@3 MLX2E_;-7%T?\GB'W!4PIO3IUD95EMJ:/. AA&ULW59M;^)&$/XK(_=4)1*)7WC)2P&)MUR1 LD!Z:D?%WN 56RO M;W<-=_^^LVOCD#N@5=5^:(6 6>_,,_/,S*ZGO1/R56T0-7Q-XE1UG(W6V;WK MJG"#"5/7(L.4=E9")DS34JY=E4EDD35*8C?PO):;,)XZW;9]]BR[;9'KF*?X M+$'E2<+DMS[&8M=Q?&?_8,;7&VT>N-UVQM8X1_V2/4M:N15*Q!-,%1=.I#!,%D*\6H6XZCC>"8@C#'4!H'1WQ8'&,<&B,+X4F(Z ME4MC>"COT1\L=^*R9 H'(O[,([WI.+<.1+AB>:QG8O%O_L:YF' X-;[X1!4!H$-N["D8URR#3KMJ78@33:A&8$ M2]5:4W \-469:TF[G.QT=_XRF?1FO\/3 \S''Z?CA_&@-UU ;S!X>IDNQM./ M\/ST.!Z,1W/H38R;]X"S@'+-KJ'LU"+P@.(-7KS)3MWCU?R4S MQQ)2^&L<]V=.W[W*6(@=AXZ70KE%I_OS3W[+^^4,FT;%IG$.O3NGTQSE,8)8 MP8IQ"5L6YP@),I5+I%.FS0Y3"K4"ED80<[;D,=<OEJXF.;B+@$47,0X(K0[YXQ"W&X%_" MG*]3OJ(]0TEO"%DL302F40DMR]^T@_?:>7I2LWX)XW2+2MM,44SX)>?Z&R@, MM^3]_R[YH';G^27A0[D@?Z:#FU4' M-_]R!],]S$/;IA&/O>'1SY,\P0ETT+>PQ1-^D*1X#[,#W!Q4V3*RG[-;[;*Y1!301=^8?G9OETP MNF); EMCF0'+4 &];)6F;% "H-F\JP6WMOW>R:/5BEZ$)GDV9::G#NIW19\? M?.QS6WHYA=RWH9PL@.'E7>\9EM+PS\IVU&I*E8+DGR]!4*O7&V]5J-=:7O/_ M7@7_;U6!K(X=9?=@ *%4K^V8I2 4>:J+6:1Z6DURO6* >5,OQL )DVN>*HAQ M1:;>]0T=5EF,5L5"B\R.,TNA:3BRXH:F491&@?97@F[0&ULG91=;]HP%(;_RE$V3:V$F@]H!QU$*BW;<@&M&M9IER8Y$*N.G=D. M=/OULYV048URL1OBC_.^?@[V.>.=D,^J0-3P4C*N)EZA=77M^RHKL"3J0E3( MSY$)?.C(+CR2T*Y%X_=VH.,QZ+6C')\D*#JLB3RUQ29 MV$V\T-LO/-)-H>V"'X\KLL$4];?J09J9W[GDM$2NJ. @<3WQ;L+KZ<#&NX G MBCMU, :;R4J(9SM)\HD76"!DF&GK0,QGB[?(F#4R&#];3Z\[T@H/QWOWSRYW MD\N**+P5[#O-=3'QAA[DN"8UTX]B]Q7;?"ZM7R:8?,E+^S\<"(;!&X*H%42.NSG(4=X13>*Q%#N0-MJXV8%+U:D-'.7V4E(M MS2XU.ATGBZ=9NIS/%DM(%I#,;[XD]PN8)O?ICW0YFZ=PMB0KANI\[&MSG!7Y M66L];:RC-ZQ',!=<%PIF/,?\M=XWF!UKM&>=1B<-4ZPNH!_T( JBZ(1?O\N] M[_SZ_YG[L90;Q\%Q1UM!UZHB&4X\4R(*Y1:]^,.[\"KX=()WT/$.3KG'J:G( MO&8(8@U90?@&%6@!ND"@?(M*FV+19@A)23;FR1_C/WG"X)U.D 5:8U9)J:IC/HJ$+/M^'&V0; M6G/35AC]C3FL"96P):S^1QOVAL&HE;\F,\]#MVCM&S%H!NMJX,*/78!_4#@E MRHUK#PHR47/=U%"WVG6@FZ;P_H8W[6M.Y(9R!0S71AIVBIMNTCPX< =78S#:E_?>S#6&)E.;+OH#/OO?Q M>^!SV CYK')$#:\EXRHBN=;5S/-4DF-)U5!4R,U*)F1)M0GEUE.51)HZ4G7DD+3N+0S:UD'(I:LX+C2H*JRY+*MP4RT41D1'83C\4VUW;"B\.*;G&- M^D>UDB;R>DI:E,A5(3A(S"(R'\T6$YOO$GX6V*B],=A*-D(\V^!;&A'?&D*& MB;8$:EXO>(V,69"Q\:=CDGY+*]P?[^A?7>VFE@U5>"W8KR+5>40N":28T9KI M1]'<8E?/A>4E@BGWA*;-#:8$DEII479BXZ L>/NFK]UWV!-<^N\(@DX0.-_M M1L[E#=4T#J5H0-IL0[,#5ZI3&W,%MS]EK:59+8Q.QP_?GY9K6,U_SQ=W2SA[ MHAN&ZCSTM&';#"_I.(N6$[S#N8)[P76N8,E33 _UGO'4&PMVQA;!2> :JR&, M_0$$?A".-_[O0EO.Y#C'-LE,533!B)@N4"A?D,2?/HRF_I<3+B>] MR\DI>KPV39?6#$%DYFQM-*2%2D3-]3&C)U''C3X(C0HJ^F;+AX\PFO@#W_?A M#I6:P4VWF0+3+_P@]6SD\L[A@# ;NX-Z[57&N;XRN4>^QS>WDDM46Y=/RIP MVO;0]K-]R\_;D_XOO;TO[JG<%EP!P\Q(_>'G"P*R[<$VT*)RYWXCM.DB-\S- MM872)ICU3)A2NL!NT%^$\5]02P,$% @ FXIN5<1C@SLG P ? @ !D M !X;"]W;W)K&ULE59M3]LP$/XKIVS:BP3-2YO" M6%NI%+8A\5)1!I_=Y)I:)'%F.Q3^_6S'#2F$L*E28Y_O'C_G>YS+:,/XO5@C M2GC,TER,G;64Q9'KBFB-&1$]5F"N5E:,9T2J*4]<47 DL0G*4C?PO*&;$9H[ MDY&QS?EDQ$J9TASG'$29980_'6/*-F/'=[:&:YJLI3:XDU%!$ER@_%W,N9JY M-4I,,\P%93EP7(V=J7]T'&I_XW!+<2,:8]"9+!F[UY.S>.QXFA"F&$F-0-3C M 6>8IAI(T?AC,9UZ2QW8'&_1?YC<52Y+(G#&TCL:R_78.70@QA4I4WG--K_0 MYF,(1BP5YA\VUM=S("J%9)D-5@PRFE=/\FC/X5\" AL0&-[51H;E"9%D,N)L M UQ[*S0],*F::$6.YKHH"\G5*E5QJ+;2C&UFXXPHN> /N&URP7*X%G.8QQKOQKJ)6\PNV_(Z#3L %%CWH M>WL0>$'0@=>O\^T;O/Y_Y-N69H4R:$?1-^5(%"3"L:.N@D#^@,[DTP=_Z'WO MX#BH.0ZZT">+ZH( 6\&,907)GSX+4$J([H$5SUJF\JF->2=V.W.X++,EGN=Y\!&\ MGC> 8<\;[IK]T Q^(2]X4MZT"&( ML!9$V"F(^NP+??8"%#'8V +L$UN 2%T\KH11DA12]:8SK)NJ48;GK-J4TTGB M#>5LJ]L\L+:*OY"/E40P@;WL/^:ZLUZ(<_:*#X6^P=JS68H$ K>"NC@]ZAWV*VEC:!N8V.D"%/ M3-\32B-E+JOF4%OKUCJM.LJS>]67+PA/U V%%%!5KZLFDA6FORR9 M5-W*#-?J\P"Y=E#K*\;D=J(WJ#\X)G\!4$L#!!0 ( )N*;E6/S1BX0P( M . % 9 >&PO=V]R:W-H965T4L1")1ZOQ8121=OULD@M8=>+,-M#]^]E.B$!-T:;M2^+'/>>>.[ M;L_)"2UP'-FSA8@COE.,%K 02.[RG(A?8V#\,,0>/AXLZ6:KS($31R790 +J MJ5P(O7,:EHSF4$C*"R1@/<0C;S )3;P-^$'A($_6R#A9R99FH[Q'V,,EB3'5-+ M?O@&M9^NX4LYD_:)#E5LU\2TJ-[DM:[#"< +WP'X-<#_4T!0 M P)KM%)F;4V)(G$D^ $)$ZW9S,+6QJ*U&UJ8KY@HH6^IQJEX/$IF"7JX1XOE M77(W?QP]SA[FZ&H*BE FT9P(04RAK]$->DJFZ.KC=>0HG=C G;1.,JZ2^.\D M2:#LH,#]C'S7]UO@D\OP*:0:[EFX=PYWM-W&L]]X]BU?\*^>VYQ6U&$[M>FY M@2Q)"D.LFTJ"V ../WWP>N[7-M__B>RL"D%3A> 2>SQ*TUV^8T1!9OY[FE+5 MYK6=D_XSL^\[$1M:2,1@K>G=SFT7(U'-DVJC M>&E;#/7X-U!+ P04 " ";BFY582LQ MU^X" "0"0 &0 'AL+W=O)1U$(F&MHM4*..Q:9KVP80+6$WBU':@E?;C9R=I!(5FK<27 MQ';N.3[WGOC1WC!^)U:($AZB,!8=8R5E($AVW0,VW@:&-'E M2NH!TVTG9(ECE--DR%7/+%GF-,)84!8#QT7'Z-KG7DO'9P$_*&[$5AMT)C/& M[G3'GW<,2PO"$ .I&8AZK='#,-1$2L9]P6F44VK@=ON)_2K+7>4R(P(]%OZD M<[GJ&"T#YK@@:2A';/,-BWP:FB]@HL"EB+0."5$@6%6"E(*)Q_B8/11VV M ';]!8!3 )S7 FH%H)8EFBO+TNH12=PV9QO@.EJQZ496FPRMLJ&Q=G$LN?I* M%4ZZXVF_WQW]@MLK&/O7 __*][J#"70][W8ZF/B#:QC>WOB>?SF&[J 'H\N; M[N2R!_WN9'(Y&L-)#R6AH?@(GV$Z[L')^X]M4RI=FMT,"@T7N0;G)0V8G$+- M^@2.Y3@'X%XUO(>!@ML9W-Z%FZH:94F2HCB47T[8S CUNEF[MM6L6Y;5-M?;B>S'.5\L>SMN1W&M5%RK5/P] M91+GD' :H-"B\\6A_A-^AU* 6NQ YRHA&I 0B!!Z\'9<)"3 CJ$V$X%\C8;[X9W=M+X>,O1(9#O%JI?%JA_;WIRP\5][ M]^,J[6V4BAN5BL=T&=.%\DY)9G*%'-A,5X7,0E0Y).DA-YU*-RLG?*N;1R+; MJ4VSK$WSV&XV]UQZ[F-5Q([*LU+EV:L=3.-7N%>K=*]RLK>Z=R2RG;JTRKJT MCNU>:V\+?>Y>542NTMPZ+_5=I4_XDL8"0EPHC'5ZIJSG^?F?=R1+LB-TQJ0Z MD+/F2EV9D.L ]7W!U 9<=/2I7%["W']02P,$% @ FXIN52T5E4RB P M0@X !D !X;"]W;W)K&ULK5?O;]HZ%/U7K.SI MJ9->&R MWSK7@P-EW_@68P%^)''*A\96B*QOFCS@8JE6=*OZG! M-!H:4$6$8QP*)8'DSQY//N(B(5?IA33F^B\X%%AH@'#'!4T*LHP@(6G^BWX41AP1 MI$XUP2X(]CFA]0;!*0A.TQ5:!:'5= 6W(.C4S3QW;9R/!/(&C!X 4VBIIAZT M^YHM_2*I*I2E8/(MD3SA+9]FL]'B*WBX!\OIA_GT?CH9S5=@-)D\/,U7T_D' M\/CP:3J9!DLPFOM@$7P:K0(?S$:K5;!8@AL?"T1B#JSWX!8\+7UP\]?[@2ED M9$K?#(LHQGD4]AM1.&!&4['E($@C'%7P_7I^KX9O2D=*6^P76\9VK> 29W? M@?\ &]IV13R3YG2K*IT_6SWX[=5/S'#*&G&TGO.&WGR78(8$9?VJG# MI"%-,+B)*>>5_V&Y1%M+J,_#WKOM6!#"@;D_=K@"9EEN^Q70KP#:CM-Z!0PJ M@$X;NL? DZS=,FNWMNQ\G%)YXKU9>.XU"^^:8OXUQ8(KB9UL0;O<@G9MX7W1 MWUDH.O< MGP 8[#'2."5/O0?17)^>ET$>%?1 1UB),\>V6>O=H\Q[KH,6*I MK'1>',$@PRS?\JI,>Z_.Q/-,+R+\BX@@1W2/3UYX!ZWJ;"WXLR6$M?GZ14'_ M4L:%9EW*ER'^94A00"YE;1[UQ+)]V>C+" 47EGP@:*8[\F9 LCW:TK%RT M4%X;O?\!4$L#!!0 ( )N*;E7#:F>WTP4 "0@ 9 M >&PO=V]R:W-H965T8\_"5Z)K6O04WED M[$G?#./+AJ-'A!,<20V!U-<2^SA)-)(:Q[+.:>$Q<@B?H7 MG*V Z]X*35_D[.?6BB]"]4*92*Y^)>;X?70']S< MP\#WOSS.!O=A ./!_7UX-X$/ 9:() )N$.=( MQ_PC_ 8/DP ^_/SQHBG5"+6?9K0>S54Q&N^=T?1@S*B<"PAIC.,:^\!L[WH& M@*:BIN3'>^7GRC,B3O#B!%K.)_ ]KM M=APUDN4V@T:?NE">BP6*\&5#54*!^1(W^K_^Y':=W^OXM D66@*K<-TNN6X; MN;[E+,(X%C#E+ 6!$@QL"D@(+ 7,<1*#>DKD[77D%]C=+?);COY[0_UAW8+# MNH7&"?T@79V2KHZ1KCNLGXJ$S@"E+*-R0U8=/4:L(U>);Q,LZ.QD3:^.:DL^ M*U1W2ZJ[YBJ Q!RN@Z$/A(J,JR)04%Y'='=G.EZG9AT:'1Y+H4VPT!)8A>C3 MDNC3_43C9UT&],+>S_;I;IZV=\G>[?4VWXW#.I9!2V 5!L]*!L^,# [B?]46 M2G.F2P$L49(AO3^M(\^(=&Q-L D6V 0+SW:B[WJ5C*P0W2N)[AF)GFP_G^K8 M-9H?RZY-L*"WCY""-TL^*^RZSF:7[ACY'=*(I1CNT3.$STCI@'P9?X(1><() MF3,6:_8?Z!0M&4>/*AA*XLD$*TE7&XX][@84,AIAKO;V5-6=W+=4OA=,D%S? MK4B2 &42'K&2BQ&;4?)=I1F9 I$P1P(2+ 3(.5)2$#K.+Y!4!OJ(=4$3*C>5 M QR?U 79/,1CHVP5+;2%5ET-6YK--8;G:RY_=5E;8J[D/- L?<0<8I)DTK@I M7P-7'LAG/<_KN:=OGA(']PS,@SV:6DMH56J]#;6>D=JQVD2F60I_C[&F])]: M$HT0QQ8SJVB!5;30%EHU&!NYZ9KUIM) "U6$7@#1&/"WC"QT/8-,X&F6J)*R M?&>1FU%;\((1K[/TS99'Q\*J&+6%5HW%1HZZ9CTZ1L_[$\.2 EP'PR9:8!4M MM(56#<9&[+IFM?NCB6%&=1U#9EA5N5;10EMHU6!LY+!KUL-#"FK#V"LS _Z# M6R1U/!(282HPH!G'^59LN\^("1@D2LSIEZ=Z4X42M6F+,DY47$CV;; MJEBWA59E>R/7W3UZ/65Q/%M%"VVA%3PWMTX]4\QG^7&S4 LWH[(X MTRI;RR/M07Z0^Z;]RCWWW9KVP#T/BP/K#7QQ?CY&?$:H?LLQ5:Z,R=<;[:#\QX#^_U!+ P04 " "; MBFY5^+[)-S8# !5# &0 'AL+W=OH9)KKGCCN>(U7$(*X7]\R.=,;EIADD'-"<\1@.=&NS2M_I.Q+@R\$MGQG MC%0D#Y1^5Y,@GFB&VA"D$ G%@.5C S-(4T4DM_&CYM0:EPJX.WYB?U_&+F-Y MP!QF-/U*8I%,M L-Q;#$12KNZ/8CU/$,%5]$4U[^HFUE.[(U%!5^+'680<@>;H!5@VP_@8,G@'8-< ^UL.@!@R.]3"L 67H>A5[*9R'!7;' MC&X14]:230U*]4NTU(ODJDY"P>1;(G'"#6Z^^.%B[M\L4'"#_,_WP>(;"OW9 M_5VP"/P0G03SZP_!IQLT#3Z%W\*%/P]/T8D' I.4GZ(S=!]ZZ.3UZ5@7* M4X]JS]/*L_6,9QO-:2X2COP\AK@#[QW&7Q[ ZU*%1@KK28JI=9 PA/4YLHVW MR#(LJV,_L^/A9EV+835W8)9]]5%VTBZ KWQ7CH)M1'7A7?(TC MF&CR1./ -J"Y;UZ9CO&N2^P^R;P^R?R>R/;2,FC2,CC$[DYQBO,($.:(+I$' M$60/P)!M/EMVTX.$+\U*GV1>1>:49.H^V[C6I6$:AC'6-[N"]^1T3_!A(_CP MH."S!.>>Z$XCNG.,Z"0O!2]RV0"EY!?$:(D)0QN<%D=DP&E5EVD,6G'.VF9GEZ.V M'I[3ELV\,"[;PG40VH:S9[@GRJ@19?2"3U^>]Z+^]I^_,Z8'&5]:A7V2>:.. M[#CM]/@].:T4UW?ZI S8JFQ0.8IHD8OJ:FQ6FQ[XNFS]_EJ?FE+^H:\:[CEF*Y)SE,)2NC+.1[*26-7$5A-!UV67]D"%[/G*82+[?F#*0+Y? M4BJ>)LI!\T_"_0U02P,$% @ FXIN5>=LV+$ P %PD !D !X;"]W M;W)K&ULM99M;]HP$,>_RBF;IE9J20@0: =(A=*- M%]"JT$[3M!:4Q+;K.)Z=$,JL;CL; MNQ'=-E^HF#*\$2 724+$4P]CONI856LS<$O#2)D!N]M.28@35'?IC= ]NU ) M:(),4LY X+QC753/^RUCGQG<4US)K388DAGG#Z8S##J68Q+"&'UE%(A^++&/ M<6R$=!H_UII6$=(X;KU0 MRT#SS#*L2Z)(MRWX"H2QUFJFD#V&WO!Z\G4R'8PF<'2)BM!8PI@(0C]<=M6.@>C M9/OK>+T\GOM"O#,8<:8B"0,68+#K;^O<"P!W ]!S2P4GF%:@YIR Z[CN@7SZ MKW>OEJ13*^:SENG57]#K1X2%")3!@NE3%=.?&$"H3Q-DOR5*I<^ .C1QN;"7 M"9O#M^R>5EO.F>,X;7NY373 L.9X.X8[N=>+W.NEN0\3$IJCU:-NW*E&;R1SROXO'(^GB1Z)R*4]MC*8WV1I96 MP=(J9;DB5,"2Q L$/O_#=FL]VVY5QZL_WVVE$?^6Q]ZJ,0F*,"N]$GR^8"J_ MK8O1HKI?9$5M;[RGJWY>I'_+Y)\,(R)"RB3$.->23J6I]Y_(RW#>43S-*MF, M*UT7LV:DOUQ0& /]?LZYVG1,@.);J/L+4$L#!!0 ( )N*;E6UZY$$2@( M ((& 9 >&PO=V]R:W-H965TV_GVT((@K-HFKY$'SL\[X^ M#Y8/0<7XH\@ )'K*:2%"*Y.RG-BVB#/(L1BP$@JUDC*>8ZE"OK%%R0$G1I13 MVW.K@:Q):CBX( M*,12.V#UV,$<*-5&JHP_C:?5;JF%W?'>_;-A5RQK+&#.Z"^2R"RT/E@H@11O MJ;QGU1=H>$R!,:/"_*.JSO6'%HJW0K*\$:L*.P'U)X#4"[UR! MWPA\ UI79K 66.(HX*Q"7&K1.ED=/?]Q\T*+:>_ MI[/;&W2Q (D)%9?H&CVL%NCB[65@2[6-3K;CQG)66WHO6*Z@'"#?N4*>XWD] M\OEI^0)B)7>-W#V4VPJN)?1:0L_X^><0]M'4\F&_7-^BB2AQ#*&EKHD O@,K M>O?&'3N?^MC^D]D!J=^2^J?O$OK-IQU,&Z=H^I3N[[2JI12S4Z M_V2N4*&Z,TM1LJ?L@QH=GY7_\9BJ+^W@2.MZ[4Z'T-WY&^8;4@A$(55"9_!> M^?"ZX]6!9*5I&FLF50LRPTQ])(#K!+6>,H74!+H/M9^=Z"]02P,$% @ MFXIN59GQ4JHP! DAD !D !X;"]W;W)K&UL MK9E=C^(V%(;_BI56U:[4)1\$&*: !"115RJS:.BVJJI>F.0 T28Q:QN8[:]? M.\D$ L$#6M] 8OP^QSYO<.*3P8'0+VP#P-%+FF1L:&PXWSZ:)@LWD&+6(EO( MQ"\K0E/,Q2E=FVQ+ 4>Y*$U,Q[*Z9HKCS!@-\K8Y'0W(CB=Q!G.*V"Y-,?TV M@80U* M0=[CKQ@.[.08R:DL"?DB3SY&0\.2(X($0BX16'SM80I)(DEB'%]+J%'%E,+3 MXU=ZD$]>3&:)&4Q)\G<<\#!0!"N\2_@S.?P.Y80ZDA>2A.6?Z%#T=5T# MA3O&25J*Q0C2."N^\4N9B!.!X#0+G%+@G NN16B7@O:YH'=%X)8"]]8A=4I! MY]8A=4M!-\]]D:P\TQ[F>#2@Y("H["UH\B"W*U>+!,>9O+(6G(I?8Z'CHZ=/ M?_H+-!__,Y[\X:-W'G <)PP]84JQ]/P]^H ^+SST[N?W Y.+@%)FAB5\4L"= M*W ;S4C&-PSY6011@]Y7Z_L*O2DF6LW6>9WMQ%$"/X6\A1SW5^18CM,PGJE: MOH!M"[6MJW+OANAV3\KM?E,V?BQZ<+O<5N2R75TY[9SG7N&-4T)Y_#_.%PBR M0AXL.?)B%I)=QINN%25.KJ"/;(M#&!IBB61 ]V",?OG)[EJ_-1FE$^;IA/D% MK)O#Y+J^']E]R[(&YO[4J\M>XEYPTJMFB5M9XBHM>88M_B:6?@C'! MH@4O$V@RQ+T80]NZ&.GTLI=]V%!:PCCID<#FP*^GK5.GK*-/W)/+% MT/QZPCJ7J6@8V%09Y=YK4R?,UPD+-,%J5G4KJ[I*JSYF4;R/HQT6]ZI_9Y N M@?[7Y)B2J=W MCI9E=\Z\TADRT 2K>=6OO.J_L5AR$%2.Q"-]HU-*^;U.Z81Y!:Q?<\H^\TEG MP$ 3K.:3;1TW8Y;2J?P9.MH!BJXXI=;?:Y56FO?&W,3NAXC;=+D!:MS!^%H' M%.BBUK6.D=KG1_;*:CU M=_OJ7&Z(W(9-F-:H_HU1 UU1ZUXT1O5OC!KHBEIX89Z4C%.@Z[RXSU!> MO"MJ@%5K]0)AG)?-S]HG]J-G-[3[\H5#7J(^XHNW%3-,UW'&4 (K$G7,34$ #T%@ &0 'AL+W=ODQ@(T ,DH-V[2KLM*MW=UR89(-HDYFP#[;<_ MYP\)M&%24MH7Q4D\S_AG9YQ'[FVY^"V7 (H\A4$D^\92J=65:4IW"2&3EWP% MD7XRYR)D2E^*A2E7 IB7!(6!22W+,4/F1\:@E]R;B$&/KU7@1S 11*[#D(GG M$01\VS=L8W?CP5\L57S#'/16; %34#]6$Z&OS%S%\T.(I,\C(F#>-X;VU9@V MXX"DQT\?MG*O36*4&>>_XXM;KV]8\8@@ %?%$DS_;& ,01 KZ7'\EXD:>2"3_V2;]FU9 M!G'74O$P"]8C"/TH_65/V43L!6C0\@":!= 7 ;9S)*"1!302T'1D"=8U4VS0 M$WQ+1-Q;J\6-9&Z2:$WC1_$R3I703WT=IP;CX>3V/M_=V4 M?+X&Q?Q ?B%_D1_3:_+YTY>>J72V.,9T,^51JDR/*'?)=QZII20WD0=>2?P8 MC[4H&L8H[72>>M=?*&C@<$ MW9R@6_/=8K, R.)XS70K5P;-7'-E;*OX8EKO(4,K*)/&X/#L=>GV_(#]/KJC M%94)HVQH[KILM&"CZ!?W5V+JP"/##0AM4LDW?UY:/9G.F;ZYYU([I"YLAHU^ MU,NI#_>3F\K]I")'BSP#$Y*T29AZMB[QV+,LG0U^PFZ>M M^TU6HV0B_".\J)4Y^0TXD]HA?V%9;-RS5/!?D-G.>I5.12K>V:_K2ZOYLK0_ MPLC8A9.Q<2M3B8B8-+O:U^#9Z](5SL;&K4TEW0VR+5<['3Q[7;K"Z]BXV:FD M2^U.*5SG3>]F1:_#<1<.Q^ZBV\IPL1"P8 J('RGA1])WR88%Z_(-Y4RF)2/Z M" M$"PM$<0MTE+QB*\EDG;V%L%NO/2F>O2Y=88$H;H$0.L2VTFK[@^>MRU78 M'XH:#8P+V3\R493K(PP.+0P.Q2T#RH68\4P6)?N(\Q):&!>*GY@@9,?WQ$S3 MP;!>=SFLPW2\YMZY8@ABD1RW2N+R=:32(\;\;GZD.TP.,LVB>WH>_)T)O2]( M$L![BSA!?M ]^!]0 M2P,$% @ FXIN56HZR'^)!0 RC( !D !X;"]W;W)K&ULM9MM;^HV%,>_BI5-TR9U36((M!T@4;"U3KN& @ MNGG@.J:TWWYQ" FFP227T[YHD^#SL^,_QSG]R^FM8_$M67 NT5L81$G?6DBY MO++M9++@(4O.XR6/TD]FL0B93$_%W$Z6@K-I%A0&-G:S:@QCT MXI4,_(@_")2LPI")]VL>Q.N^Y5K;"X_^?"'5!7O06[(Y?^+R[^6#2,_L@C+U M0QXE?APAP6=]:^A>4=Q5 5F+?WR^3G:.D;J5ESC^IDYNIGW+42/B 9](A6#I MGU<^XD&@2.DXON=0J^A3!>X>;^DTN_GT9EY8PD=Q\-6?RD7?NK#0E,_8*I"/ M\?I/GM^0IWB3.$BRWVB]:=M)>YRL$AF'>7!Z'OK1YB][RR=B)P![!P)P'H#W M MSV@8!6'M"J&]#. ]IU [P\P*L;T,D#.MG<;R8KF^DQDVS0$_$:"=4ZI:F# M3*XL.IU@/U+?K";^[OGM"O8RZ9'R3( M_0W]CGY&-DH63/"D9\NT2Q5H3W+\]0:/#^ OT6T3H=:C!=O MQWN-C< GOCQ'+><,80?CBO&,S.%_K2)C^-@#"?F\#&?%.%N13BM M'^X8YK)5:-_*>.T#O+M5^,(%BF?H?JG2/#E#]RN92!9-_6B.KOG%D/:A5['>".YZB?GOVZJTO=AN.Z#4G=AK1&0VW^VL7\M8WS1]ZX MF/@)1P_"GW#DG#L>^O>6JTG]KVJNC#3U"+E*EFS"^U;ZC$BX>.76X)>?W([S M1]7W'!(VAH012!@%@FGZ>H6^WJ?GA_?AN]=RJM+#.)*FN=,).@2 MA=D#KRIEC82F&D/"""2, L$TC;N%QMUF&NMK=)6N&^#%3H:JA7PO/8V]-I4. M$D8@810(IDEW44AWT6RUW6K'7@+^ ROO1V4E;$8UEAR21D!I%(JF2UXZ/*[9XOF!>C@G[CUM._M) M:^RWL8*0- )*HU T7<'28W+-)A-T69QW5V-9!G680&D$E$:A:+K"I2:G2:0$KE;TZ,PCZ6QJJ &%"B-0M%T54L/RC6;4*>6R&:ZFY7(1H_8 M3&BL-*@?!4JC4#1=Z=*2?='5^-S>-JJC HC8#2*!1-5[BTH;#9ACJU,L[Q1Q+6/(C&D[X\[<5X8][=ERO M3"-904UHD!I%(JFRUH:4=AL1)U8&A^A=_?V3R#L'G2/S:C&DH,Z4Z T M"D73)2^=*7R2,U4I3%M2, J414!J%HND*EF84-IM1X#5RI_:Z#&I$ M@=((*(U"T72)2R,*G[3EZ7B17+D!ZD/&@CI0H#0"2J-0M(V<]L[6_)"+>?82 M18(F\2J2FUWZQ=7B18UA]GJ"73;?O.5QRT2:H0D*^"P-=6YY;<$\EQ8B(1DL&.)%FF+VYQH2NAMIIO9R MX9[$&Z$NZ)Z;XQA"$(_Y@LF9WJBL2 H9)S1##-8C;6Q>!8Z*+P.^$]CQO3%2 M*UE2^J0FL]5(,]0#00*14 I8_FQA DFBA.1C_*XUM2:E O?'+^I!N7:YEB7F M,*')#[(2FY'V64,K6.,B$?=T=P/U>FRE%]&$E]]H5\7:,F-4<$'3&I;SE&35 M+WZNZ[ 'F,,3@%4#5E=@4 .#KL"P!H9= ;L&[*Z 4P.EF7I5K++2/A;83A]G=/$1G/@A, M$H[FF#&LK#]'']%CZ*.S]^>N+F1>1>M1G>.ZRF&=R!%"?HD&Q@6R#,LZ@D_: M\:]%UHK[[?@M9A(W3^+3=MR'J,'-(WC0'3<.<5U:U?AE-7Y9I=[PA-Z\2)? M$%VCNUS]-?D%NBL$%SA;D2P^YDVE9Y=ZJLUL/V^"UT#_:Z!TZZ! M08? @VH-FFH-6JLUCF,&,1: 2"88D>TP0EN<%'"L4*U2JL%?\1Q',-)D!^? MMJ!Y']Z9CO'EV);N4\ROQ)R]\OQ;Z=<1IOVZS#T]U($5P\:*8:L5H:#14[UI MT<];4-OXUS$;6F7>:D.?8GZ?8M,^Q8*>Q Z,M1MC[9X[DMVU([4F?JM[?8I- MNRXAZ"GK@3-.XXS37_=S_M=C)JW)WNI&GV+3/L6"GL0JQ_2]DYDZJ,O#2"R- M0 FLI;QQ^4GN#U8=?JN)H'EY6%M2(8]^Y7 CWQ> J0!Y?TVI>)FH\U_S!N+] M!5!+ P04 " ";BFY5IMS-M5\" "X!0 &0 'AL+W=OL;)I::2(A0+9V(5)I65=I( 3K]ME-#F+5 M/S+[ N6_G^U QJ843_?.T;MTI_2S*0&0O @NS3@H$:OK,#1Y"8*: MGJI VI.UTH*B7>I-:"H-M/ @P<,XBI)04":#+/5["YVEJD;.)"PT,;405.\G MP-5N'/2#X\:2;4IT&V&65G0#*\#':J'M*FQ9"B9 &J8DT; >!S?]ZTGB\GW" M=P8[GJB!6\5_L ++9+7P[W< *(XU< \0$0>]U-(:_RCB+-4JUV1+MLR^8"WZI'6W%,NI^R M0FU/F<5A]O7A=CI?30?_VG]7KPW%L)O"V>;:5#2'<6!]84!O(O>DGT:MP.$Y M]FS&)!.U($NUIQSW9$'WUA/8);,A2CR1,^,V&T7V2<-M1_U16W]TMOZQ;@4Z MMW6M48DU4^%"3BJMBCI'TZ6FH;TZ41/U^MU:DE9+\A]:%):@"6=VRT!Q5E/2 MH2D:_24J/'&3 +WQ,\.07-42&V.UN^U8NFG<^#N]F6DSJC=,&L)A;:%1[X.] M%-W,B6:!JO+>?%)HG>[#THY6T"[!GJ^5PN/"%6B'=?8+4$L#!!0 ( )N* M;E6"G7,ML0( 'L) 9 >&PO=V]R:W-H965T6$[P2VHM5& MFF3)V(/N7,L'AN8 *7:2*7QI_8TFI!:V&X_NG\IV17+$@N8 M,/J#Q#(=&4,#Q9#@-95SMOT*-4]?^T6,BO(7;:NY_8&!HK60+*O%*H.,Y-43 M[^IU: GLWA,"IQ8X_RMP:X%;@E:9E5A3+''@<[9%7,]6;KI1KDVI5C0DUU4, M)5=OB=+)8'[U;;RXFJ+9>+[XB1;S\6TXGBRN[VY#=#(%B0D5Z!9SCO5JGZ)/ MZ#ZU2;N_+ M3<7<@#L-N%/Z]9[P&T<17T.,8*Z:DWR":P MW;YM699O;MHL1^;9SGE[WE[2;I.TVYETR"B@NR0A$7#TZP:R)?#?Q_+LM-$G MPX4H< 0C0VU] 7P#1O#AG>U9GX\5YI7,]HA[#7'O#?9;R^^ZWF&5.D._ M$*S?@/4[P28I)NH8RCO+V&GQW#*^DMD>K=?0>F]01N^@C.?N^6$9.T._$&S0 M@ TZP2X9YC%B"9H2KFXFUKTM.[V>6\]7,MO#'C;8PS>HY_#@5!P,#\O9&?FY M7&;K:M2?)3>8KT@N$(5$V5MG _7OXM557W4D*\K;I] MPIA\[.@+N/G>"OX!4$L#!!0 ( )N*;E5)Q@V=4 , *P/ 9 >&PO M=V]R:W-H965TVC'2ML]3'LPX0)1DSBU#;32?ORNDS2%$B)0S4.([7O.];W''[F=->,/8@$@ MR5,<):)K+*1,+TQ3! N(J3AE*20X,F,\IA*;?&Z*E .=9J X,AW+(K;N&;;QTW(3SA50=9J^3TCF,0=ZE(XXM MLV29AC$D(F0)X3#K&I?VA=]6]IG!?0AKL?%.5"03QAY4X\>T:UAJ0A!!(!4# MQ;\5#""*%!%.X['@-$J7"KCY_L+N9[%C+!,J8,"BW^%4+KI&VR!3F-%E)&_8 M^CL4\;047\ BD3W).K=USPT2+(5D<0'&&<1ADO_3IR(/&P#DJ08X!0W>Q&#+B)V7B/M. M+>'/0)Z2AOV%.);C5,QG< #<:>Z%#^OA8TC1N[47[KT/[A\.MVMRV2A73R/C M:^[ANX&4/N,Q(P7!,XXD3 +!'CJ)H&JEU)*I(_1"I#2 KH%GI "^ J/WZ8/M M6M^J9,K)W(Q,'9^K7L/"7\=<;:JQ:V7O6GD'6?F[5J\66^EKENEKUJ;O&O,E MR&A_PFKAQR:LN1MD191#G3X]G62^)K(MJ5JE5*U:J7#;LPEPX%7E>&^8-R=*LEIDPB951]KK &PO.RUI^_7QVFK[@0XP/&RQ5B7V/[[G'=Q<<=5B;M6 W"\9,M"J%K$=D M84SU,8[KV8*5M#Y3%9,6*90NJ;%3/8_K2C.:U^!4BKC7Z:1Q2;DDXZ%E MJ:.96DHS(N>M*?*W+_F(=--S$GFZB3O1Q^.CCIWIY>' M]A,'G)(X2-I_!NE9IX,3 XB1I\\C?XH;H[[8IW;+CRV1=SQV;G&3U_&P4'*; MWH1X@^6E)8ONJ1B1"15\JCEX%;3D8NW-/3#,E% Z,K:N-E 7+/6#A[M^!B5O M>$HNE7:Q?03_=]HL/P V,Q#(A6@%]H@WC(<5-89I>64G;K$S/H*B9GR[KJS" MN:;K;J]/M@[N9H-,EAH_ ?Y=-L^]2]MY$6]4\7ME M/B_M=J2;0X^Q:\T*OG+S5=$*P-B[.#NM*K'^)/AH^>_F><[DHP/.TALZM:^1>_QV?X9UF M69*D*9;1R22H8(+E+4WA&V;#M($'%@6A:N-Q0$/K I8[T#\-8?20$3;8T.P6BP^0"X99K>] M9!:GS_? JY,M:B!?T(\^*LN_LE-K?NVZ9[EB> ME%_$GA6Z92MDGBA=E,]NN9N7ZKU7/SA!?.X\/Y73/IF@6A6*JX M*'1E5;'D[+7\TUX5T9&7?,TSKG[VG?H^8P[*><%S_L8V?:?EH'(G7K\*R=]$ MH9*,IE)D6=_Q3@U+)A5/_ZJF%62:)!^DZOI5^XY;)4]1/U^Q/- M>&3ZX5/IH,03SQ23PT2QD12'/2^>J]?H7KA&-^HXG*^G(-[+?PFCV&YYRH8B M/>2L4*EH8Q(R7NN&R39U'@6 M4:;1,(QH.$3ZCD['9(AC71C@,8Z"$!F0/@#I7Q'RNV] M@'(]E4@::PODS R M(#L 9.>*D(U(=@'([C4AVP9D#X#LV84<8$HHFCZAV3RD8:39R-00M WMJ%)-$RI+&>&#$B$2(3/-+Q M0P,RI2NJA]F O ,@[^Q"1M,XI&B&5W@P#LV$W8(R=LOR], S$N,QBN-85,IF0^G>C"$=U9HG)*(P"$C:" M!PG$LVR0>3BN$]T,S^/5A\,+V<.SK ^Z&-#PVZ*:M.&RBJ4)!AG#LZP,,.4U MO.9!SO L2P/&-,WF0?[P+ L$S,W-:$(&\2PKI)&=T2>]T,]8^=FD@]3A67;' MI31]"=*'7.);=LG%50SZ-&0JX5G96/Y#6O$M:P6>-QT3$]RF6)8,C-DU,2'/ M^)8] V/V3$Q(-KYEV32SD-8.T5:D8;"8D[AI;1]2CV]9/7"R-'.Z#ZG'MZR> M=\GR]PQO)")(.;YEY5S&0U$BI7[X:&)"RO$M*^=R4K\43$@]_E74.>SVHW;,L+MHGT)TI=GR99.I.HNIQVGIUNM1;<'K(LT'738BR2S?GH M]WQL_?@+4$L#!!0 ( )N*;E6,WU^M;@$ -T4 : >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSE5U(FXFHW;B3= L("1 MO]!.1N]^""[P([.8C>E9D4(X?1?D">GAR]:9OW:MJZZ]B^Y-W;I45=[W'UJ[ MO+)-YE9=;]OQ2=$-3>;'Y5#J/LMO66DUQW&BA]<9ZGAXG1F='[W]S\2N**ZY M_>SR[\:V_H_!^J<;;JZRUJOHG VE]:G2]WJ^[?1TH=4X646G2ZJ&TX64#AW$ M$,3A@PP$F?!!:PA:AP_:0- F?% "04GXH"T$;<,'[2!H%SYH#T'[\$$4HXRQ M@*0%U@*T)N2:!'A-"#8)$)N0;!)@-B':)$!M0K9)@-N$<), N0GI)@%V$^)- M O1FU)L%Z,VH-PO0FQ<_VP+T9M2;!>C-J#<+T)M1;Q:@-Z/>+$!O1KU9@-Z, M>K, O1GU9@%Z&]3;"-#;H-Y&@-X&]38"]#:+PQ(!>AO4V[Q3;^/ 0 M7!E&ULS9C-;L(P$(1?)^@)MLB$426[:A\/9UPH_4BD8@*G4NL1+OSHR]TG?(Y'UKR$6;NFK< M-"Z]-X^,N:RD6KI$&VK"3J%M+7UXM0MF9+:4"V)B-!JS3#>>&C_TK48\FSQ3 M(5>5CUXVX;-3NIG&EBH71T^[PM9K&DMC*I5)'_;9NLE_N SW#DGH[&I]KK0 MDCAC2>:N)/)UE>Q$!_W./MPP[9[\:O].IL\P5,ZM-BY,S-+E=H>1M-U#$X3( M>M5_Q*-CD+[Z?-1..Z?\3.]PO9_:+KMY.-8MU]_Q]QD?]2_,(4!RI" Y;D!R MW(+D&(/DN /)<0^2XP$D!Q^A!$$A*D=!*D=A*D>!*D>A*D?!*D?A*D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( )N* M;E7!38.QH 4 . = 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ FXIN53N^P2CB P UQ( !@ ("!2A0 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ FXIN5;^CG?2"!0 M31< !@ ("!&R4 'AL+W=O.8: !240 & @(%H,@ >&PO=V]R:W-H965T&UL4$L! A0#% @ FXIN5>QDEEMC P _0< !@ M ("!A$T 'AL+W=O&UL4$L! A0#% @ FXIN594K22ZU P J@D !D M ("!K50 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ FXIN5>!?QT&N @ -08 !D ("!$V M 'AL+W=O M0&<" !N!0 &0 @('X8@ >&PO=V]R:W-H965T&UL4$L! A0#% @ MFXIN590N=!VD P ZPH !D ("!C($ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FXIN52T5E4RB P 0@X !D M ("!DI, 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ FXIN5>=LV+$ P %PD !D ("!XJ 'AL M+W=ON1!$H" M ""!@ &0 @($9I >&PO=V]R:W-H965T&UL4$L! A0#% @ FXIN M51WIUS$U! ]!8 !D ("! :L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ FXIN5:;&PO=V]R:W-H965T] !X;"]W;W)K&UL4$L! A0#% @ FXIN5?4!;!,= P :!$ T M ( !/L$ 'AL+W-T>6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ FXIN58S?7ZUN 0 W10 !H ( ! M\<@ 'AL+U]R96QS+W=O/ 0 XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 116 175 1 false 32 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://mahatten.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mahatten.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - BASIS OF PRESENTATION Sheet http://mahatten.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Notes 8 false false R9.htm 000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS Sheet http://mahatten.com/role/InvestmentInImagionBiosystems INVESTMENT IN IMAGION BIOSYSTEMS Notes 9 false false R10.htm 000010 - Disclosure - NOTES PAYABLE Notes http://mahatten.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 000011 - Disclosure - CAPITAL TRANSACTIONS Sheet http://mahatten.com/role/CapitalTransactions CAPITAL TRANSACTIONS Notes 11 false false R12.htm 000012 - Disclosure - LICENSE AGREEMENT Sheet http://mahatten.com/role/LicenseAgreement LICENSE AGREEMENT Notes 12 false false R13.htm 000013 - Disclosure - COMMITMENTS AND CONTIGENCIES Sheet http://mahatten.com/role/CommitmentsAndContigencies COMMITMENTS AND CONTIGENCIES Notes 13 false false R14.htm 000014 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://mahatten.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://mahatten.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Policies 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Tables http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters 17 false false R18.htm 000018 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables) Sheet http://mahatten.com/role/InvestmentInImagionBiosystemsTables INVESTMENT IN IMAGION BIOSYSTEMS (Tables) Tables http://mahatten.com/role/InvestmentInImagionBiosystems 18 false false R19.htm 000019 - Disclosure - NOTES PAYABLE (Tables) Notes http://mahatten.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://mahatten.com/role/NotesPayable 19 false false R20.htm 000020 - Disclosure - CAPITAL TRANSACTIONS (Tables) Sheet http://mahatten.com/role/CapitalTransactionsTables CAPITAL TRANSACTIONS (Tables) Tables http://mahatten.com/role/CapitalTransactions 20 false false R21.htm 000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://mahatten.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://mahatten.com/role/BasisOfPresentation 21 false false R22.htm 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Details http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 22 false false R23.htm 000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) Details http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 23 false false R24.htm 000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Details http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 24 false false R25.htm 000025 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) Sheet http://mahatten.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) Details 25 false false R26.htm 000026 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Sheet http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Details http://mahatten.com/role/InvestmentInImagionBiosystemsTables 26 false false R27.htm 000027 - Disclosure - NOTES PAYABLE (Details) Notes http://mahatten.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://mahatten.com/role/NotesPayableTables 27 false false R28.htm 000028 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://mahatten.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://mahatten.com/role/NotesPayableTables 28 false false R29.htm 000029 - Disclosure - CAPITAL TRANSACTIONS (Details) Sheet http://mahatten.com/role/CapitalTransactionsDetails CAPITAL TRANSACTIONS (Details) Details http://mahatten.com/role/CapitalTransactionsTables 29 false false R30.htm 000030 - Disclosure - CAPITAL TRANSACTIONS (Details 1) Sheet http://mahatten.com/role/CapitalTransactionsDetails1 CAPITAL TRANSACTIONS (Details 1) Details http://mahatten.com/role/CapitalTransactionsTables 30 false false R31.htm 000031 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) Sheet http://mahatten.com/role/CapitalTransactionsDetailsNarrative CAPITAL TRANSACTIONS (Details Narrative) Details http://mahatten.com/role/CapitalTransactionsTables 31 false false R32.htm 000032 - Disclosure - LICENSE AGREEMENT (Details Narrative) Sheet http://mahatten.com/role/LicenseAgreementDetailsNarrative LICENSE AGREEMENT (Details Narrative) Details http://mahatten.com/role/LicenseAgreement 32 false false R33.htm 000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://mahatten.com/role/RelatedPartyTransactions 33 false false R34.htm 000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://mahatten.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://mahatten.com/role/SubsequentEvents 34 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 36 fact(s) appearing in ix:hidden were eligible for transformation: mhtx:AggregateIntrinsicValueExercised, mhtx:AggregateIntrinsicValueExpired, mhtx:AggregateIntrinsicValueGranted, mhtx:EffectOfDilutiveSecurities, mhtx:NumberOfOptionsExercisableExercised, mhtx:NumberOfOptionsExercisableExpired, mhtx:NumberOfOptionsExercisableGranted, mhtx:NumberOfOptionsExpired, mhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding, mhtx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding60, mhtx:WeightedAverageExercisePriceExpired, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:GainLossOnSaleOfInvestments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber, us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding - mhtx_10q.htm 1 mhtx_10q.htm mhtx-20220930.xsd mhtx-20220930_cal.xml mhtx-20220930_def.xml mhtx-20220930_lab.xml mhtx-20220930_pre.xml mhtx_ex311.htm mhtx_ex321.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mhtx_10q.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 116, "dts": { "calculationLink": { "local": [ "mhtx-20220930_cal.xml" ] }, "definitionLink": { "local": [ "mhtx-20220930_def.xml" ] }, "inline": { "local": [ "mhtx_10q.htm" ] }, "labelLink": { "local": [ "mhtx-20220930_lab.xml" ] }, "presentationLink": { "local": [ "mhtx-20220930_pre.xml" ] }, "schema": { "local": [ "mhtx-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 272, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 22, "http://mahatten.com/20220930": 14, "http://xbrl.sec.gov/dei/2022": 5, "total": 41 }, "keyCustom": 42, "keyStandard": 133, "memberCustom": 22, "memberStandard": 10, "nsprefix": "mhtx", "nsuri": "http://mahatten.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://mahatten.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - NOTES PAYABLE", "role": "http://mahatten.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - CAPITAL TRANSACTIONS", "role": "http://mahatten.com/role/CapitalTransactions", "shortName": "CAPITAL TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - LICENSE AGREEMENT", "role": "http://mahatten.com/role/LicenseAgreement", "shortName": "LICENSE AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - COMMITMENTS AND CONTIGENCIES", "role": "http://mahatten.com/role/CommitmentsAndContigencies", "shortName": "COMMITMENTS AND CONTIGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://mahatten.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - SUBSEQUENT EVENTS", "role": "http://mahatten.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables)", "role": "http://mahatten.com/role/InvestmentInImagionBiosystemsTables", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfDebtDiscount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://mahatten.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfDebtDiscount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - CAPITAL TRANSACTIONS (Tables)", "role": "http://mahatten.com/role/CapitalTransactionsTables", "shortName": "CAPITAL TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative)", "role": "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "shortName": "BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "lang": null, "name": "mhtx:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details)", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30_mhtx_QuotedPricesInActiveMarketsForIdenticalAssetsMember_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:ProfitLoss1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1)", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:ProfitLoss1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:CommonStockOwnedShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative)", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:CommonStockOwnedShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:BeginingBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details)", "role": "http://mahatten.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails", "shortName": "INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:BeginingBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSaleOfInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative)", "role": "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30_mhtx_ImagionBiosystemsIncMember", "decimals": "0", "lang": null, "name": "mhtx:CommonStockOwnedShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfDebtDiscount", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:NotesPayableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - NOTES PAYABLE (Details)", "role": "http://mahatten.com/role/NotesPayableDetails", "shortName": "NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfDebtDiscount", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:NotesPayableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://mahatten.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2019-10-01to2019-10-17_mhtx_IndividualsMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromSecuredNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - CAPITAL TRANSACTIONS (Details)", "role": "http://mahatten.com/role/CapitalTransactionsDetails", "shortName": "CAPITAL TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "lang": "en-US", "name": "mhtx:WeightedAverageLifeOutstandingEndingBalance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - CAPITAL TRANSACTIONS (Details 1)", "role": "http://mahatten.com/role/CapitalTransactionsDetails1", "shortName": "CAPITAL TRANSACTIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "mhtx:ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30_mhtx_ExercisePriceRangeTwoMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative)", "role": "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "shortName": "CAPITAL TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30_us-gaap_StockOptionMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "mhtx:LicenseAgreementTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - LICENSE AGREEMENT (Details Narrative)", "role": "http://mahatten.com/role/LicenseAgreementDetailsNarrative", "shortName": "LICENSE AGREEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "mhtx:LicenseAgreementTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2022-09-30_mhtx_SoleOfficerMember", "decimals": "0", "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-10-01to2022-10-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://mahatten.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfSubsequentEventsTextBlock", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-10-01to2022-10-31_mhtx_OctoberTwoThousandTwentyTwoMember_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "mhtx:CommonStockSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "AsOf2020-12-31_mhtx_PreferredStockSeriesBMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "role": "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2021-01-01to2021-03-31", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:ProfitsLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "mhtx:ProfitsLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - BASIS OF PRESENTATION", "role": "http://mahatten.com/role/BasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS", "role": "http://mahatten.com/role/InvestmentInImagionBiosystems", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 32, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "mhtx_AdjustedAssetValuation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Adjusted asset valuation" } } }, "localname": "AdjustedAssetValuation", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_AggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value" } } }, "localname": "AggregateIntrinsicValueAbstract", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "mhtx_AggregateIntrinsicValueExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Exercised" } } }, "localname": "AggregateIntrinsicValueExercised", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_AggregateIntrinsicValueExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Expired" } } }, "localname": "AggregateIntrinsicValueExpired", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_AggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, granted" } } }, "localname": "AggregateIntrinsicValueGranted", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_AnnualLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Annual license fee" } } }, "localname": "AnnualLicenseFee", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_BasicAndDilutedIncomeLossPerCommonShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted income (loss) per common share (Basic and Diluted)" } } }, "localname": "BasicAndDilutedIncomeLossPerCommonShareBasicAndDiluted", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "mhtx_BeginingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Balance as of December 31, 2021" } } }, "localname": "BeginingBalance", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_BoardOfDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Director [Member]" } } }, "localname": "BoardOfDirectorMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_CashConcentration": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH CONCENTRATION" } } }, "localname": "CashConcentration", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "mhtx_ChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chairman [Member]" } } }, "localname": "ChairmanMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_ChangeDueToTheSaleOfSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change due to the sale of securities" } } }, "localname": "ChangeDueToTheSaleOfSecurities", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_ClassAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Convertible Preferred Stock [Member]" } } }, "localname": "ClassAConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Convertible Preferred Stock [Member]" } } }, "localname": "ClassBConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassCRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class C Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "ClassCRedeemableConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassDConvertibleMandatoryRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class D Convertible Mandatory Redeemable Preferred Stock [Member]" } } }, "localname": "ClassDConvertibleMandatoryRedeemablePreferredStockMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_CommonStockOwnedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to", "label": "Common stock owned shares" } } }, "localname": "CommonStockOwnedShare", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_CommonStockOwnedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to", "label": "[Common stock owned shares]", "verboseLabel": "Common stock owned shares" } } }, "localname": "CommonStockOwnedShares", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_CommonStockSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock sold" } } }, "localname": "CommonStockSold", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_DebtDueDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt due date" } } }, "localname": "DebtDueDate", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "mhtx_DueFromTheSaleOfAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DUE FROM THE SALE OF ASSETS" } } }, "localname": "DueFromTheSaleOfAssetsPolicyTextBlock", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "mhtx_EarningsPerSharesBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "EarningsPerSharesBasicAndDilutedAbstract", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "stringItemType" }, "mhtx_EffectOfDilutiveSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect of dilutive securities" } } }, "localname": "EffectOfDilutiveSecurities", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "sharesItemType" }, "mhtx_EndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Balance as of September 30, 2022" } } }, "localname": "EndingBalance", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.02 [Member]" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.14 [Member]" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.06 [Member]" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.05 [Member]" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise prices and weighted-average contractual lives of stock options outstanding" } } }, "localname": "ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsTables" ], "xbrltype": "textBlockItemType" }, "mhtx_ImagionBiosystemsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Imagion Biosystems, Inc. [Member]" } } }, "localname": "ImagionBiosystemsIncMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_InTwoThousandNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In 2009 [Member]" } } }, "localname": "InTwoThousandNineMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_IndividualsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Individuals [Member]" } } }, "localname": "IndividualsMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_LessDiscountsOnNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less: Discounts on notes payable" } } }, "localname": "LessDiscountsOnNotesPayable", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[LICENSE AGREEMENT]", "verboseLabel": "LICENSE AGREEMENT" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/LicenseAgreement" ], "xbrltype": "textBlockItemType" }, "mhtx_LosAlamosNationalSecurityLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Los Alamos National Security LLC [Member]" } } }, "localname": "LosAlamosNationalSecurityLLCMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_MarketableSecuritiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MARKETABLE SECURITIES" } } }, "localname": "MarketableSecuritiesPolicyTextBlock", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "mhtx_NotesPayableGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Notes payable" } } }, "localname": "NotesPayableGross", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_NumberOfOptionsExercisableExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options, exercisable exercised" } } }, "localname": "NumberOfOptionsExercisableExercised", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_NumberOfOptionsExercisableExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options, exercisable expired" } } }, "localname": "NumberOfOptionsExercisableExpired", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_NumberOfOptionsExercisableGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options, exercisable granted" } } }, "localname": "NumberOfOptionsExercisableGranted", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_NumberOfOptionsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options, expired" } } }, "localname": "NumberOfOptionsExpired", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_OctoberTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October Two Thousand Twenty Two [Member]" } } }, "localname": "OctoberTwoThousandTwentyTwoMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_PatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patent license agreement [Member]" } } }, "localname": "PatentLicenseAgreementMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_PreferredStockSeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Series B" } } }, "localname": "PreferredStockSeriesBMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "mhtx_PricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Price per share" } } }, "localname": "PricePerShare", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "mhtx_ProfitLoss1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net income (loss)" } } }, "localname": "ProfitLoss1", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "monetaryItemType" }, "mhtx_ProfitsLoss": { "auth_ref": [], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Net loss]", "negatedLabel": "Net loss" } } }, "localname": "ProfitsLoss", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "mhtx_QuotedPricesInActiveMarketsForIdenticalAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quoted prices in active markets for identical assets [Member]" } } }, "localname": "QuotedPricesInActiveMarketsForIdenticalAssetsMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "mhtx_RemainingAmountOfAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Remaining amount of assets" } } }, "localname": "RemainingAmountOfAssets", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_RoyaltyPercentageOnDentalProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty percentage on dental products" } } }, "localname": "RoyaltyPercentageOnDentalProducts", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "mhtx_RoyaltyPercentageOnOtherLicensedProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty percentage on other licensed products" } } }, "localname": "RoyaltyPercentageOnOtherLicensedProducts", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "mhtx_SaleOfAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Sale of asset" } } }, "localname": "SaleOfAsset", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_ScheduleOfDebtDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of debt discount" } } }, "localname": "ScheduleOfDebtDiscount", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "mhtx_ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value measurement of assets and liabilities" } } }, "localname": "ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables" ], "xbrltype": "textBlockItemType" }, "mhtx_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B convertible preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "mhtx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding60": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Aggregate intrinsic value, ending]", "periodEndLabel": "Aggregate intrinsic value, ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding60", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_SignificantOtherObservableInputsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant other observable inputs [Member]" } } }, "localname": "SignificantOtherObservableInputsMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "mhtx_SignificantUnobservableInputsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant unobservable inputs [Member]" } } }, "localname": "SignificantUnobservableInputsMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "mhtx_SoleOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sole Officer [Member]" } } }, "localname": "SoleOfficerMember", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_TradingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trading price per share" } } }, "localname": "TradingPricePerShare", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "mhtx_WeightedAverageExercisePriceExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, exercisable" } } }, "localname": "WeightedAverageExercisePriceExercisable", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "perShareItemType" }, "mhtx_WeightedAverageExercisePriceExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "WeightedAverageExercisePriceExpired", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "mhtx_WeightedAverageLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life" } } }, "localname": "WeightedAverageLifeAbstract", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "mhtx_WeightedAverageLifeOutstandingEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life, Outstanding Ending Balance" } } }, "localname": "WeightedAverageLifeOutstandingEndingBalance", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "durationItemType" }, "mhtx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding (Basic and Diluted)" } } }, "localname": "WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "mhtx_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Working capital deficit" } } }, "localname": "WorkingCapital", "nsuri": "http://mahatten.com/20220930", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [ "r157", "r158", "r159", "r160", "r175", "r198", "r225", "r226", "r324", "r325", "r326", "r327", "r328", "r329", "r348", "r388", "r389", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r157", "r158", "r159", "r160", "r175", "r198", "r225", "r226", "r324", "r325", "r326", "r327", "r328", "r329", "r348", "r388", "r389", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r152", "r157", "r158", "r159", "r160", "r175", "r198", "r215", "r225", "r226", "r257", "r258", "r259", "r324", "r325", "r326", "r327", "r328", "r329", "r348", "r388", "r389", "r401", "r402" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r152", "r157", "r158", "r159", "r160", "r175", "r198", "r215", "r225", "r226", "r257", "r258", "r259", "r324", "r325", "r326", "r327", "r328", "r329", "r348", "r388", "r389", "r401", "r402" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION (Details Narrative)" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpenseIncludingAssetRetirementObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative)" } } }, "localname": "AccretionExpenseIncludingAssetRetirementObligationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses - related parties", "verboseLabel": "Accrued expenses - related parties" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcruedIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details)" } } }, "localname": "AcruedIncomeTaxesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AdditionalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL TRANSACTIONS (Details Narrative)" } } }, "localname": "AdditionalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r316" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r73", "r74", "r75", "r262", "r263", "r264", "r285" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r44", "r53", "r186", "r302" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount", "verboseLabel": "Amortization of Debt Discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r10", "r70", "r113", "r116", "r122", "r135", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r173", "r174", "r278", "r281", "r292", "r314", "r316", "r368", "r379" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r22", "r70", "r135", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r173", "r174", "r278", "r281", "r292", "r314", "r316" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r227", "r228", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r251", "r252", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r227", "r228", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r251", "r252", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r227", "r228", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r251", "r252", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL TRANSACTIONS" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r72", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r8", "r55" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r49", "r55", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "CASH, END OF PERIOD", "periodStartLabel": "CASH, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r49", "r293" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r12", "r13", "r14", "r68", "r70", "r87", "r88", "r89", "r91", "r93", "r99", "r100", "r101", "r135", "r162", "r167", "r168", "r169", "r173", "r174", "r196", "r197", "r200", "r204", "r211", "r292", "r408" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r371", "r384" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies - Note 7" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTIGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r153", "r154", "r155", "r161", "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTIGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CommitmentsAndContigencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r73", "r74", "r285" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r316" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common, authorized 950,000,000 shares, 559,281,064 and 559,281,064 shares issued, and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r63", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "BASIS OF CONSOLIDATION" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue": { "auth_ref": [ "r13", "r212" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.", "label": "Class D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively" } } }, "localname": "ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE (Tables)" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r67", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r187", "r188", "r190", "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r27", "r185", "r303" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r53", "r150" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r4", "r15", "r71", "r165", "r167", "r168", "r172", "r173", "r174", "r310" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from the sale of assets - current portion" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r39", "r78", "r79", "r80", "r81", "r82", "r86", "r87", "r91", "r92", "r93", "r96", "r97", "r286", "r287", "r373", "r387" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic earnings (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r39", "r78", "r79", "r80", "r81", "r82", "r87", "r91", "r92", "r93", "r96", "r97", "r286", "r287", "r373", "r387" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted earnings (loss) per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "BASIC AND DILUTED EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r33", "r34", "r35", "r73", "r74", "r75", "r77", "r83", "r85", "r98", "r137", "r211", "r213", "r262", "r263", "r264", "r276", "r277", "r285", "r294", "r295", "r296", "r297", "r298", "r299", "r306", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "NOTE 3 - INVESTMENT IN IMAGION BIOSYSTEMS" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystems" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r288", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r183", "r191", "r192", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r289", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r183", "r216", "r217", "r222", "r224", "r289", "r321" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r183", "r191", "r192", "r216", "r217", "r222", "r224", "r289", "r322" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r183", "r191", "r192", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r289", "r323" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r183", "r191", "r192", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.", "label": "Cash exceeding insured amount" } } }, "localname": "FederalDepositInsuranceCorporationPremiumExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r129", "r130", "r132", "r133", "r134", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r189", "r209", "r283", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Amortization period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r42", "r53", "r128" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on fair value adjustment of investments", "verboseLabel": "Change in the unrealized fair value of securities" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://mahatten.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r53" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "[Gain (Loss) on Sale of Investments]", "negatedLabel": "Loss on fair value adjustment of investments", "verboseLabel": "Change in unrealized gain in investment" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r156" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "[Gain (Loss) Related to Litigation Settlement]", "negatedLabel": "Gain on settelement of legal fees" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r53", "r193", "r194" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on settlement of legal fees" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r268", "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income Tax Examination, Likelihood of Unfavorable Settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r32", "r269", "r270", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r50", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r52" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r52" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r52" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r64", "r149", "r350", "r351", "r352", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r36", "r112", "r301", "r304", "r375" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r395", "r396", "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Fair value of investment" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r385" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investment in equity securities", "verboseLabel": "Investment in equity securities" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT IN IMAGION BIOSYSTEMS" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENT" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r70", "r117", "r135", "r162", "r163", "r164", "r167", "r168", "r169", "r170", "r171", "r173", "r174", "r279", "r281", "r282", "r292", "r314", "r315" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r70", "r135", "r292", "r316", "r370", "r382" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r26", "r70", "r135", "r162", "r163", "r164", "r167", "r168", "r169", "r170", "r171", "r173", "r174", "r279", "r281", "r282", "r292", "r314", "r315", "r316" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r49", "r51", "r54" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r30", "r31", "r35", "r38", "r54", "r70", "r76", "r78", "r79", "r80", "r81", "r84", "r85", "r90", "r113", "r115", "r118", "r121", "r123", "r135", "r162", "r163", "r164", "r167", "r168", "r169", "r170", "r171", "r173", "r174", "r287", "r292", "r372", "r386" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "[Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r11", "r369", "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable, net of discounts", "verboseLabel": "Notes payable, net of discounts" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "[Operating Costs and Expenses]", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating costs:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r113", "r115", "r118", "r121", "r123" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME (LOSS) PER COMMON SHARE:" } } }, "localname": "OperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r9", "r367", "r378" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r227", "r228", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r251", "r252", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r227", "r228", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r251", "r252", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r196" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Capital stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r196" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r316" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r21", "r147", "r148" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.", "label": "Weighted average number diluted shares" } } }, "localname": "ProFormaWeightedAverageSharesOutstandingDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "auth_ref": [ "r46" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of investments classified as other.", "label": "Proceeds from the sale of investments" } } }, "localname": "ProceedsFromSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "auth_ref": [ "r45" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Proceeds from sale of assets held for sale", "verboseLabel": "Proceeds from sale of assets held for sale" } } }, "localname": "ProceedsFromSaleOfPropertyHeldForSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSecuredNotesPayable": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Secured note" } } }, "localname": "ProceedsFromSecuredNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r151", "r316", "r377", "r383" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r151", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property and equipment useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r223", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r223", "r309", "r310", "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r223", "r309", "r311", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r307", "r308", "r310", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r48" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayments for note payable", "terseLabel": "Repayments for note payable", "verboseLabel": "Repayments for note payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r267", "r349", "r403" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r213", "r316", "r381", "r393", "r394" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r73", "r74", "r75", "r77", "r83", "r85", "r137", "r262", "r263", "r264", "r276", "r277", "r285", "r390", "r392" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "REVENUE RECOGNITION" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r37", "r70", "r110", "r111", "r114", "r119", "r120", "r124", "r125", "r126", "r135", "r162", "r163", "r164", "r167", "r168", "r169", "r170", "r171", "r173", "r174", "r292", "r376" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Minimum Royalty Payment" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of basic and diluted earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r231", "r247", "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Summary of Company's stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsequentEventsTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.", "label": "Schedule of Subsequent Events [Table Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "ScheduleOfSubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of changes to the investment in Imagion" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of Options, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of Options Exercisable, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of Options, Outstanding ending Balance", "periodStartLabel": "Number of Options, Outstanding Beginning Balance", "terseLabel": "Number of Options, Outstanding", "verboseLabel": "Number of Options, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails", "http://mahatten.com/role/CapitalTransactionsDetails1", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodStartLabel": "Weighted Average Exercise Price, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r227", "r228", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r248", "r249", "r251", "r252", "r256", "r257", "r258", "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]", "verboseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r230", "r254", "r255", "r256", "r257", "r260", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "STOCK BASED COMPENSATION" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding]", "periodStartLabel": "Aggregate intrinsic value, beginning", "verboseLabel": "Aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, September 30, 2021, shares", "periodStartLabel": "Balance, December 31, 2020, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeasesPolicyTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.", "label": "LEASES" } } }, "localname": "ShortTermLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r62", "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r68", "r70", "r87", "r88", "r89", "r91", "r93", "r99", "r100", "r101", "r135", "r162", "r167", "r168", "r169", "r173", "r174", "r196", "r197", "r200", "r204", "r211", "r292", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r29", "r33", "r34", "r35", "r73", "r74", "r75", "r77", "r83", "r85", "r98", "r137", "r211", "r213", "r262", "r263", "r264", "r276", "r277", "r285", "r294", "r295", "r296", "r297", "r298", "r299", "r306", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r73", "r74", "r75", "r98", "r353" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r211", "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Fair value of common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r70", "r127", "r135", "r292", "r316" ], "calculation": { "http://mahatten.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, September 30, 2021, amount", "periodStartLabel": "Balance, December 31, 2020, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets", "http://mahatten.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r197", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r213", "r214", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "CAPITAL TRANSACTIONS" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r300", "r317" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r300", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r300", "r317" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r58", "r59", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Licenses purchased price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r129", "r130", "r132", "r133", "r134", "r189", "r209", "r283", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r102", "r103", "r104", "r105", "r106", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "USE OF ESTIMATES" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted-average diluted shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r86", "r93" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average basic shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918418-209957" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r404": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r405": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r406": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r407": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r408": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r409": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r410": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r411": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r412": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r415": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" } }, "version": "2.1" } ZIP 51 0001477932-22-008553-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-22-008553-xbrl.zip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end

	(1)	The Quarterly Report of Form 10-Q for the period ending September 30, 2022 (the “Report”), of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.